Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU769418B2 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors - Google Patents
[go: Go Back, main page]

AU769418B2 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors - Google Patents

Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors Download PDF

Info

Publication number
AU769418B2
AU769418B2 AU26305/00A AU2630500A AU769418B2 AU 769418 B2 AU769418 B2 AU 769418B2 AU 26305/00 A AU26305/00 A AU 26305/00A AU 2630500 A AU2630500 A AU 2630500A AU 769418 B2 AU769418 B2 AU 769418B2
Authority
AU
Australia
Prior art keywords
ynyloxy
phenyl
methyl
piperidine
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26305/00A
Other versions
AU2630500A (en
Inventor
Jannie Lea Baker
James Ming Chen
Mila Ti Du
Jeremy Ian Levin
Vincent Premarana Sandanayaka
Aranapakam Mudumbai Venkatesan
Arie Zask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Priority claimed from PCT/US2000/001864 external-priority patent/WO2000044723A1/en
Publication of AU2630500A publication Critical patent/AU2630500A/en
Assigned to WYETH HOLDINGS CORPORATION reassignment WYETH HOLDINGS CORPORATION Change of Name of Applicant under S 104 Assignors: AMERICAN CYANAMID COMPANY
Application granted granted Critical
Publication of AU769418B2 publication Critical patent/AU769418B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

WO 00/44723 PCT/US00/01864 -1- ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS FIELD OF INVENTION This invention relates to acetylenic hydroxamic acids which act as inhibitors of TNF-a converting enzyme (TACE). The compounds of the present invention are useful in disease conditions mediated by TNF-oa, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
BACKGROUND OF THE INVENTION Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. Of these classes, the gelatinases have been shown to be the MMPs most intimately involved with the growth and spread of tumors. It is known that the level of expression of gelatinase is elevated in malignancies, and that gelatinase can degrade the basement membrane which leads to tumor metastasis. Angiogenesis, required for the growth of solid tumors, has also recently been shown to have a gelatinase component to its pathology.
Furthermore, there is evidence to suggest that gelatinase is involved in plaque rupture associated with atherosclerosis. Other conditions mediated by MMPs are restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, periodontal disease, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neo- ~~~iwrrR~~n~n~i~~u~r~%U~~IH~~~~j~YI~IYW WO 00/44723 PCT/US00/01864 -2vascularization and corneal graft rejection. For recent reviews, see: Recent Advances in Matrix Metalloproteinase Inhibitor Research, R. P. Beckett, A. H.
Davidson, A. H. Drummond, P. Huxley and M. Whittaker, Research Focus, Vol. 1, 16-26, (1996), Curr. Opin. Ther. Patents (1994) 7-16, Curr. Medicinal Chem. (1995) 2: 743-762, Exp. Opin. Ther. Patents (1995) 1087-110, Exp. Opin. Ther. Patents (1995) 5(12): 1287-1196: Exp. Opin. Ther. Patents (1998) 281-259.
TNF-at converting enzyme (TACE) catalyzes the formation of TNF-a from membrane bound TNF-a precursor protein. TNF-a is a pro-inflammatory cytokine that is believed to have a role in rheumatoid arthritis [Shire, M. Muller, G. W.
Exp. Opin. Ther. Patents 1998, 531; Grossman, J. Brahn, E. J. Women's Health 1997, 627; Isomaki, Punnonen, J. Ann. Med. 1997, 29, 499; Camussi, Lupia, E. Drugs, 1998, 55(5), 613.] septic shock [Mathison, et. al. J. Clin. Invest.
1988, 81, 1925; Miethke, et. al. J. Exp. Med. 1992, 175, graft rejection [Piguet, P. Grau, G. et. al. J. Exp. Med. 1987, 166, 1280.], cachexia [Beutler, B.; Cerami, A. Ann. Rev. Biochem. 1988, 57, 505.], anorexia, inflammation [Ksontini, MacKay, S. L. Moldawer, L. L. Arch. Surg. 1998, 133, 558.], congestive heart failure [Packer, M. Circulation, 1995, 92(6), 1379; Ferrari, Bachetti, et. al.
Circulation, 1995, 92(6), 1479.], post-ischaemic reperfusion injury, inflammatory disease of the central nervous system, inflammatory bowel disease, insulin resistance [Hotamisligil, G. Shargill, N. Spiegelman, B. et. al. Science, 1993, 259, 87.] and HIV infection [Peterson, P. Gekker, et. al. J. Clin. Invest. 1992, 89, 574; Pallares-Trujillo, Lopez-Soriano, F. J. Argiles, J. M. Med. Res. Reviews, 1995, 15(6), in addition to its well-documented antitumor properties [Old, L.
Science, 1985, 230, 630.]. For example, research with anti-TNF-a antibodies and transgenic animals has demonstrated that blocking the formation of TNF-a inhibits the progression of arthritis [Rankin, Choy, Kassimos, Kingsley, G.H.; Sopwith, Isenberg, Panayi, G.S. Br. J. Rheumatol. 1995, 34, 334; Pharmaprojects, 1996, Therapeutic Updates 17 au197-M2Z.]. This observation has recently been extended to humans as well as described in "TNF-a in Human Diseases", Current Pharmaceutical Design, 1996, 2, 662.
~~~~"II~Jil~N;U;~V~,W~I~YI~~U~kW~U*1IWIW WO 00/44723 PCT/US00/01864 -3- It is expected that small molecule inhibitors of TACE would have the potential for treating a variety of disease states. Although a variety of TACE inhibitors are known, many of these molecules are peptidic and peptide-like which suffer from bioavailability and pharmacokinetic problems. In addition, many of these molecules are non-selective, being potent inhibitors of matrix metalloproteinases and, in particular, MMP-1. Inhibition of MMP-1 (collagenase 1) has been postulated to cause joint pain in clinical trials of MMP inhibitors [Scrip, 1998, 2349, 20] Long acting, selective, orally bioavailable non-peptide inhibitors of TACE would thus be highly desirable for the treatment of the disease states discussed above.
Sulfone hydroxamic acid inhibitors of MMPs, of general structure I have been disclosed [Burgess, Rizzi, Rawson, D.J. Eur Patent Appl. 818442.
Groneberg, Neuenschwander, Djuric, McGeehan, Bums, Condon, Morrissette, Salvino, Scotese, Ullrich, J.W.
PCT Int. Appl. WO 97/24117. Bender, Broka, Campbell, J.A.; Castelhano,A.L.; Fisher, Hendricks, Sarma, K. Eur. Patent Appl.
780386. Venkatesan, A. Grosu, G. Davis, J. Hu, O'Dell, M. J. PCT Int. Appl. WO 98/38163.]. An exemplification of this class of MMP inhibitor is RS- 130830, shown below.
0 HOHN ~R3CI WCR2 n 02 02 RS-130830 Within the sulfone-hydroxamic acid class of MMP inhibitor, the linker between the sulfone and hydroxamic acid moieties has been extended to three carbons n 2) without significant loss in potency [Barta, T. Becker, D. Villamil, C. I.; 1' ,U 11 MARMAREW UMH11F,_,M WO 00/44723 PCT/USOO/O1 864 -4- Freskos, J. Mischke, B. Mullins, P. Heintz, R. Getman, D. P.; McDonald, J. J. PCT Int. Appi. WO 98/39316. McDonald, J. Barta, T. E.; Becker, D. Bedell, L. Rao, S. Freskos, J. Mischke, B. V. PCT Int.
Appi. WO 98/38859.].
Piperidine sulfone hydroxamic acids, UI (n 1) have been reported [Becker, D. Villamil, C. Boehm, T. Getman, D. McDonald, J. DeCrescenzo, G. A. PCT Int. Appi. WO 98/39315.]. Similar piperidine derivatives in which the methylene linking the piperidine ring to the sulfone has been deleted n 0) have been reported [Venkatesan, A. Grosu, G. Davis, J. Baker, J. L. PCT Int.
AppI. WO 98/37877.].
00 HOxH Sulfone-hydroxamic acids Ell, in which a hydroxyl group has been placed alpha to the hydroxamic acid, have been disclosed [Freskos, J. Boehm, T. L.; Mischke, B. Heintz, R. McDonald, J. DeCrescenzo, G. Howard, S. C.
PCT Int. Appi. WO 98/39326. Robinson, R. P. PCT Int. Appi. WO 98/34915.].
HOH H-o HO Ri 0 Sulfone-based MMP inhibitors of general structure IV, which utilize a thiol as the zinc chelator, have been reported [Freskos, Abbas, DeCrescenzo, G.A.; Getman, Heintz, Mischke, McDonald, J.J. PCT lInt. Appi.
WO 98/03164].
02
HS,
IV
WRINYORIA IVA, WO 00/44723 WO 0044723PCT/USOO/0I 864 Inhibitors of stromelysin with general structure V have been disclosed [Shuker, Haijduk, Meadows, Fesik, S.W. Science, 1996, 274, 1531- 1534. Hajduk, Sheppard, Nettesheim, Oleiniczak, Shuker, S.B.; Meadows, Steinman, Carrera, Jr., Marcotte, Severin, J.; Walter, Smith, Gubbins, Simmer, Holzman, Morgan, D.W.; Davidsen, Summers, Fesik, S.W. J. Am. Chem. Soc. 1997, 119, 5818- 5827. Olejniczak, Hajduk, Marcotte, Nettesheim, Meadows, Edaiji, Holzman, Fesik, S.W. J. Am. Chem. Soc. 1997, 119, 5828- 5832. Fesik, S. Summers, J. Davicisen, S. Sheppard, G. Steinman, D.
Carrera, G. Florjancic, Hoims, J. H. PCT Int. Appi. WO 97/18188.].
NHOH
V
Salah et al., Liebigs Ann. Chem. 195, (1973) discloses some aryl substituted thio and aryl substituted sulfonyl acetohydroxamic acid derivatives of general formula 1. These compounds were prepared to study the Mannich reaction.
Subsequently, they were tested for their fungicidal activity.
Mannich Reaction (OI (O)n HN.
Some sulfone carboxylic acids are disclosed in U.S. patent 4,933,367. Those compounds were shown to exhibit hypoglycemic activity.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- a converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, peridontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
According to a first embodiment the present invention provides a compound of formula
O
R2 R3 R R9 II Y R12 X (C)n N R
R
io R 11
OH
I
to wherein:
R
1 is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C 4
-C
8 cycloheteroalkyl;
R
2 and R 3 are each, independently, hydrogen, alkyl or 1-6 carbon atoms, -CN, or -CCH;
R
7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms,
-C(O)RINR
5
R
6 -C(O)-ORI, -C(NH)-NH 2
R
5 and R 6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, aralkyl, heteroaryl, heteroaralkyl or -C 4 -Cs-cycloheteroalkyl; 20 R 8
R
9 Rio, and R 1 1 are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3- 6 carbon atoms, -C 4
-C
8 -cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2- 18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs Rs and R9, R9 and Rio, or Rio and RII, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C 4
-C
8 25 cycloheteroalkyl ring; R1 2 is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C 4
-C
8 cycloheteroalkyl, or alkyl of 1-6 carbon atoms; A is O, S, SO, S02, NR 7 or CH 2 X is O, S, SO, SO2, NR 7 or CH 2 s ,S OS2*m7*rC2 [I:\DAYLIB\LIBXX]0067.doc:NSS UW AMAMIDMI 1AMWOMMOMW I 111, k7i "AIVVvftlh w AFAT'FWi!4kie A dMi 1 WAI WNW Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof, said aryl being phenyl or naphthyl optionally mono- or di substituted; said heteroaryl being a 5-10 membered mono- or bicyclic aromatic ring having from 1-3 heteroatoms selected from N, NR 7 S and O optionally mono- or di- substituted; said aralkyl being aryl as defined herein and the alkyl portion has 1-3 carbon atoms, said heteroalkyl being heteroaryl as defined herein and the alkyl portion has 1-3 carbon atoms, said -C 4 -C8-cycloheteroalkyl being defined as optionally mono- or disubstituted:
-ON
K R7 NR7 K) K K K K
K
K KK
NR
7 Or or R wherein K is O, S or NR 7 and R 7 is as hereinbefore defined; and said alkyl, alkenyl, alkynyl, cycloalkyl groups being optionally mono or poly substituted; S* and said substituents being selected from: halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -OR 5 -CN, -COR 5 perfluoroalkyl of 1-4 carbon atoms, perfluoroalkyl of 1-4 carbon atoms, -CONR 5
R
6 -S(O)nR 5 OPO(ORs)OR 6
-PO(OR
5
)R
6
-OC(O)NR
5
R
6
-C(O)NR
5
OR
6
-COOR
5
-SO
3 H,
NR
5
R
6
-N[(CH
2 2 2
NR
5
-NR
5
COOR
6
-NR
5
COR
6
-SO
2
NR
5
R
6
-NO
2 -N(Rs)S0 2
R
6
NR
5
CONR
5 R6, -NRsC(=NR 6
)NRR
6 -NRsC(=NR 6 )N(S0 2
R
5
)R
6 25 NRsC(=N 6 )N(C=0R 5
)R
6 tetrazol-5-yl, -SO 2 NHCN, -SO 2
NHCONR
5 R phenyl, heteroaryl or C 4 -C 8 -cycloheteroalkyl; wherein -NR 5
R
6 may form a pyrrolidine, piperidine, morpholine, thiomorpholine, oxazolidine, thiazolidine, pyrazolidine, piperazine, or azetidine ring.
[I:\DAYLIB\LIBXX]0667.doc:NSS According to a second embodiment the present invention provides a process for preparing a compound of the first embodiment which comprises one of the following: a) reacting a compound of formula O0 R2 R3 R8
R
Iy \0 (C)n H
R
Rl wherein n, X, Y, A, RI, R 2
R
3
R
8 R9, Rio and R 1 are as defined in the first or a reactive derivative thereof, with a compound of formula
R
1 2
NHOH
wherein R12 is as defined in the first embodiment, to give a compound of formula I; or b) deprotecting a compound of formula: 0 R2 R3 R8 R
/\XA
X \A (C)n NR 12 0R 30 o R1 Ro R 11 wherein n, X, Y, A, RI, R 2 R3, Rg, R 9 Rio, R1 and R 12 are as defined in the first embodiment, and R 30 is a suitable protecting group such as t-butyl, benzyl, and 15 trialkylsilyl, to give a corresponding compound of formula I or c) cleaving a resin supported hydroxamate derivative containing the group 0
|R
8
R
9 R3 R2 -O-NH (C)n A/Y x Nx Ri R11 R, Rio •wherein n, X, Y, A, R 1 R2, R 3 Rg, R 9 Ri 0 and RI are as defined in the first embodiment 20 to give a compound of formula I wherein R12 is hydrogen; o or [I;\DAYLIB\UBXX]06067.doc:NSS -ill, I d) resolving a mixture racemate) of optically active isomers of a compound of formula I to isolate one enantiomer or diastereomer substantially free of the other enantiomer or diastereomers; or e) acidifying a basic compound of formula I with a pharmaceutically acceptable acid to give a pharmaceutically acceptable salt; or f) converting a compound of formula I having a reactive substituent group or site to a compound of formula I having a different substituent group or site.
According to a third embodiment the present invention provides a pharmaceutical composition comprising a compound of the first embodiment, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
According to a fourth embodiment the present invention provides the use of a compound according to the first embodiment in the preparation of a medicament for inhibiting pathological changes mediated by TNF-a converting enzyme (TACE) in a mammal.
According to a fifth embodiment the present invention provides a method of inhibiting pathological changes mediated by TNF-a converting enzyme (TACE) in a mammal said method comprising administration to said mammal of a therapeutically effective amount of a compound according to the first embodiment, or a pharmaceutical composition according to the third embodiment.
According to a sixth embodiment the present invention provides a compound according to the first embodiment, or a pharmaceutical composition according to the third embodiment when used for inhibiting pathological changes mediated by TNF-a *0 25 converting enzyme (TACE) in a mammal.
There is disclosed herein a group of compounds of general formula I: 0 O R2 R3 R R R 1 2 oX A (C)n N S: R Rio R 11
OH
wherein: [I:\DAYLIB\LIBXX]6067.doc:NSS 6d R, is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl. of 3-6 carbon atoms, or -C 4
-C
8 cycloheteroalkyl;
R
2 and R 3 are each, independently, hydrogen, alkyl or 1-6 carbon atoms, -CN, or -CCH;
R
7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms,
-C(O)-R
1 -S0 2 RI, -C(O)-NHIIR, -C(O)NR 5
R
6
-C(O)RINR
5
R
6 -C(O)-0R 1
-C(NH)-NH
2
R
5 and R 6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, aralkyl, heteroaryl, heteroaralkyl or -C 4
-C
8 -cycloheteroalkyl; [1:\DAYLIB\LIBXX]06067.doc:NSS ICIII VK06 WO 00/44723 PCT/US00/01864 -7- R R R and R are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl 8 9 10 11 of 3-6 carbon atoms, -C4-C8-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R8 and R9, R9 and R10 or R10 and R11, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C4-C8-cycloheteroalkyl ring;
R
1 2 is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C4-C8-cycloheteroalkyl, or alkyl of 1-6 carbon atoms; A is O, S, SO, SO,, NR,, or CH,; X is O, S, SO, SO,, NR,, or CH,; Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof.
In some preferred aspects of the invention, Y is phenyl, pyridyl, thienyl, furanyl, imidazolyl, triazolyl or thiadiazolyl, with the proviso that A and X are not bonded to adjacent atoms of Y.
In still other preferred embodiments of the invention Y is phenyl, thienyl or furanyl.
In accordance with certain preferred embodiments of the invention R. and R 9 together with the carbon atom to which they are attached form a C,-C 8 cycloheteroalkyl ring and K is NR The most preferred matrix metalloproteinase and TACE inhibiting compounds of this invention are: 1- (4-Bromo-benzyl)-4-(4-but-2-ynyxoy-benzenesulfonyl)-piperdine-4carboxylic acid hydroxyamide; 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1-(4-methoxy-benzyl)-piperdine-4carboxylic acid hydroxyamide;
TMEWWW
WO 00/44723 WO 0044723PCTIUSOO/01864 -8- 4 4 -But-2-ynyloxy-benzenesulfonyl)- I 4 -chloro-benzyl)-piperdine-4.
carboxylic acid hydroxyamide; I -Benzyl- 4 4 -but-2ynyoxybenzenesulfonyl)>piperdine-4carboxyic acid hydroxamide; 1-4Boobny)4(-et2yylx-eznsloy)pprie4 carboxylic acid hydroxyamide; l-( 4 -Bromo-benzyI)-4-(4-oct-2-ynyloxy-benzenesulfonyl)ypiperdine-4 carboxylic acid hydroxyamide; 4 4 -But-2-ynyloxy-benzenesulfonyl.. 1 4 -fluoro-benzyl)-piperdine-4carboxylic acid hydroxyamide; 4 -(4-But-2-ynyloxy-benzenesulfonyi)- 1 4 -cyano-benzyl)-piperidine-4carboxylic acid hydroxamide; 4 -(4-But-2-ynyloxy-benzenesulfonyl)- 1 4 -methyl-benzyl)-piperidine.4carboxylic acid hydroxamide; 4- (4-But-2-ynyloxy-benzenesulfonyl)- dichloro-benzyl)-piperidine-4 carboxylic acid hydroxamide; 1-( 4 -Bromo-benzyl)- 4 4 -prop-2-ynyloxy-benzenesulfonyl)..piperdine-4carboxylic acid hydroxyamide; I -(4-Bromo-benzyl)-4- 4 4 -piperdin-4-y-but-2-ynyloxy)-benzenesulfonyl] piperdine-4-carboxylic acid hydroxyamide; 1 -(4-Bromo-benzyl)-4- 4 4 -morpholin-4-y1-but-2-.ynyloxy)-benzene.
sulfonyl]-piperdine-4-carboxylic acid hydroxyamide; 4 4 -But- 2 -ynyloxy-phenylsulfany)4hydroxycarbamoy..piperidine- 1carboxylic acid tert-butyl ester; 4 4 -But- 2 -ynyloxy-phenysufany)-piperidne-4-.carboxylic acid hydroxyamide,
I-(
4 -Bromo-benzyl)- 4 4 -but-2-ynyloxy-phenysufany)piperidine-4 carboxylic acid hydroxyainide; 4 4 -But- 2 -ynyloxy-phenylsulfanylmethyl)-tetrahydropyran-4carboxylic acid hydroxyamide; -Y TT" WIVI WO 00/44723 WO 0044723PCTUSOO/O1 864 -9- 4 4 -But- 2 -ynyloxy-benzenesufonymethy)tetrahydropyrn4-caboxylic acid hydroxyamide; 4-(4Bt2yyoyb eesliymty)ttaydoprn4croyi acid hydroxyamide; 4 2 -butynyloxy)phenyl]sulfonyl)-Nhydroxytetrahydro.2H.pyrn4carboxamide; 1 -benzyl-4- -(2-butynyloxy)phenyl] sulfonyl)}-N-hydroxy-4-piperdine carboxanide; 4- 4 2 -butynyloxy)phenyl]sulfonyl} -N-hydroxy- I-isopropyl-4-piperidine carboxamide; 4- 4 2 -butynyloxy)phenyljsulfonyl)}-N-hydroxy- 1-(3 -pyridinylmethyl)-4piperidine carboxamide; 3 4 2 -Butynyloxy)phenyl] sulfonyl -I -ethyl-N-hydroxy-3 -piperidinecarboxamide; 3 [4-(2-butynyloxy)phenyl] sulfonyl -I -(4-chlorobenzyl)-N-hydroxy-3 piperidinecarboxamide; 4- f 4 -(2-Butynyloxy)phenyl] sulfonyl} I -[4-(2-pipenidin- 1 -yI-ethoxy)-benzyl]piperidine-4-carboxylic acid hydroxyamaide; 4 2 -Butynyloxy)phenyl]sulfonyl} -pentanyl)-piperidine-4-carboxylic acid hydroxyamide; ]-4Mtoybny)4(-rp2yyoybneeufnl-ieiie4 carboxylic acid hydroxyamide; 1-4Clr-ezl4(-rp2yyoybneeufnl-ieiie4croyi acid hydroxyamide; tert-butyl-4-( 4 -(2-butynyloxy)phenyl]sulfanyl }methyl)-4-[(hydroxyamino)carbonyl]- I -piperidinecarboxylate;- 4 -(But-2-ynyloxy)phenyl]tliioj methyl)-N-hydroxypiperidine-4.
carboxamide; tert-Butyl-4-( {[4-(2-butynyloxy)phenyl]sulfinyl }methyl)-4-[(hydroxyamino)carbonyl]- 1 -pip eridinecarboxylate; WO 00/44723 WO 0044723PCT/USOO/01864 4-[[[4-(2-Butynyloxy)phenyl]sulfinyl]methyl]-N-hydroxy-4-piperidinecarboxamide; tert-Butyl-4-( {[4-(but-2-ynyloxy)phenyl] sulfonyl }methyl)-4-[(hydroxyamnino)carbonyl]piperidine- 1 -carboxylate;tert-butyl-4-( {[4-(2-butynyloxy)phenyl] sulfonyl} methyl)-4-[(hydroxyamino)carbonyl]- I -piperidinecarboxylate; 1 -Acetyl-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-N-hydroxy-4piperidinecarboxamide; I -(2-Butynyl)-4-({ [4-(2-butynyloxy)phenyl]sulfonyl} methyl) -N-hydroxy-4piperidinecarboxamide hydrochloride; N-I -(tert-Butyl)-4-( {[4-(2-butynyloxy)phenyl] sulfonyl~methyl)-N-4-hydroxy- 1 ,4-[4-(2-butynyloxy)phenyl]sulfonyl }methyl)-N-4-hydroxy- 1,4-1] sulfonyl methyl)-N-4-hydroxy-1I,4-piperidinedicarboxamide; Methyl [4-(2-butynyloxy)phenyl]sulfonyl) methyl)-4-[(hydroxyamino)carbonyl]- 1 -piperidinecarboxylate; Benzyl [4-(2-butynyloxy)phenyl] sulfonyl)methyl)-4-[(hydroxyamino)carbonyl]- 1 -pip eridinecarboxylate; 1 -Benzyl-4-({ [4-(2-butynyloxy)phenyl] sulfonyl) methyl)-N-hydroxy-4butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy-4-piperidinecarboxamide; [4-(2-Butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy-l1-[(2,2,5-trimethyl- 1 ,3-dioxan-5-yl)carbonyl]-4-piperidinecarboxamide; {[4-(2-Butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy-l1-[3 -hydroxy-2- (hydroxymethyl)-2-methylpropanoyl] -4-pip eridinecarboxamide;, I -[Amino(imnino)methyl]-4-( {[4-(2-butynyloxy)phenyl]sulfonyllmethyl)-Nhydroxy-4-1]-4-({ [4-(2-butynyloxy)phenyl] sulfonyl }methyl)-N-hydroxy-4oxy)phenyl]sulfonyl) methyl)-N-hydroxy-4-piperidinecarboxaniide; [4-(2-Butynyloxy)phenyl]sulfonyl) methyl)-N-hydroxy- I -(4-hydroxy-2butynyl)- henyl] sulfonyl) methyl)-N-hydroxy-1I -(4-hydroxy-2-butynyl)-4piperidinecarboxamide; 2, 'A q 1 WO 00/44723PCUS/086 PCT/USOO/01864 -11- 4 -(But-2-ynyloxy)phenyl]sulfonyl }methyl)- 1 -ethyl-N-hydroxypiperidine- 4- carboxamide triflouroacetic acid salt; thiophene4-({ 4 -{But- 2 -ynyloxy)phenyl]-sulfonyl methyl)- -chlorothien-2-yl)methyl]-N- hydroxypiperidine-4-carboxarnjde triflouroacetic acid salt; 4 -(But- 2 -ynyloxy)phenyl~sulfonyl~methyl)Nhydroxy 1 -(pyridin-4ylmethyl)piperidine-4-carboxamide triflouroacetic acid salt; 4 -(But-2-ynyloxy)phenyl] sulfonyl) methyl)-N-hydroxy-l1-(pyridin-3 ylcarbonyl)piperidine-4-carboxamide triflouroacetic acid salt; 1 -Benzoyl-4-( 4 -(but-2-ynyloxy)pheny1]sulfonyl}methyl)-N-.hydroxypiperidine-4- carboxamide; 4 -(But-2-ynyloxy)phenyl]sulfonyl} methyl)-N-hydroxy-l1-(thien-2ylcarbonyl) piperidine-4-carboxamide; 4 -(But-2-ynyloxy)phenyl]sulfonyl~methyl)..N-l-ethyl-N-4-hydroxypiperidine-1I,4-dicarboxamide; 4 -(But- 2 -ynyloxy)phenylsulfonyl~methyl).N4hydroyN-.1- phenylpiperidine- 1 ,4-dicarboxamide; 4 -(But-2-ynyloxy)phenyl]sulfonyl~methyl).N 1 I -diethyl-N-4hydroxypiperidine- 1,4-dicarboxamide-, 4 -(But-2-ynyloxy)pheny]sulfonyl)methy)Nhydroxy- 1 -(morpholin-4ylcarbonyl)piperidine-4-carboxamide; 4 -(But- 2 -ynyloxy)phenyl]sulfony1)methyl)-N4hydrxyN.. I1-methyl-N- I phenylpiperidine- 1,4-dicarboxamide-, Octyl-4-({ [4-(but-2-ynyloxy)phenyl]sulfonyl )methyl)-4-[(hydroxyamino)carbonyl] piperidine- 1-carboxylate; 4-Methoxyphenyl4-({ 4 -(but- 2 -ynyloxy)phenyl]sulfony~methy).4-[(hydroxy,.
amnino) carbonyl]piperidine- 1-carboxylate;, 4 -(But- 2 -ynyloxy)phenyl]sulfonyllmethyl)Nhydroxy- I -(phenylsulfonyl) piperidine-4-carboxamnide; 4 -(But-2-ynyloxy)phenyl]sulfonyl )methyl)-N-hydroxy- I -[(1-methyl- I Hin ao--lsloy~ieiie4croaie WO 00/44723PCISOI86 PCT/USOO/01864 -12- I -[2-(Benzylamino)acetyl]-4-( {[4-(but-2-ynyloxy)phenyl]-sulfonyl }methyl)-Nhydroxypiperidine-4-carboxamide; [4-(But-2-ynyloxy)phenyllsulfonyl~methyl)-N-hydroxy- 1 -(2-morpholin-4ylacetyl)piperidine-4-carboxamide; [4-(But-2-ynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy- I -[2-(4-methylpiperazin- I -yl)acetyl]piperidine-4-carboxamide; I -Acetyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide; I -Benzoyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide; I -(4-Methoxybenzoyl)-4-(4-but-2-ynyloxy benzenesulfonyl)piperidine-4carboxylic acid hydroxamide; 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy- I -(pyrrolidine- I -carbonyl)-4piperidinecarboxamide; Ethyl 4-(4-but-2-ynyloxybenzenesulfonyl)-4-[(hydroxyamino)carbonyl]- 1piperidinecarboxylate; 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy- 1 -[(trifluoromethyl)sulfonyl]- 4- piperidinecarboxamide; 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy-l1-(3-pyridinylcarbonyl)- 4piperidinecarboxamide; 4-(4-but-2-ynyloxybenzenesulfonyl)-N-hydroxy-1I-(2-thienylcarbonyl)- 4piperidinecarboxamide; 4-(4-but-2-ynyloxybenzenesulfonyl)-N-hydroxy- 1 -1(4-methoxyphenyl)sulfonyl]-4-piperidinecarboxamide; 4-(4-but-2-ynyloxybenzenesulfonyl)-N-hydroxy- I 5-trimethyl- I ,3-dioxan- 5-yl)carbonyl]-4-piperidinecarboxamide; Tert-butyl-4- [4-(2-butynyloxy)phenyl]sulfonyl )-4-[(hydroxyami no)carbonyl]- I -piperidinecarboxalate; 4- {[4-(2-butynyloxy)phenyl]sulfonyl )-N-hydroxy-4-piperidinecarboxamide hydrochloride; lh WkAll iAltl A" yfi&WA WI 6 SV Ahek%,', WO 00/44723 WO 0044723PCTIUSOO/01864 -13- Methyl 4- {[4-(2-butynyloxy)phenylsulfonyl)}-4-[(hydroxyamino)carbonyl]- I -piperidinyl }methyl)benzo ate hydrochloride; {[4-(2-butynyloxy)phenyl] sulfonyll -4-[(hydroxyamino)carbonyl]- 1piperidinyl) methyl)benzoic acid hydrochloride; 1 -[4-(Aminocarbonyl)benzyl] {[4-(2-butynyloxy)phenyl]sulfonyl} -Nhydroxy-4-piperidinecarboxamide hydrochloride; Tert-butyl 4- {[4-(but-2-ynyloxy)phenyl]sulfinyl }-4-[(hydroxyamino)carbonyl]piperidine- I -carboxalate;- 4-(4-(But-2-ynyloxy-benzenesulfinyl)-piperidine-4-carboxylic acid hydroxamide hydrochloride; and 1 -(4-Bromo-benzyl)-4-(4-But-2-ynyloxy-benzenesulfinyl)-piperidine-4carboxylic acid hydroxanide hydrochloride; and pharmaceutical salts thereof.
Heteroaryl, as used throughout, is a 5-10 membered mono- or bicycdic aromatic ring having from 1-3 heteroatoms selected from N, NR7, S and 0.
Heteroaryl is preferably co F- n, k'.7Y R7 R7
N
RAHNM
WO 00/44723 WO 0044723PCTIUSOO/O1 864 -14wherein K is defined as 0, S or and R 7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(0)-R 1 -S0 2 -C(0)NRR 6
C(O)R
1 NR 5
R
6 -C(0)-0R 1
-C(NH)-NH
2 Preferred heteroaryl rings include pyrrole, furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine, triazole, pyrazole, imidazole, isothiazole, thiazole, isoxazole, oxazole, indole, isoindole, benzofuran, benzothiophene, quinoline, isoquinoline, quinoxaline, quinazoline, benzotriazole, indazole, benzimidazole, benzothiazole, benzisoxazole, and benzoxazole. Heteroaryl groups of the present invention may be mono or disubstituted.
-C4-C8-cycloheteroalcyl is defined as 4-)~Q 4 K R7 KK
KK
IPJ ,or K n-_N wherein K is 0, S or NR7 and R7 is as defined before. Preferred heterocycloalkyl rings include piperidine, piperazine, morpholine, tetrahydropyran, tetrahydrofuran or pyrrolidine. Heterocycloalkyl groups of the present invention may optionally be mono- or disubstituted.
WO 00/44723 PCT/USOO/01864 Aryl, as used herein refers to phenyl or naphthyl aromatic rings which may, optionally be mono- or di- substituted.
Alkyl, alkenyl, alkynyl, and perfluoroalkyl include both straight chain as well as branched moieties. Alkyl, alkenyl, alkynyl, and cycloalkyl groups may be unsubstituted (carbons bonded to hydrogen, or other carbons in the chain or ring) or may be mono- or poly-substituted.
Aralkyl as used herein refers to a substituted alkyl group, -alkyl-aryl, wherein alkyl is lower alkyl and preferably from 1-3 carbon atoms, and aryl is as previously defined.
Heteroaralkyl as used herein refers to a substituted alkyl group, alkylheteroaryl wherein alkyl is lower alkyl and preferably from 1-3 carbon atoms, and heteroaryl is as previously defined.
Halogen means bromine, chlorine, fluorine, and iodine.
Suitable substituents of aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, alkenyl, alkynyl and cycloalkyl include, but are not limited to halogen, alkyl of 1-6 carbon atoms; alkenyl of 2-6 carbon atoms; alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -OR, -CN, -COR,, perfluoroalkyl of 1-4 carbon atoms, -O-perfluoroalkyl of 1-4 carbon atoms, -CONR,R 6 -S(O)nR,, -OPO(OR)OR, -OC(0)OR,, -ORNRR -OC(O)NRR 6
-C(O)NR,OR
6 -COOR,, -SO 3 H, -NRR,, -N[(CH 2
-NR
5
COR,,
-NRCOOR, -SO 2 NRsR 6 -NO, -N(R,)SO,R 6
-NR,CONR,
R
-NRC(=NR,)NRR,, -NRC(=NR,)N(S02R,)R, -NRC(=NR,)N(C=0R,)R
-SO
2 NHCN, -SO2NHCONR 5
R
6 phenyl, heteroaryl or -C 4
-C
8 cycloheteroalkyl; wherein -NR,R, may form a pyrrolidine, piperidine, morpholine, thiomorpholine, oxazolidine, thiazolidine, pyrazolidine, piperazine, or azetidine ring; ~i.X WO 00/44723 PCT/US00/01864 -16- R and R 6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, aralkyl, heteroaryl, heteroaralkyl or -C4-C8cycloheteroalkyl; R, is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms or cycloalkyl of 3-6 carbon atoms,
-C(NH)-NH,;
and n is 0-2.
When a moiety contains more than one substituent with the same designation each of those substituents may be the same or different.
Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety. Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains an acidic moiety.
The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. It is recognized that one optical isomer, including diastereomer and enantiomer, or stereoisomer may have favorable properties over the other. Thus when disclosing and claiming the invention, when one racemic mixture is disclosed, it is clearly contemplated that both optical isomers, including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well.
"rt l WO 00/44723 PCT/USOO/01864 -17- The compounds of this invention are shown to inhibit the enzymes MMP-1, MMP-9, MMP-13 and TNF-a converting enzyme (TACE) and are therefore useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, graft rejection, insulin resistance, bone disease and HIV infection. In particular, the compounds of the invention provide enhanced levels of inhibition of the activity of TACE in vitro and in cellular assay and/or enhanced selectivity over MMP-1 and are thus particularly useful in the treatment of diseases mediated by TNF.
Also according to the present invention, there are provided processes for producing the compounds of the present invention, which processes comprise one of the following: a) reacting a compound of formula 0
R
2 R3 R 8
R
9 X C)n
OH
R oR 1 wherein n, X, Y, A, R 1
R
2
R
3 R8, R 9 Ro, and R 11 are as defined above or a reactive derivative thereof, with a compound of formula
R
12
-NHOH
wherein R 1 2 is as defined above, to give a compound of formula I; or b) deprotecting a compound of formula: Y0 R2 R3 R8 R9 I x C NR12OR:30 R1o/ Rl1 WO 00/44723 PCT/USOO/01864 -18wherein n, X, Y, A, R, R, and R, 2 are defined above, and is a suitable protecting group such as t-butyl, benzyl, and trialkylsilyl, to give a corresponding compound of formula I or c) cleaving a resin supported hydroxamate derivative containing the group
O
R8 R 9 R3 R2 lR, RiO R11 wherein n, X, Y, A, R R R R, R, and RI,, are defined above to give a compound of formula I; or d) resolving a mixture racemate) of optically active isomers of a compound of formula I to isolate one enantiomer or diastereomer substantially free of the other enantiomer or diastereomers; or e) acidifying a basic compound of formula I with a pharmaceutically acceptable acid to give a pharmaceutically acceptable salt; or f) converting a compound of formula I having a reactive substituent group or site to a compound of formula I having a different substituent group or site.
With regard to process a) the reaction can be carried out by processes known in the art, e.g. by reaction of an acid chloride or mixed anhydride reactive derivative with the compound of formula R,,NHOH.
~r r U;IUY ~YiYt~~~l:jy~i~WI~1~~~ WO 00/44723 PCT/US00/01864 -19- Removal of protecting groups, as illustrated by process b) can be carried out by processes known in the art to provide the hydroxamic acid, -see for example Scheme 16 below.
Process c) may be carried using a strong acid such as TFA to cleave the hydroxamate from the resin.
With regard to process d) standard separation techniques may be used to isolate particular enantiomeric or diastereomeric forms. For example a racemic mixture may be converted to a mixture of optically active diastereoisomers by reaction with a single enantiomer of a 'resolving agent' (for example by diastereomeric salt formation or formation of a covalent bond). The resulting mixture of optically active diastereoisomers may be separated by standard techniques (e.g.
crystallisation or chromatography) and individual optically active diastereoisomers then treated to remove the 'resolving agent' thereby releasing the single enantiomer of the compound of the invention. Chiral chromatography (using a chiral support, eluent or ion pairing agent) may also be used to separate enantiomeric mixtures directly.
The compounds of formula I may be isolated in the form of a salt of a pharmaceutically acceptable acid e.g. an organic or inorganic acid by treatment with an acid such as described above.
With regard to process e) compounds of formula I having a reactive substituent group such as hydroxy or amino or site such as can be converted to other compounds of formula I in known manner, e.g. alcohol to ester or ether.
Reactive sites such as a sulfur atom can be oxidized to SO or SO,. as shown in Scheme 4 below). If necessary reactive substituent groups may be protected during the synthesis of compounds of formula I and removed as a last step -see Schemes 4 and 17 below.
*a~r r ri*, I-\,ii ri u il. ihl. 1I.*II1 .l)ll WO 00/44723 PCT/US00/01864 PROCESS OF THE INVENTION.
The compounds of the present invention may be conveniently prepared according to one of the general processes outlined below.
The compounds of the present invention, where n 0, X O, S or NR 7 and R" and R 9 taken with the carbon atom to which they are attached, form a six membered heterocyclic ring containing N-R 7 S or O and A S, SO or SO 2 may be prepared according to one of the general processes outlined below.
As outlined in scheme 1, the appropriately substituted mercaptan derivative was alkylated using o-bromo acetic acid ester derivative in refluxing chloroform using N,N-diisopropylethylamine as base. The sulfide derivative thus obtained was reacted with appropriately substituted propargyl bromide derivative in refluxing acetone using K 2 CO, as base. In the case of X=-N-R 7 the N-alkylation can be carried out in DMF/NaH at room temperature. The sulfide derivative thus obtained was oxidized using m-chloroperbenzoic acid in CH 2 C1l or by using Oxone in methanol/ water. The sulfone thus obtained can be converted to the corresponding piperidine derivative by reacting it with bis(2-chloroethyl)N-substituted amine derivative.
WO 00/44723 WO 0044723PCTUSOO/01864 -21- SCHEME I
SYNTHESIS:
x i NI
SH
X= OH, SH, NHR 7
A=S
B r- 0 x t 0
C
e a. Diisopropylethyamine/ CHC1 3 RT/ 3 Hr; b. K 2 C0 3 Acetone/ Prpargyl bromide derivative; c. Oxone/ MeOH:THF/THF/ RT; d: K 2 C0 3 I 8-Crown-6/
(C
4
H
9 4 NBr/ Acetone/Bis-2..chloroethyl N-subs tituted amine derivative! Reflux; e: NaOWV THF:MeOWjRT and (COCI)j NH 2 OH.HCII Et 3 N/ THF/ DMF.
Bis-2-chloroethyl N-substituted amines can be prepared from the substituted diethanolamine and thionyl chloride. (Scheme The cyclic product obtained by the above mentioned operation, can be hydrolyzed to carboxylic acid and subsequently converted to the hydroxan-ic acid as outlined in scheme 1.
WO 00/44723 PTUO/16 PCT/USOO/01864 -22- SCHEME 2 HOf OH a HOfROH b o Cif N>,C a: Diisopropylethylamine/R 7 Br/CHC 3 Reflux; b: SOCI] Reflux The corresponding sulfides and sulfoxides can be prepared starting from the corresponding saturated heterocyclic carboxylic acid derivative. (Scheme-3). N-Boc protected isonipecotic acid can be lithiated using tert-butyllithium and the resulting anion was reacted with appropriately substituted disufides. The sufide derivative can be converted to hydroxamic acids by the procedure outlined above.
SCHEME:3
COOH
a II 1 S
COOH
b
'CONHOH
IHOH
a: tert-Butyllithium/-7 8 0 C1 THF/Bis(4-but-2-ynyloxyphenyl)disufide; b: (COC1)/
NH
2 OH. CL'Et 3 N/DMF/CH.Cl, c: 1 .HC]I Dioxane; c: 2:R 7 BrI Et 3 N; d: MeOI3O% H 20 2 These sulfides subsequently can be converted to the sulfoxides using hydrogen peroxide at room temperature. The required disulfides can be prepared from the appropriately substituted thiol and DMSO/HCl oxidation. This procedure can be applied to any saturated, fused or non-fused heterocyclic carboxylic acid derivative. Scheme 4 shows procedure for related compounds.
SCHEME:4
,.COOH
-C
e r* a: tert-Butyllithiuml/-78*C/ THFfBis(4-but-2-ynyloxyphenyl)disufide; b: (COCI)2I 10 NH2OH.HClfEt 3
N/DMF/CH
2
C
2
::CH
2 ClJ HCl/ MeOH RBr/ Et 3 N; d: McOIV3O% H-202; e: Oxone/MeOH/THF/Rt.
Alternatively, sulfone derivatives can also be lithiated and carbonylkted using either dry ice or C0 2 gas. (Scheme The sulfone derivative can be a mono I TIMAILIM A- W 8MMU01-1; ANAMMU IF04 heterocyclic, bicyclic benzo fused or hetero aryl such as pyridyl, thienyl, furanyl, pyrazinyl, pyrimidyl, thiazolyl fused ring systems.
i~l x- 0 0 baRz S n-Butyllithiumn and quench with CO 2 (COCl) 2
/DMF/NH
2 OH.HCI/ EtN The oxygen analogue can be prepared (Scheme 6) from the appropriately substituted alkynyloxy-benzenesulfonyl aectic acid ethyl ester and 2-chioroethyl ether.
The corresponding pyran derivative can be hydrolyzed to carboxylic acid, which can be converted to the hydroxamic acid derivative.
Go% SCH*EME 6 0 C 2H5 CO0C2H 00 0, I b so.
C
GosCONHOH S COOH .0 0 o 1 a: 2-Chioroethyl ether! K 2 C0 3 /l 8-Crown-6/n-(C 4
H
9 4 Br/Acetone! Reflux;.
15 b: I ON. NaOIIITHFJMeQH!RT; 000.00C:(COCl)2/DMF/NH 2 OH.HCl/Et 3
N.
!I'm Omw?" awh' We WO 00/44723 PCT/US00/01864 The thiols used as intermediates for the synthesis of compounds of the invention can be made according to Scheme 7. Thus, sulfonic acid salts 1, where XR.o is a hydroxy, thiol or substituted amino moiety may be alkylated with acetylenes 2, where J is a suitable leaving group such as halogen mesylate, tosylate, or triflate to give 3. Acetylenes 2 are commercially available or known compounds, or they may be synthesized by known methods by those skilled in the art. The sulfonic acid salts 3 may be converted into the corresponding sulfonyl chloride or other sulfonylating agent 4 by known methods, such as reaction with oxalyl chloride, phosphorus oxychloride or other reagent compatible with substituents R, and R 3 and the acetylene. The sulfonyl chloride 4 can then be reduced to the corresponding thiol using triphenylphosphine in a suitable solvent mixture such as dichloromethane/DMF at a temperature of between -20°C and 30 0
C.
4M-- WO 00/44723 PCT/US00/01864 -26- SCHEME 7 Na+ R 1--L Q R2 X ONa S3Na Na 1 2 RI 3 RsoX- -S-S-L-XRso 6
I
R1 Ri
'V
R2-S4
R
1
RSH
4 R1 2 Ri 9 50
XH
12
CISO
3 H R 3 R S 0 3
H
Ri
R
1
H
I
XH
11 Alternatively, disulfide 6 may be converted into di-acetylene 7 by reaction with compounds 2, followed by reduction of the disulfide bond to provide the desired thiols 5. Bisacetylenes 7 may also be converted into thiols 5 via sulfonyl chlorides 4.
Alkylation of the phenol, thiophenol, aniline or protected aniline 8 with 2 to give 9, followed by reaction with chlorosulfonic acid provides sulfonic acids 10 which are readily converted into 4 with oxalyl chloride or similar reagents and subsequently WO 00/44723 PCTUSOO/01 864 -27reduced to thiols 5. Thiophenols 11 are also precursors to 5 via protection of the thiol with a triphenylmethyl or other suitable protecting group, alkylation of XH, where X is 0, N or S, and deprotection of the sulfur.
Scheme 8:
XH
AH
14 R2 7--=-Rj
R
3 2
K
2
CO
3
RZL~
AH
+OK
Rit
R
R2
R
16 0 COOR30 R,
R
11 2
R
1 R
CONHOH
R9 CO0R~
AH
19 XR2 2OOR30 20 R9
XH
.*-I11 C00R 3 21 Rg 0K Ri
XH
b 16/17 SA C 11-1-IM-PT 11 1.1 1 d o* -OVAY&'W WO 00/44723 PCT/USOO/01864 -28- Compounds of the invention wherein X is N, O, S, SO or SO 2 can be synthesized according to Scheme 8 and Scheme 9. Alkylation of the paradisubstituted aryl 14, or its protected equivalent, with acetylene 2 in the presence of a base such as potassium carbonate in a polar aprotic solvent such as acetone or DMF at a temperature of between 20 0 C and 120 0 C provides the mono-propargylic ether Those skilled in the art will recognize that protecting groups may be required to avoid undesirable side reactions and increase the yield of the reaction. The need and choice of protecting group for a particular reaction is known to those skilled in the art.
Reaction of this compound with *-propiolactone, or a substituted propiolactone derivative (wherein the substituents are defined as before), in the presence of a base such as potassium t-butoxide in a polar solvent, or solvent mixture, such as THF or DMF affords the carboxylic acid 16. Conversion of carboxylic acid 16 into the corresponding hydroxamic acid, 17, is accomplished via formation of an activated ester derivative such as an acid chloride or acid anhydride followed by reaction with hydroxylamine. It is understood by those skilled in the art that when A is sulfur, in Scheme 8 and all relevant subsequent Schemes, the sulfur can be oxidized to the corresponding sulfoxide or sulfone at any stage after formation of the thioether, using a suitable oxidant such as oxone, air, m-chloroperbenzoic acid or hydrogen peroxide.
Compounds 18 are also accessible from the Michael addition of compound to a cyclic acrylate ester, or substituted acrylate ester (substituents are defined as before), to provide 18, in which Ro is hydrogen or a suitable carboxylic acid protecting group. Deprotection of the ester moiety then provides carboxylic acid, which can be converted into the analogous hydroxamic acid. Similarly, Michael addition of mono-protected 1,4-disubstituted aryl 19, where XR, is hydroxy or protected hydroxy, thiol or amine, gives compound 20. Unmasking of the protecting group gives thiol, aniline or phenol 21 which can be alkylated with propargyl derivative 2 to provide 18. Mono protected compound 19 can also be reacted with (3-propionolactone to provide 22. Alternatively, 22 can be deprotected followed by alkylation to give 16 and 17.
i l-r i ;a i 1 WO 00/44723 PCT/US00/01864 -29- Synthesis of compounds of the invention wherein X is N, O, S, SO or SO and the linker between the proximal heteroatom and the hydroxamic acid is a one or three carbon chain can be synthesized according to Scheme 9. Compound 19, where
XR
2 is hydroxy or protected hydroxy, thiol or amine, can react with ester 24 or lactone 24a, in which R 3 is hydrogen or a suitable carboxylic acid protecting group, with an appropriately substituted leaving group such as halogen, tosylate, mesylate or triflate, to provide 25. Unmasking of the heteroatom X of compound 25 then provides 26, which may next be alkylated with propargylic derivative 2 to give acetylene-ester 27. Ester 27 can be converted into the corresponding hydroxamic acid 28 through conversion of the ester into the carboxylic acid by acid or base hydrolysis, followed by conversion into the hydroxamic acid as described in Scheme 1. Alternatively, compound 15, prepared as shown in Scheme 8, can be alkylated directly with ester 24 or lactone 24a to give 27 and then 28. Substituents on the carbon alpha to the hydroxamic are defined as before.
SCHEME 9 R~n 11 XHR25 XH 24 Deprotect 24 SBase RPjpj AHBase A P1 R11
A
AH or 1' COOR 3
COOR
3 0 19 R26 Ril to2 0~c
R
2 24a R3 (for A S) R2 ~101 A/C 1NHOH
CR
3 0 28 27 11 o ro J%.IXCOO or R 1 0 Base I 24a (for A S)
R
R3 R2~
AH
Compounds of the invention wherein A is a methylene or substituted 0. 5 methylene group, and X is oxygen, can be obtained according to Scheme 10. Esters or carboxylic acids 29, commercially available or known in the literature, can be 04 0converted into the corresponding phenols, 30. Alkylation of the phenol with acetylene 2 gives the propargylic ethers, 31, which can be converted into the corresponding carboxylic acids and thence the hydroxamic acids, 33, as described in Scheme 1.
10 Substituents on the carbon alpha to the hydroxamic, are defined as before.
Wr TWiTy!V V Who "IMVA't' SCHEME H
R
a'o 1v 0i R.R~ R 3
R
1 ~Y COORxn I COOR 29 30RI 3 RI4 R~ K~ CONHOH -IJCOOH 33 32 Compounds of the invention wherein A is -S02-, and Rs and R 9 are not hydrogen, are available starting from 4-fluorobenzenethiol 34 as shown in Scheme 11.
Deprotonation of the thiol followed by reaction with 0-propiolactone, or an acrylate ester, or ester deriavtive 24, and subsequent oxidation of the resulting thioether provides sulfone-acid 35. Displacement of the 4-fluoro substituent of 35, or its corresponding ester, with propargyl derivative 36, wherein X is N, 0 or S, then provides sulfone 16. Compound 16 can be converted into the compounds' of the .~.invention according to Scheme 1. Fluoroaryl 35 can also react with a masked hydroxyl, thiol or amino group (HXR 4 o, wherein R40 is a suitable protecting group) in the presencc of a base such as sodium hydride in a polar aprotic solvent such as DMI to provide 36. Deprotection of 36 followed by alkylation with acetylenic derivative 2 then gives 16.
-32- SCHEME 11
F
Y
SH
34 1) Base 1p-proplolactone or acrylate or 24.
2) OxIdatdon 10R1 0~.~1 C0 2
F
R336
HXR
4 0 Base
Y
RA-=-Ri
R
3 2 Deprotect
XH
Ri R 1 1 02S-,XOR 0* Compounds of the invention wherein X is NH are also available starting from the. appropriate commercially available nitro aiyi compound 38 (Scheme 12).Thus, the anion of compound 38 can be used to alkylate P-propiolactone, or a substituted derivative, or a cyclic acrylate ester to provide 40 and 39 respectively. Reduction of the nitro group followed by alicylation of the resulting aniline then gives 16.
Compound 38 can also be alkylated with ester derivative 24 to afford nitro-ester followed by reduction .to give the corresponding aniline, analogous to compound 26 of Scheme 9.
0.00 0000 0 I 11-' SCHEME 12 N0 2
Y
AH
38 &0 2
R
3 0 Base N402 6i 1) Redudton 2)RA
=R
R
3 2 R2
R
3 x
I
1 J)Rio A 7-C2 16 C00R 3 o
NO
2
NH
2 ~IIRIIi IA &COO3 Base or Rilf THIS PAGE IS INTENTIONALLY LEFT BLANK [I:\DAYLlB\LlBXX]06067.doc:NSS
X
Compounds described in the present invention (from Example 30 to 63) were prepared as per the Schemes 15 and Scheme 16. In scheme 15, the t-Bod-protected ethyl isonipecotate 51 was carefully alkylated using dijodomethane to yield the monoiodo compound 52. This was subsequently converted to different hydroxamlic acid derivatives as depicted in Scheme 15. In scheme 16, the N-Boc group was selectively removed using TMSOTf/ 2,6-Lutidine. After the derivatisation of the nitrogen, the O-tBu was removed using TFA in methylene chloride.
r" 1 .1 I I I I I I I I I'll I I I I. I I I I I 11 11 1 1 1 I 11 M '40 e t I A- 0 ARIMO WO 00/44723 WO 0044723PCTUSOO/Oi 864 -36- Scheme 1 j~ySONaH HO B r, (COCI)2 CH2CI2
DMF
I I ys 0 2 C1
SN
PPh3 Oa
S
DMF
COQEt
N
BOC
COOEt COQEt KJ (BOC)20
LDA
N N 2
CH
2 1 2 H t OCL kNHOH 1. NaOH/MeOH/THF 2.EDCIHOBTINH 2
ON
N 3.HCI R BOC
R=H
130% H 2 0 2 I Oxne NaOHIMeOHITNF 2.EDCIHOBTINH 2
ON
3.HCI 1. CI 2.RX, RCOX,RNCO, ROCOX 3. NaOHIMeOHrrHF 4. EDCJHOBT/NH 2 ON R=
O
R=H
WO 00/44723 WO 0044723PCT/USOO/01864 -37- Scheme 16
CO
2 Et
BOC
1. NaOH/MeOHITHF C2H
N
BOC
\\\\"-0'Cka20 1 EDC/HOBT/NH 2 OtBU L CONHOtB, I.RX, RCOX,RNCO, ROCOX TMSOTf 2,6-Lutidine TFAI CH 2
CI
2 Alternatively, compounds wherein A S02 and n 0) described in examples 64 to 74 and 80 were prepared as depicted in Scheme 17.
WO 00/44723 PCT/USOO/01 864 Scheme 17 COOMe
N
IBOC
LDN/ 78 0 C S0 2
F
NaOH/ MeOH/THF 1. HCI/MeOH 2. RXI Et 3
N
HOHN
1. HCi/MeOH 2. RX/ Et 3
N
l.NaOH/ MeOHITHF 2.EDC,HOBTNH 2 0H WO 00/44723 PCT/US00/01864 -39- Example 1 1-(4-Bromo-benzyl)-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperdine- 4-carboxylic acid hydroxyamide Step 1: To a stirred solution of 4-mercapto phenol (12.6 g. 100 mmol) and N,Ndiisopropylethylamine (13.0 g, 100 mmol) in chloroform (200 ml), ethyl bromoacetate (17.0 g, 100 mmol) in chloroform (30 ml) solution was added slowly at room temperature. After the addition was complete, the reaction mixture was refluxed for 1 hr and cooled to room temperature. The reaction mixture was washed well with water, dried over anhydrous MgSO; filtered and concentrated. The oily product obtained was taken to next step without purification.
Step 2: A mixture of KCO, (15 gm, excess), (4-hydroxy-phenylsulfanyl)-acetic acid ethyl ester (5 g, 23.6 mmol) and 1-bromo-2-butyne (9.34 g, 35.4 mmol) was refluxed with stirring for 8 hrs. The reaction mixture was then cooled to room temperature and filtered. The filtrate was concentrated and extracted with chloroform. The chloroform layer was washed with water, dried over anhydrous MgSO filtered and concentrated. The product obtained was taken to next step with out purification. Yield g yellow oil; MS: 264.0 El Step 3: To a stirred solution of (4-but-2-ynyloxy-phenyl sulfanyl)-acetic acid ethyl ester (101 g, 380 mmol) in MeOH: THF (1000 ml), Oxone (670.0 g, excess) in water (1000 ml) was added at room temperature. The reaction mixture was stirred at room temperature for 8 hrs. The reaction mixture was then diluted with chloroform (600 ml) and filtered. The organic layer was separated and washed once with a saturated solution of NaHSO, (400 ml). The chloroform layer was washed well with water, dried and concentrated. The oily product was dissolved in MeOH (100 ml) y~u mvuai~w~~iu~ R~l~ iFl~ XIII "I AWrU, W~iO~h~i~ ~il WO 00/44723 PCT/US00/01864 and hexane (600 ml) was added. The separated colorless solid was filtered and washed with hexane. Yield 108 g mp. 91 93°C; MS: 297 Step 4: A mixture of diethanolamine (22.5 g, 150 mmol), 4-bromobenzyl bromide g, 100 mml) and N,N-diisopropylethylamine (19.0 g, 150 mmol) was refluxed for 24 hrs in chloroform (500 ml) solution. The reaction mixture was then concentrated and the residue was extracted with chloroform. It was washed well with water, dried over anhydrous MgSO,, filtered and concentrated. The crude product obtained was taken to next step with out purification. Yield 33.6 g Yellow oil, MS: 273.8 Step 2-[(4-Bromobenzyl)-(2-hydroxy-ethyl)-amino]-ethanol (33.28 g, 122 mmol) was dissolved in methanolic hydrogen chloride (100 ml) at 0° C. Methanol was removed in vacuo and the hydrochloride salt was suspended in CHCl 2 300 ml). To a stirred solution of the above mentioned suspension, thionyl chloride (30 g, excess) was added slowly at room temperature. The reaction mixture was brought to gentle reflux for 3 hrs. The reaction mixture was then concentrated and the (4-bromobenzyl)-bis-(2-chloro-ethyl)-amine was used in the next step with out purification.
Yield: 47 g brown solid; mp 125" C; MS: 309.8 Step 6: A stirred mixture of anhydrous KCO 3 10 g, excess), 18-crown-6 (1 g), tetrabutylammonium bromide (1.0 (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (2.8 g, 9.46 mmol) and (4-bromo-benzyl)-bis-(2-chloro-ethyl)-amine (4.9 g, 14.2 mmol) in anhydrous acetone (200 ml) was refluxed for 24 hrs. The reaction mixture was then cooled and filtered and the filtrate was concentrated. The crude product was extracted with chloroform, washed well with water, dried and concentrated. The brown colored material was purified by column chromatography i MKIZOWIM WO 00/44723 PCT/US00/01864 -41on silica gel by eluting with 50% ethylacetate hexane. Yield 1.36 g brown oil; MS: 534 Step 7: 1-( 4 -Bromo-benzyl)-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperdine-4carboxylic acid was prepared starting from 1-( 4 -bromo-benzyl)-4-(4-but-2-ynyloxybenzenesulfonyl)-piperdine-4-carboxylic acid ethyl ester (1.36 g, 2.54 mmol) dissolved in THF:methanol (100: 50 ml) and 10 N NaOH (15 ml). The reaction mixture was stirred at room temperature for 24 hrs. The reaction mixture was then concentrated and residue was cooled and neutralized with concentrated HC1. The separated solid was extracted with chloroform:methanol (300 ml) and washed with water. The chloroform layer was dried and concentrated. The product was crystallized from methanol. Yield 800 mg off white solid; mp 197 MS: 507.9 Step 8: To a stirred solution of 1-( 4 -bromo-benzyl)-4-(4-but-2-ynyxoy-benzenesulfonyl)-piperdine-4-carboxylic acid (750 mg, 1.5 mmol) and DMF (1 ml) in CHC1, (100 ml), oxalyl chloride (508 mg, 4.0 mmol) in methylene chloride (2 ml) was added dropwise at 0° C. After the addition, the reaction mixture was warmed to room temperature and stirred for 1 hr. The acid chloride thus formed was concentrated to remove excess oxalyl chloride and redissolved in CHCI, (30 ml). In a separate flask, hydroxylamine hydrochloride (690 mg, 10 mmol) was dissolved in DMF (10 ml) and triethylamine (10 g, 10 mmol) was added. The reaction mixture was further diluted with acetonitrile (25 ml) and stirred at 0° C. The acid chloride was slowly added into the hydroxylamine and after the addition was complete, the reaction mixture was brought to room temperature and stirred for 24 hrs. The reaction mixture was concentrated and the residue was extracted with chloroform, washed well with water and dried over anhydrous Na 2
SO
4 The product was purified by silica gel column chromatography by eluting it with 10% methanol:ethyl acetate. 270 mg of 1-(4bromo-benzyl)-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperdine-4-carboxylic acid V I 1-MAM_. WO 00/44723PCIS/I86 PCT/USOO/01864 -42hydroxyamnide was isolated as a hydrochloride salt, a white powder. Yield 52%; mp 153 MS: 522.9 'H NMR (300 MHz, DMSO-d,): 5 1.85 J=2.04 Hz, 3H), 2.23 (in, 2H), 2.49 (in, 2H4), 2.83 (in, 2H), 3.36 (mn, 2H), 4.28 2H) 4.89 (d, J=2.2 Hz, 2H), 7.18 J= 9 Hz, 2H), 7.47 J=8.1 Hz, 2H), 7.68 (in, 4H), 9.37 (s, 1H), 10.25 1H) Example 2 4-(4-But-2-ynyloxy-benzenesulfonyl)-1-(4-methoxy-benzyl)-piperdine- 4-carboxylic acid hydroxyamide 2- [(2-Hydroxy-ethyl)- (4-methoxy-benzyl)-aminol-ethanol was prepared according to the general method as outlined in Example 1 (Step Starting from diethanolamine 10.5g, lO0inmol). and 4-inethoxy benzyl chloride 15.6g, 100 minol). Yield 21g, yellow oil; MS: 226 Bis-(2-chloro-ethyl)-(4-methoxy-benzyl)-amine was prepared according to the general method as outlined in Example 1 (Step Starting from 2-1(2-hydroxyethyl)-(4-methoxy-benzyl)-ainino] -ethanol (11.2 g, 50mmol). Yield 14g, 99%); dark brown low melting solid; MS: 263 4-(4-but-2-ynyloxy-benzenesulfonyl)- 1 -(4-methoxy-benzyl)-piperidine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1. Starting from (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (2 g, 6.73 inmol) and bis-(2-chloro-ethyl)-(4-methoxy-benzyl)-amine (2.61 g, 8.75 minol) and following the procedure as outlined in Example 1 (Step 6) 2.5 g of the product was isolated. Yield 2.5 g yellow oil; MS: 486 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1 -(4-inethoxy-benzyl)-piperdine-4carboxylic acid was prepared starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)- I- (4-inethoxy-benzyl)-piperdine-4-carboxylic acid ethyl ester (2.5 g, 5.15 inmol) dissolved in THF:methanol 200 ml) and 10 N NaOH (15 ml). The resulting via I qVO V 1 EWAffilffilwhy&yt WO 00/44723 WO 0044723PCT/USOO/01864 -43reaction mixture was worked up as outlined in Example I (Step Yield 1.26 g off white solid; mp 223 MS: 458 Starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)- I-(4-methoxy-benzyl)piperdine-4-carboxylic acid (1 g, 2-.19 mmol) and following the procedure as outlined in Example 1, (Step 350 mg of 4-(4-but-2-ynyloxy-benzenesulfonyl)-l-(4methoxy-benzyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as a hydrochloride salt, an off white solid. Yield 31%; mp 162 MS: 473 'H NMR (300 MHz, DMSO-d,): 5 1.86 2.13 Hz, 3H), 2.23 (in, 2H), 2.49 (in, 2H), 2.73 (mn, 2H), 3.39 (in, 2H), 3.77 3H), 4.21 J= 4.26 Hz, 2H), 4.89 J=2.28 Hz, 2H), 6.99 J= 8.7 Hz, 2H), 7.17 J=9 Hz, 2H), 7.43 J=8.4 Hz, 2H), 7.68 J= 9 Hz, 2H), 9.37 IlH), 10. 21 IlH), 11. 17 IlH).
Example 3 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1-(4-chloro-benzyl)-piperdine- 4-carboxylic acid hydroxyamide 2- [(4-chlorobenzyl)- (2-hydroxy-ethyl)-amino] -ethanol was prepared according to the general method as outlined in Example 1 (Step Starting from diethanolamine (14.3 g, 95 minol). and 4-chlorobenzyl chloride (10.2 g, 63 iniol).
Yield 12.1 g, yellow oil; MS: 230 (4-Chloro-benzyl)-bis-(2-c hloro-ethyl)-amine was prepared according to the general method as outlined in Example 1 (Step Starting from 2-[4chlorobenzyl)-(2-hydroxy-ethyl)-amnino] -ethanol (12 g, 52.4 iniol). Yield 41.27 g, yellow powder; mp 115 MS: 303 4-(4-But-2-ynyloxy-benzenesulfonyl)- I-(4-chloro-benzyl)-piperdine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (4 g, 13.5 mmiol) and (4-chloro-benzyl)-bis-(2-chloro-ethyl)-amine (4.9 g, 16.2 minol). Yield 3.5 g white crystals; MP 91.8'C; MS: 490 (M+H)Y 14 W A W A WO 00/44723 WO 0044723PCT/USOO/0I 864 -44- 4-(4-But-2-ynyloxy-benzenesulfonyl)- I -(4-chloro-benzyl)-piperdine-4carboxylic acid was prepared starting from 4 4 -but-2-ynyloxy-benzenesulfonyl)-l- (4-chloro-benzyl)-piperdine-4-carboxylic acid ethyl ester (3.14 g, 6.42 mmol) dissolved in THF:methanol 3:1 (100 ml) and 10 N NaGH (10 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 2.37 g white solid; mp 205 MS: 461.9 Starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)- 1 -(4-chloro-benzyl)piperdine-4-carboxylic acid (2.31 g, 5.01 mmol) and following the procedure as outlined in Example 1 (Step 790 mg of 4-(4-but-2-ynyloxy-benzenesulfonyl)- 1- (4-chloro-benzyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as a hydrochloride salt, a yellow solid. Yield 31%; mp 130 MS: 476.9 H NMR (300 MHz, DMSO-d,): 5 1.856 3H), 2.23 (in, 2H), 2.73-2.89 (in, 4H), 3.37 2H), 4.28 (in, 2H4), 4.89 2H), 7.18 J 8.94 Hz, 2H), 7.54 4H), (d, J=8.88 Hz, 2H), 9.40 1H), 10.3 1H).
Example 4 l-Benzyl-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperdine- 4-carboxylic acid hydroxyainide Bis-(2-Chloro-ethyl)-benzyl amine was prepared according to the general method as outlined in Example 1 (Step Starting from N-benzyldiethanolamine (164.6 g, 844 mmol). Yield 178.5 g brown solid; MS: 231.9 1 -Benzyl-4-(4-but-2-ynyloxy-benzenesulfonyl)-pipeidine4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (2 g, 6.73 inmol) and bis-(2-chloro-ethyl)-benzyl amine (2.3 g, 8.8 inmol). Yield 3.33 g yellow oil; MS: 455.9 ~2 Y WO 00/44723 WO 0044723PCT/USOO/01864 1 -Benzyl- 4 4 -but-2-ynyloxy-benzenesulfony).piperdine4carboxylic acid was prepared starting from 1 -benzyl- 4 4 -but-2-ynyloxy-benzenesulfonyl).piperdine- 4-carboxylic acid ethyl ester (3 g, 6.6 mmol) dissolved in THF:methanol (3:1 150 ml) and 10 N NaOH (15 ml). The resulting reaction mixture was worked up as outlined in Example 1 (Step Yield 1.65 g off white powder; mp 191 0 C; MS: 428 Starting from 1 -benzyl- 4 4 -but-2-ynyloxy-benzenesulfonyl)piperdine.4 carboxylic acid (1.55 g, 3.63 mmol) and following the procedure as outlined in Example 1 (Step 1.08 g of l-benzyl-4-(4-but-2-ynyloxy-benzenesulfonyl).
piperdine-4-carboxylic acid hydroxyamide was isolated as a hydrochloride salt, an off white powder. Yield 62%; mp 175 MS: 443 'H NMR (300 MHz, DMSO-1 6 8 1.85 J= 2.16 Hz, 3H), 2.25 (in, 2H), 2.49 (in, 4H), 2.77 (mn, 2H), 4.28 J=4.3 Hz, 2H), 4.89 J= 2.28, 2H), 7.18 (mn, 2H), 7.46 (in, 5 7.73 (in, 2H), 9.36 1H), 10.27 lH), 11.08 1H).
Example l-( 4 -Bromo-benzyl)-4-(4-pent-2-ynyloxy..benzenesufony)piperdine- 4-carboxylic acid hydroxyamide 4 -Pent-2-ynyloxy-phenylsulfanyl).acetic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4hydroxy-phenylsulfanyl)-acetic acid ethyl ester (5 g, 30 minol) and 2-pentynyl chloride (3.7 g, 36.6 minol) 7.15 g of the product isolated. Yield 7.15 g brown oil; MS: 278 El 4 -Pent-2-ynyloxy-benzenesulfonyl).acetic acid ethyl ester was prepared according to the general method as outlined in Example I (Step Starting from (4pent- 2 -ynyloxy..phenylsulfanyl).acetic acid ethyl ester (7.04 g, 25.3 mmol) and oxone g) 4 -Pent-2ynyloxy.benzenesulfonyl)..acetic acid ethyl ester was isolated. Yield 8 g yellow oil; MS: 310.9 Wp- I "qA I W 1 4 'w I j N .11,111,111,111,11, 111 1 1 11 1. 1111U WO 00/44723 WO 0044723PCTIUSOO0I864 -46- 1 -(4-Bromo-benzyl)-4- 4 -pent- 2 -ynyloxy-benzenesulfonyl)-pipeidine-4 carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from 4 -pent-2-ynyloxy-benzenesulfonyl)-acetuc acid ethyl ester (4 g, 12.9 mmol) and 4 -bromo-benzyl)-bis-(2-chloro-ethyl)anline (5.83 g, 16.8 mmol, 2.85 g of the product was isolated. Yield 2.85 g (3 low melting white solid; MS: 549.9 l-( 4 -Bromo-benzyl)-4-(4-pent-2-ynyloxy-benzenesulfonyl)..piperdine-4 carboxylic acid was prepared starting from 1 4 -bromo-benzyl)-4-(4-pent-2-ynyloxybenzenesulfonyl)-piperdine-4-carboxylic acid ethyl ester (2.64 g 4.8 mmol) dissolved in THF:methanol (100:50 ml) and 10 N NaOH (10 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 1.6 g off white solid; mp 217 MS: 521.9 Starting from 1 4 -bromo-benzyl)-4-(4-pent-2-ynyloxy.benzenesulfonyl).
piperdine-4-carboxylic acid (1.55 g, 2.98 mmol) and following the procedure as outlined in Example 1 (Step 200 mg of 1-( 4 -bromo-benzyl)-4-(4-pent-2-ynyloxybenzenesulfonyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as a HCl salt, a yellow solid. Yield 12%; mp 62 MS: 536.9 'H NMR (300 MHz, DMSO-d,): 5 1.069 J 7.47 Hz, 3H), 2.26 (in, 2H), 2.49 (in, 2H), 2.73 (mn, 2H), 2.89 2H), 3.40 2H), 4.26 2H), 4.9 (in, 2H) 7.18 (mn, 2H), 7.48 J= 8.4 Hz, 2H), 7.66 (in, 4H), 10.39 1H4), 1 1. 19 IlH).
Example 6 1-4Boobny)4(-c--nlx-eznsloy)pprie 4-carboxylic acid hydroxyamide 4 -Oct- 2 -ynyloxy-phenylsulfanyl)-acetic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4hydroxy-phenyl-sulfanyl)-acetic acid ethyl ester (5 g, 30 minol) and l-bromo-2octyne (6.9 g, 36.6 mmol) 8.9 g of 4 oct- 2 -ynyloxy-phenylsulfanyl)-acetic acid ethyl ester was isolated. Yield 8.9 g yellow oil; MS: 320 El 0 W rr Wjiffi WO 00/44723 WO 0044723PCTUSOO/0I 864 -47- (4-Oct-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester was prepared according to the general method as outlined in Example I (Step Starting from (4oct-2-ynyloxy-phenylsulfanyl)-acetic acid ethyl ester (8.8 g, 27.5 mmol) 8.45 g of (4- -oct-2-ynyloxy-phenylsulfonyl)-acetic acid ethyl ester was isolated. Yield 8.45 g yellow oil; MS: 352 El l-4romo-benzyl)-4-(4-oct-2-ynyloxy-benzenesulfonyl)-piperdine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example l(Step Starting from (4-oct-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (4 g, 11.4 mmol) and (4-bromo-benzyl)-bis-(2-chloro-ethyl)-amine (5.13 g, 14.8 mmol) 1.47 g of 1-(4-bromo-benzyl)-4-(4-oct-2-ynyloxy-benzenesulfonyl)piperdine-4-carboxylic acid ethyl ester was isolated .Yield 1.47 g yellow solid; MS: 591.9 1 -(4-Bromobenzyl)-4-(4-oct-2-ynyloxy-benzenesulfonyl)-piperdine-4carboxylic acid was prepared starting from I -(4-bromobenzyl)-4-(4-oct-2-ynyloxybenzenesulfonyl)-piperdine-4-carboxylic acid ethyl ester (1.36 g, 2.3 mmol) dissolved in THF:methanol (50:50 ml) and 10 N NaOH (10 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 660 mg off white solid; mp 199 0 C; MS: 562 Starting from 1 -(4-bromo-benzyl)-4-(4-oct-2-ynyloxy-benzenesulfonyl)piperdine-4-carboxylic acid (570 mg, 1.01 mmol) and following the procedure as outlined in Example 1 (Step 100 mg of l-(4-bromo-benzyl)-4-(4-oct-2-ynyloxybenzenesulfonyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as a hydrochloride salt, a white powder. Yield 17%; mp 140 0 C; MS: 579 'H NMR (300 MHz, DMSO-d 6 8 0.828 J=7.14 Hz, 3H), 1.25 (in, 6H), 1.38 (in, 2H), 2.27 (in, 2H), 2.49 (in, 4H), 2.73 (in, 2H), 4.03 (mn, 2H), 4.91 2H), 7.18 (d, J= 9 Hz, 2H), 7.47 J= 8.1 Hz, 2H), 7.68 (mn, 4H), 9.43 1H), 10.25 1H), 11. 19 I H).
WO 0 0/44723 PCTUSOO/01 864 -48- Example 7 4-(4-But-2-ynyloxy-benzenesulfolyl)--(4-fluoro-benlZY)-piperidile- 4-carboxylic acid hydroxyamide 2-[(4-Fluoro-benzyI)-(2-hydroxy-ethyl)-amilo] ethanol was prepared according to the general method as outlined in Example 1 (Step Starting from diethanolamine (15.7 g, 150 mmol). and 4-fluoro-benzyl chloride (14.4 g, 100 mmol) 20 g of the product was isolated. Yield 20 g, yellow oil; MS: 215 (4-Flouro-benzyl)-bis-(2-chloro-ethyl)-amine was prepared according to the general method as outlined in Example I (Step Starting from 2-[4-fluorobenzyl)- (2-hydroxy-ethyl)-aminol -ethanol (23.6g, 110 mmol) 28 gins of the product was isolated. Yield 28 g, brown solid; mp 98-99 0 C; MS: 251 4-(4-But-2-ynyloxy-benzenesulfonYl)- 1 -(4-fluoro-benzyl)-piperidine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (5 g, 16.9 mmol) and (4-fluoro-benzyl)-bis-(2-chloro-ethyl)-amflrne (5.8 g, 20.1 minol) 5.3 g of the product was isolated. Yield 5.3 g Brown oil; MS: 474 4-(4-But-2-ynyloxy-benzenesulfoflyl)- I -(4-fluoro-benzyl)-piperidine-4carboxylic acid was prepared starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)-l- (4-fluoro-benzyl)-piperidine-4-carboxylic acid ethyl ester (9.5g, 20 inmol) dissolved in THF:methanol 3:1 (100 ml) and 10 N NaOH (20 ml). The resulting reaction mixture was worked up as outlined in Example 1 (Step Yield 5.7 g white solid; mp 106-106 MS: 447 (M-iH)* Starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)- 1-(4-fluoro-benzyl)piperidine-4-carboxylic acid (5.7 g, 13 inmol) and following the procedure as WO 00/44723 WO 0044723PCT/USOOIOI 864 -49outlined in Example 1 (Step 4.1 g of 4- but- 2-ynyloxy-benzenesulfonyl)- I fluoro-benzyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as a HCl salt, a yellow solid. Yield: 64%; mp 162-4 MS: 461 'H NMR (300 MHz, CDC1 3 6 1.92 3H), 2.02-2.32 (in, 6H), 2.86 (in, 2H), 3.41 2H), 4.84 2H), 7.01 J 8.94 Hz, 2H), 7.15 J=8.88 Hz, 2H), 7.25 J=9 Hz, 2H), 7.74 J= Hz, 2H), 9.4-9.7 (bs, 1H).
Example 8 4 4 -But- 2 -ynyloxy-benzenesulfonyl)-1-(4-cyano.benzyl)..piperidine.
4-carboxylic acid hydroxyamide 4-f [Bis-(2-hydroxyethyl)-ainino]-methyl }benzonitrile was prepared according to the general method as outlined in Example I (Step 4) starting from diethanolamine (10.2 g, 97 inmol) and cc-bromo-p-tolunitrile (15.8g, 81 minol). Yield, white solid; mp 163 'C MS: 221.2 4- {[Bis- (2-chloroethyl)-aminol -methyl }benzonitrile was prepared according to the general method as outlined in Example 1 (Step 5) starting from 4- [bis-(2hydroxyethyl)-amino]-methyl~benzonitrile (33.28 g, 122 minol). Yield g, brown solid; mp MS: 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1 -(4-cyano-benzyl)-piperidine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from 4-(4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (5.86g, 19.8 mmol) and 4-cyano-benzyl-bis-(2-chloro-ethyl)-amnine (5.4g, 18 mmol) 4.7 g of the product was isolated. Yield amber oil; MS: 481.0 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1- (4-cyano-benzyl)-piperidine-4carboxylic acid was prepared starting from 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1- 4 -cyano-benzyil)-piperidine-4-.carboxylic acid ethyl ester(4 g, 8.3 mmol) dissolved in THF:Methanol (60: 30 ml) and 10 N NaOH (10 ml). The resulting reaction mixture
UP
WO 00/44723 WO 0044723PCTUSOO/O1 864 was worked up as outlined in Example I (Step Yield 1.8g off white solid; MS: 441.9 Starting from 4-(4-But-2-ynyloxy-benzenesulfonyl)- I -(4-cyano-benzyl)piperidine-4-carboxylic acid (1.8g, 4 mmol) and following the procedure as outlined in Example I (Step 0.20 g of 4 4 -But-2-ynyloxy-benzenesulfonyl)-l-(4-cyano.
benzyl)-piperidine-4-carboxylic acid hydroxamide was isolated as a hydrochloride salt, white solid. Yield 20%; mp 109.6 0 C; MS: 468.0 'H NMR (300 MHz, DMSO-d,): 6 1.86 (in, 3H), 2.25 (in, 4H), 2.5 (in, 2H), 2.85 2H), 4.39 2H), 4.88 2H), 7.15-7.19 J=13.2, 2H), 7.67-7.70 J=13.5, 2H), 7.78 (mn, 2H), 7.96-7.99 J=9.6, 2H), 9.42 I 10. 14 I1H), 11.20 lH) Example 9 4 4 -But- 2 -ynyloxy-benzenesulfonyI)-l-(4-methyl-benzyl)..piperidine- 4-carboxylic acid bydroxamide 2- [(2-Hydroxy-ethyl)- (4-methyl-benzyl)-amino] -ethanol was prepared according to the general method as outlined in Example I (Step Starting from diethanolamine (4.84g, 46 inmol) and 4-inethylbenzyl bromide (8.5g, 46 inmol), 8.2 g of the product was isolated. Yield, white solid; MS: 210.1 4-Methyl-benzyl-bis-(2-chloro-ethyl)-amine was prepared according to the general method as outlined in example 1 (Step Starting from 2-[(2-Hydroxyethyl)- (4-inethyl-benzyl)-ainino] -ethanol (6.0 g, 20 inmol) 5.2 g of the product was isolated. Yield: yellow solid; mp 145-147 MS: 245.9 4-(4-But-2-ynyloxy-benzenesulfonyl)-1- (4-methyl-benzyl)-piperidine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from 4-(4-but -2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (5.75g, 19.0 inmol) and 4-inethyl-benzyl-bis-(2-chloro-ethyl)-amine (6.04, 208 mmol) 6.47 g of the product was isolate. Yield: amber oil; MS: 470 1, 1 LiMMY W WO 00/44723 WO 0044723PCT/USOO/0I 864 -51- 4 4 -But-2-ynyloxy-benzenesulfonyl). I 4 -methyl-benzyl)-piperidine-4 carboxylic acid was prepared starting from 4 4 -But-2-ynyloxy-benzenesulfonyl)> I 4 -methyl-benzyl)-piperidine4carboxylic acid ethyl ester ester (6.4 g, 13.6 mmol) dissolved in THF:Methanol (30: 20 ml) and 10 N NaOH (15 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 2.3g off white solid; mp 213 'C MS: 441.9 Starting from 4 4 -But-2-ynyloxy-benzenesulfonyl). 1 -(4-methyl-benzyl)piperidine-4-carboxylic acid (2.0g, 5.0 mmol) and following the procedure as outlined in Example I (Step 3.6g of 4 -(4-But-2-ynyloxy-benzenesulfonyly-I.(4methyl-benzyl)-piperidme-4carboxylic acid hydroxamide was isolated as a HCl salt, off-white solid. Yield 1.2g mp 188 MS: 457.0 'H NMR (300 MHz, DM50-l 6 8 1.86 3H), 2.27 (in, 2H), 2.50 (in, 4H), 2.64 (in, 2H), 4.23- 4.24 J=4.5, 2H), 4.89 J=1.8, 2H), 7.16-7.19 J=9 2H), 7.24-7.26 2H), 7.37-7.40 J=8.1, 2H), 9.36 lH), 10. 11 lH), 11.20 lH) Example 4 4 -But-2-ynyloxy.benzenesufony).1.(3,4.. dichloro-benzyl)-piperidine-4carboxylic acid hydroxyamide 2 2 -Hydroxy-ethyl)- (3,4-dichlor-benzyl)..aminoy ethanol was prepared according to the general method as outlined in Example 1 (Step Starting from diethanolamine 4 .84g, 46 mmol) and 3,4-dichlorobenzyl chloride (8.97g, 46 inmol) 9.4 g of the product was isolated. Yield, white solid; MS: 264.3 3 4 -Dichloro-benzyl-bis-(2-chloro-ethyl).aiine was prepared according to the general method as outlined in Example I (Step Starting from 2-[(2-Hydroxyethyl)-( 3 4 -dichloro-benzyl)yamino] ethanol (10.7 g, 41 inmol), 10.7 g of the product was isolated. Yield: yellow solid; mp 218-220 MS: 301.8 4 4 -But-2-ynyloxy-benzenesulfonyl). 1 -(3,4-dichloro-benzyl)-piperijine-4carboxylic acid ethyl ester was prepared according to the general method as outlined WO 00/44723 WO 0044723PCT/USOO/0I 864 -52in Example I (Step Starting from 4-(4-but 2 -ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (6.1g, 23 mmol) and 3 4 -dichloro-benzyl-bis-(2-chloro.ethy1>-amine (8.6g, 25 mmol), 4.9 g of the product was isolated. Yield:(41%); amber oil; MS: 523.8 4 4 -But-2-ynyloxy-benzenesulfonyl)- I -(3,4-dichloro-benzyl)-piperidine-4 carboxylic acid was prepared starting from 4 4 -But-2-ynyloxy-benzenesulfonyl)- 1- 3 4 -dichloro-benzyl)-piperidine-4-carboxylic acid ethyl ester ester (8.6 g, 16.4 mmol) dissolved in THF:Methanol (40: 30 ml) and 10 N NaOH (15 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 2.l1g off white solid; mp 232 'C MS: 495.9 Starting from 4 4 -But-2-ynyloxy-benzenesulfonyl)- 1-(3,4-dichloro-benzyl)piperidine-4-carboxylic acid (2.06g, 4.0 mmol) and following the procedure as outlined in Example I (Step 1 .2g of 4 4 -But-2-ynyloxy-benzenesulfony1)-1-(3,4dichloro-benzyl)-piperidine-4-carboxylic acid hydroxamide was isolated as a HCI salt, off-white solid. Yield 1.2g mp 213 0 C; MS: 510.9 'H NMR (300 MHz, DMSO-d,): 5 1.86 311), 2.30 (in, 2H), 2.50 (mn, 4H), 2.80 (mn, 2H), 4.40 (s, 2H), 4.90 2H), 7.16-7.19 J=9 2H), 7.51-7.54 J=8.4, 2H), 7.66-7.69 (d, J=9.0, 2H), 7.75-7.86 J=ll1.7, 2H1), 7.88 lH), 9.38 IH), 10.44 1H), 11. 19 I1H).
Example 11
I-(
4 -Bromo-benzyI)-4-(4-prop-2-ynyloxy..benzenesulfonyl)..piperdine- 4-carboxylic acid hydroxyamide Step 1: 4 -Prop-2-ynyloxy-phenylsulfanyl)-acetic acid ethyl ester was prepared according to the general method as outlined in Example I (Step Starting from (4hydroxy-phenylsulfanyl).acetic acid ethyl ester (example 1, 1"S paragraph) 2.1 2g, 10 inmol) and propargyl bromide 1.8g, l5mol) 2.4 g of the product was isolated.
Yield: amber oil; MS: 251 WO 00/44723PcTUOI84 PCT/USOO/01864 -53- Step 2: (4-Prop-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4prop-2-ynyloxy-phenyl sulfanyl)-acetic acid ethyl ester 2.5g, 10 mmol) 2.8 g of (4- Prop-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester was isolated. Yield brown oil MS: 283 Step 3: 1- (4-Bromo-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperdine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in Example 1 (Step Starting from (4-prop-2-ynyloxy-benzenesulfonyl)- acetic acid ethyl ester (21.62 g, 76.7 mmol) and (4-bromo-benzyl)-bis-(2-chloro-ethyl)amine (31.9g, 92 mmol), 23 g of the ester derivative was isolated. Yiel: yellow oil; MS: 521.9 Step 4: I -(4-Bromo-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperdine-4carboxylic acid was prepared starting from 1 -(4-bromo-benzyl)-4-(4-prop-2-ynyloxybenzene-sulfonyl)-piperdine-4-carboxylic acid ethyl ester (5 g, 9.59 mmol) dissolved in THF:methanol (150:50 ml) and 10 N NaOH (15 ml). The resulting reaction mixture was worked up as outlined in Example I( Step Yield 3.4 g brown low melting solid; MS: 491.9 Step Starting from 1 -(4-Bromo-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)piperdine-4-carboxylic acid (3 g, 6.1 mmol) and following the procedure as outlined in Example 1 (Step 580 mng of l-(4-bromo-benzyl)-4-(4-prop-2-ynyloxybenzene-sulfonyl)-piperdine-4-carboxylic acid hydroxyamide was isolated as an HCl salt, off white powder. Yield 18%; mp 155 TC; MS: 508.8 'H NMR (300 MHz, DMSO-d1): 5 2.22 (in, 2H), 2.50 (in, 2H1), 2.79 (mn, 2H), 3.45 (in, 2H), 4.27 (in, 2H), 4.96 J=2.3 Hz, 2H), 7.2 J=9 Hz, 2H), 7.48 (in, 2H), 7.68 (in, 4H), 9.37 (s, 1H), 10.36 IH), 11.19 1H).
WO 00/44723 PCT/USOOi/i 864 -54- Example 12
I-(
4 -Bromobenzyi)44(4piperdin..4-yI.but-2.ynyloxy)-benzenesulfony]piperdine-4-carboxylic acid bydroxyaniide To a stirred solution of piperidine (1 .63 g, 19.2 mmol) diluted in dioxane (100 m.L) acetic acid (5mL) was added. The reaction fumed and stirred for 5 minutes. I- 4 -bromobenzyl)4(4prop2ynyloxybenzenesulfonyl)piperdine4carbolic acid ethyl ester (5.0 g, 9.6 mmol), paratbrmaldehyde (0.29 g, 9.6 mmol) and the copper(I)chloride (0.35g) was added to the piperidine solution. The reaction turned green and was heated at reflux for 1 hour turned brown. It was then concentrated and diluted in ice water then brought to pH 8 with NH 4 OH and extracted in CHO1 3 The organic layer was washed 4 times with water then dried over Na 2
SO
4 then concentrated. The product was purified by silica gel column chromatography by eluting it with 5% methanol: chloroform solution.
Yield 5.15 g brown oil; MS: 309.9 (M 2H) 2 618.8 l-( 4 -Bromo-benzyl)-4-[4(4piperidin-1 -yl-but-2-ynyloxy)-benzenesulfonyl] piperdine-4-carboxylic acid was prepared starting from 1 -(4-bromo-benzyl)-4-[4.(4.
piperidin- 1-yl-but- 2 -ynyloxy)-benzenesulfonyl] -piperidine-4-carboxylic acid ethyl ester (4.64 g, 7.5 mmol) dissolved in THF:methanol (50:150 ml) and 10 N NaOH ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 3.35 g off white solid; mp 180 MS: 295.9 590.9 Starting from 1 4 -bromo-benzyl)-4-[4-(4..piperidin-1 -y1-but-2-ynyloxy)benzene- sulfonyl piperidine4carboxylic acid (1.9 g, 3.2 mmol) and following the procedure as outlined in Example I (Step 810 mg of 1-(4-bromo-benzyl)-4- [4-(4-piperidin- I -yl-but- 2 -ynyloxy)benzenesufonylpiperidine4carboxylic acid hydroxyamide was isolated as a hydrochloride salt, a pale yellow solid. Yield mp 209 MS: 303.4 (M+2H) 2 605.9 'H NMR (300 MHz, DMSO-d 6 6 1.70 (in, 2H), 2.29 (in, 2H), 2.76 (in, 411), 3.40 (in, 101-1), 4.14 2H), 4.26 (2H), WO 00/44723 WO 0044723PCT/USOO/OI 864 7.24 J= 9 Hz, 2H), 7.51 (di, J=8.4 Hz, 2H), 7.67 (in, 4H), 9.39 1H), 10.45 (s, 1H).
Example 13 l.( 4 -Bromo-benzyl)-4-[4-(4-morpholin-4yi..but-2ynyoxy).benzenesufonyJpiperdine-4-carboxylic acid hydroxyaniide To a stirred solution of morpholine (1.68 g, 19.2 inmol) diluted in dioxane (100 mL) acetic acid (5 mL) was added. The reaction fumed and stirred for minutes. l-( 4 -bromo-benzyl)-4-(4-prop-2-ynyloxy..benzenesulfonyl)..piperidine-4 carboxylic acid ethyl ester (5.0 g, 9.6 mmol), paraformaldehyde (0.29 g, 9.6 mmol) and the copper(I)chloride (0.35g) was added to the piperidine solution. The reaction turned green and was heated at reflux for I hour turned brown. It was then concentrated and diluted in ice water then brought to pH 8 with NH 4 0H and extracted in CHC 3 The organic layer was washed 4 times with water then dried over Na 2
SO,
then concentrated. The product, 1-4Boobny)4[-4ropoi--lbt2 ynyloxy)-benzenesulfonyl]-pipericine4carboxylic acid ethyl ester was purified by silica gel column chromatography by eluting it with 5% methanol: chloroform solution. Yield 3.0 g colorless solid mp 110' C; MS: 311 (M+2H) 2 621 1-4Boobny)4[-4mrhln4y-u--nlx)bnee sulfonyl]-piperidine-4-carboxylic acid was prepared starting from 1-.(4-bromobezl--4(-opoi--lbt2ynlx)bneeufnl-ieiie4 carboxylic acid ethyl ester (2.87g, 4.6 minol) dissolved in THF~methanol 150 ml) and 10 N NaOH (10 ml). The resulting reaction mixture was worked up as outlined in Example I (Step Yield 2.26 g white powder; mp 198 MS: 593.1 Starting from 1-4boobny)4[-4mrhln4y-u--nlx) benzenesulfonyl]-piperidine-zl-carboxylic acid (2.1 g, 3.55 inmol) and following the procedure as outlined in example 1, 1.8 g of l-(4-bromo- benzyl)-4-[4-(4-morpholin- WO 00/44723 PCT/US00/01864 -56- 4-yl-but-2-ynyloxy)-benzenesulfonyl]-piperidine-4-carboxylic acid hydroxyamide was isolated as a hydrochloride salt, a white solid. Yield 80%; mp 94 oC; MS: 304.4 (M+2H) 2 607.9 'H NMR (300 MHz, DMSO-d 6 6 2.38 2H), 2.46 (m, 2H), 2.75 2H), 3.35 2H), 3.87, 8H), 4.21 2H), 4.26 2H), 5.10 (s, 2H), 7.24 J 9 Hz, 2H), 7.51 J= 8.4 Hz, 2H), 7.67 4H), 9.42 1H), 10.69 1H), 11.13 1H) Examples of compound where A S or S=0.
Example 14 4-(4-But-2-ynyloxy-phenylsulfanyl)-4-hydroxycarbamoyl-piperidine- 1-carboxylic acid tert-butyl ester To a solution of triphenylphosphine (24.7g, 94.2 mmol) and dimethylformamide (0.6 mL) in dichloromethane (25 mL) was added a solution of 4-but-2ynyloxy-phenylsulfonyl chloride (7.69g, 31.4 mmol) in dichloromethane dropwise over 30 min. After an additional 2h, IN aqueous hydrochloric acid (20 mL) and water was added. The organic layer was separated and concentrated in vacuo.
Aqueous sodium hydroxide (IN, 50 mL) was added and the solid removed by filtration. The aqueous phase was washed with diethyl ether treated with 1N aqueous hydrochloric acid (50 mL) and extracted with ether the combined organic extracts were dried over anhydrous magnesium sulfate and concentrated to give the thiol as an oil (3.77g). This material was dissolved in dimethylsulfoxide mL) and concentrated hydrochloric acid was added (2 mL). After 18h, diethyl ether was added and the organic phased was washed with water (5x) and dried over anhydrous magnesium sulfate. Concentration in vacuo gave a yellow solid which was filtered through silica gel with hexane:ethyl acetate to give bis (4-but-2-ynyloxy phenyl) disulfide as a yellow solid (3.0g, 'HNMR (CDC13: 300MHz): 1.86 -CH3, 3H), 4.63 -CH2, 2H), 6.90 ArH, 2H, J 9 Hz), 7.40 ArH, 2H, J 9 Hz).
To a solution of N-BOC-isonipecotic acid (0.62g, 2.7 mmol) in tetrahydrofuran (20 mL) at -78 °C was added tert-butyllithium (3.4 mL, 1.7M in WO 00/44723 PCTIUSOO/01864 -57hexane, 5.7 mmol). After 10 min at -78 C the yellow solution was warmed to 0°C in an ice bath. After 30 min the colorless solution was cooled to -78 °C whereupon bis (4-but-2-ynyloxy phenyl) disulfide(1.0 g, 2.8 mmol) was added as a solution in tetrahydrofuran (6 mL). The reaction mixture was allowed to warm to 25 After 1.5h ethyl acetate was added followed by 6 mL of lN aqueous hydrochloric acid in mL of water. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. Chromatography on silica gel (methanol/methylene chloride) gave the product (0.55g). 'H NMR (DMSO-d6): 1.38 OtBu, 9H), 1.5 1.6 CHH, 2H), 1.84 CH3, 3H), 1.89 1.99 CHH, 2H), 2.95 3.05 CHH, 2H), 3.6 3.7 CHH, 2H), 4.8 CH2, 2H), 6.95 (d, ArH, 2H, J 9 Hz), 7.38 ArH, 2H, J 9 Hz).
Dimethylformamide (0.163 mL) was added to a solution of oxalyl chloride (1.06 mL of a 2.0M solution in dichloromethane) in dichloromethane (2 mL) at 0 C.
After 15 min a solution of the acid in dimethylformamide (5 mL) was added and the reaction mixture was allowed to warm to room temperature. After Ih the reaction mixture was added to a mixture of hydroxylamine hydrochloride (0.737 g), triethylamine (2.22 mL), water (5.7 mL) and tetrahydrofuran (22.8 mL) that had been stirring at 0 °C for 15 min. The reaction was held at 0 °C for 18h then diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate then dried over potassium carbonate and concentrated in vacuo to give 480 mg of 4-(4but-2-ynyloxy-phenylsulfanyl)-4-hydroxycarbamoyl-piperidine- -carboxylic acid tert-butyl ester. 'H NMR (DMSO-d6): 1.37 OtBu, 9H), 1.5 1.6 CHH, 2H), 1.84 CH,, 3H), 1.9 2.0 CHH, 2H), 3.05 3.15 CHH, 2H), 3.5 3.6 (m, CHH, 2H), 4.8 CHI, 2H), 6.9 ArH, 2H), 7.4 ArH, 2H), 8.8 NHOH, 1H), 10.7 NHOH, 1H).
WO 00/44723 WO 0044723PCTUSOO/OI 864 -58- Example 4-(4-But-2-ynyloxy-phenylsulfanyl)-piperidine- 4-carboxylic acid hydroxyam-ide 4- (4-But-2-ynyloxy-phenylsulfanyl)-4-hydroxycarbamoyl-piperidine- 1carboxylic acid tert-butyl ester, prepared by the method outlined in Example 14 (Step 3) 175g, 0.4 mmol), was treated with 4N hydrochloric acid in dioxane (5 mL) at 'C for lh 15 min. The reaction mixture was concentrated in vacuo, diethyl ether was added and the resulting precipitate isolated by filtration to give 4-(4-but-2-ynyloxyphenylsulfanyl)-piperidine-4-carboxylic acid hydroxyamnide as a white solid 12g).
Electrospray Mass Spectroscopy: 321) Example 16 1-(4-Bromo-benzyl)-4-(4-but-2-ynyloxy-phenylsulfanyl)-piperidine- 4-carboxylic acid hydroxyamide 4-(4-But-2-ynyloxy-phenylsulfanyl)-piperidine-4-carboxylic acid hydroxyamide (prepared by the procedure outlined in example 15) (0.15g, 0.5 mmol) in methanol (5 mL) and dimethylformamide (2.5 mL) was treated with triethylamine (0.15 mL, 1.1 mmol) followed by 4-bromobenzylbromide (0.13g, 0.53 mmol). After 6h the solution was diluted with ethyl acetate, acidified to pH 6 with IN aqueous hydrochloric acid, washed sequentially with water, aqueous sodium bicarbonate and brine and dried over anhydrous sodium sulfate. Concentration in vacuo gave l-(4bromo-benzyl)-4- (4-but-2-ynyloxy-phenylsulfanyl)-piperidine-4-carboxylic acid hydroxyamide. 'HNMR (DMSO-d6): 1.5 1.6 CHH, 211), 1.8 CH3, 3H), 1.9 2.2 (in, CHH, 4H), 2.5 2.6 (in, CHH, 2H), 3.4 CH2Ar, 2H), 4.75 CH2, 2H), 6.9 ArH, 2H), 7.2 ArH, 2H), 7.3 ArH, 2H), 7.5 ArH, 2H), 8.8 (s, NHOH, lH), 10.6 NHOH, lH). Electrospray Mass Spectroscopy: 489/491) Examples of compounds where n 1 and A S, S=0 or SO, WO 00/44723 PCT/US00/01864 -59- Example 17 4-(4-But-2-ynyloxy-phenylsulfanylmethyl)-tetrahydro-pyran- 4-carboxylic acid hydroxyamide 4-But-2-ynyloxy-benzenesulfonic acid sodium salt To a solution of 52.35g (0.225 mol) of 4-hydroxybenzenesulfonate sodium salt in 1L of isopropanol and 225 mL of a 1.ON solution of sodium hydroxide was added 59.96g (0.45 mol) of 1-bromo-2-butyne. The resulting mixture was heated to 700 for 15h and then the isopropanol was removed by evaporation in vacuo. The resulting white precipitate was collected by filtration, washed with isopropanol and ether and dried in vacuo to give 56.0g (100%) of the butynyl ether as a white solid.
4-But-2-ynyloxy-benzenesulfonyl chloride To a 0° solution of 43.8 mL (0.087 mol) of oxalyl chloride in 29 mL of dichloro-methane was dropwise added 6.77 mL (0.087 mol) of DMF followed by 7.24g (0.029 mol) of 4-but-2-ynyloxy-benzenesulfonic acid sodium salt The reaction mixture was stirred for 10 minutes at 0° then let warm to room temperature and stirred for 2 days. The reaction was then poured into ice and extracted with 150 mL of hexanes. The organics were washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo to provide 6.23g of the sulfonyl chloride as a yellow solid; m.p. 63-65 0 C. El Mass Spec: 243.9 But-2-ynyloxy-benzene To a solution of 6.14g (23.40 mmol) of triphenylphosphine dissolved in 100 mL of benzene and 50 mL of THF was added 1.75 mL (23.40 mmol) of 2-butyn-l-ol.
After five minutes 2.00g (21.28 mmol) of the phenol, dissolved in 10 mL of THF, was added to the reaction followed by 3.69 mL (23.40 mmol) of diethyl azodicarboxylate. The resulting reaction mixture was stirred for 18h at room temperature and then concentrated in vacuo. The residue was chromatographed on silica gel eluting with ethyl acetate/hexanes (1:10) to provide 2.18g of the desired propargylic ether as a clear liquid. El Mass Spec: 146.0 M' RtNLIWO M"NAN-110AIRRIM11101 YOO% WRWIANPIAN W YMMACV-1111W NWRION WO 00/44723 PCT/US00/01864 4 -But- 2 -ynyloxy-benzenesulfonyl chloride To a solution of 0.146g (1.0 mmol) of the but- 2 -ynyloxy-benzene in 0.3 mL of dichloromethanein an acetone/ice bath under N, was dropwise added a solution of 0.073 mL (1.1 mmol) of chlorosulfonic acid in 0.3 mL of dichloromethane. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature for 2h. To the reaction was then dropwise added 0.113 mL (1.3 mmol) of oxalyl chloride, followed by 0.015 mL DMF. The reaction was heated to reflux for 2h and then diluted with hexane and poured into ice water. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to provide 0.130g of the desired product as a light brown solid.
4 -But-2-ynyloxy-benzenethiol To a solution of 11.8g (.045 mol) of triphenylphosphine dissolved in 10 mL of dichloromethane and 0.3 mL of DMF was added 3.67g (.015 mol) of the 4-but-2ynyloxy-benzenesulfonyl chlorid dissolved in 15 mL of dichloromethane and the resulting mixture was stirred for 2h at room temperature. After the addition of 5 mL of IN HC1 solution the reaction was stirred for 0.5h followed by the addition of mL of brine. The organics were separated and concentrated in vacuo and the residue was diluted with ether and 2.5N sodium hydroxide solution. The resulting precipitate was filtered off and the aqueous layer was acidified to pH2 and extracted with ether.
The combined organics were washed with brine, dried over NaSO,, filtered through Magnesol® and concentrated in vacuo. The residue was chromatographed on silica gel eluting with hexanes/ether to provide 1.13g of the thiol as a yellow oil. CI Mass Spec: 179 4-(4-But-2-ynyloxy-phenylsulfanylmethyl)-tetrahydro-pyran-4-carboxylic acid To a solution of 0.112g (2.81 mmol) of 60% sodium hydride in 2 mL of THF, cooled to 0° C, was added a solution of 0.500g (2.81 mmol) of 4-but-2-ynyloxybenzenethiol, dissolved in 3 mL of THF. The resulting mixture was stirred for 0.5h at room temperature, then cooled to 5° C, followed by the addition of 0.518g (3.65 mmol) of neat 2,7-dioxaspiro[3,5]nonane-l-one while keeping the reaction WOO N iW A W.N _01 11..~ WO 00/44723 PCT/US00/01864 -61temperature below 100 C. The reaction was allowed to warm to room temperature and stirred for an additional 0.5h and then quenched with 3 mL of 3N HCI solution and 3 mL of water. The resulting mixture was extracted with dichloromethane and the combined organics were washed with water and brine, dried over Na 2
SO
4 filtered through a plug of silica gel and concentrated in vacuo. The residue was triturated with hexanes and acetonitrile and filtered to give 0.72g of the carboxylic acid as a semisolid. Electrospray Mass Spec: 319 (M-H) 4 4 -But- 2 -ynyloxy-phenylsulfanylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide To a 0° C solution of 0.74g (2.31 mmol) of the product of 4-(4-but-2ynyloxy-phenylsulfanylmethyl)-tetrahydro-pyran-4-carboxylic acid, dissolved in 7 mL of dichloromethane and 0.175 mL of DMF was added 1.27 mL (2.54 mmol) of a 2M solution of oxalyl chloride. The reaction was warmed to room temperature and stirred for 2h and then recooled to 0° C. A mixture of 0.875 mL (14.2 mmol) of a hydroxylamine solution, 5.0 mL of THF and 2.0 mL of t-butanol were then added to the reaction. The reaction was stirred at room temperature for lh and then concentrated in vacuo. The residue was extracted with dichloromethane and the combined organics were washed with water and brine, dried over NaSO, filtered and concentrated in vacuo. The residue was chromatographed on silica gel eluting with dichloromethane/methanol (92:8) to provide 0.212g of the sulfide-hydroxamic acid as a white solid; m.p.135-137°C. Electrospray Mass Spec: 336 Example 18 4-(4-But-2-ynyloxy-benzenesulfonymethyl)-tetrahydropyran-4-carboxylic acid hydroxyamide To a 0° C solution of 0.186g (0.56 mmol) of the product of 4-(4-but-2ynyloxy-phenylsulfanylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide, dissolved in 1.2 mL of THF and 4.8 mL of methanol was dropwise added a solution of 0.619g (1.008 mmol) of Oxone® in 3 mL of water, while keeping the temperature below 200 C. After the addition was complete the reaction was stirred at room TW AM mllql WFININN kNIII IW WO 00/44723 PCTIUSOO/01864 -62temperature for 3h. The reaction mixture was then poured into a cooled solution of mL of toluene and 5 mL of ethyl acetate and the precipitate was filtered off. The filtrate was extracted with ethyl acetate/toluene and the combined organic layers were washed with water, dried over Na2SO4 and concentrated in vacuo. The residue was triturated with ethyl acetate/toluene filtered and dried in vacuo to provide 0.12g of the sulfone-hydroxamic acid as a white solid; m.p. 184-185° C.
Electrospray Mass Spec: 368 (M+H) Example 19 4-(4-But-2-ynyloxy-benzenesulfinylmethyl)-tetrahydro-pyran- 4-carboxylic acid hydroxyamide To a 0°C solution of 0.288g (0.80 mmol) of the product of 4-(4-but-2ynyloxy-benzenesulfanylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide dissolved in 20 mL of methanol was added 7.0 mL of 30% hydrogen peroxide solution. The reaction was allowed to warm to room temperature and stirred for 24h.
The reaction mixture was then recooled to 0°C, quenched with saturated Na 2 SO, and concentrated in vacuo. The residue was diluted with water and dichloromethane. The organics were washed with water and brine, dried over Na 2
SO
4 filtered and concentrated in vacuo. The residue was chromatographed on silica gel eluting with dichloromethane/methanol (95:5) to provide 0.050g of the sulfoxide as a white solid.
Electrospray Mass Spec: 351.9 Example 4-{[4-(2-butynyloxy)phenyl]sulfonyl}-N-hydroxytetrahydro-2H-pyran-4carboxamide Step 1: Ethyl 4- [4-(2-butynyloxy)phenyl]sulfonyl) tetrahydro-2H-pyran-4-carboxylate (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (10 g, 33.8 mmol) was added to a stirring solution of potassium carbonate (12 18-crown-6 (0.5 2chloroethyl ether (4.75 ml, 40.5 mmol), and tetrabutyl ammonium bromide (0.5 g) in methyl ethyl ketone (200 ml). The mixture was heated at reflux overnight before the WO 00/44723 PCT/USOO/0I 864 -63salts were filtered off and the filtrate was concentrated. The residue was dissolved in chloroform and washed with water. The organic layer was dried over Na 2
SO
4 filtered and concentrated. The compound was isolated using silica-gel column chromatography by eluting it with 20% ethyl acetate: hexane solution. Ethyl 2 -butynyloxy)phenyl]sulfonyl} tetrahydro-2H-pyraii-4-carboxylate was isolated as a yellow oil (10.06 Yield 80%; MS: 367.2 4- 4 2 -butynyloxy)phenyl]sulfonyl} tetrahydro-2H-pyran-4.carboxylic acid was prepared according to the general method as outlined in example I (step7), starting from ethyl 4 4 2 -butynyloxy)phenyl]sulfonyl) tetrahydro-2H-pyran-4carboxylate (10 g, 27.3 mmol); 2.7 g white solid. mp: 197 Yield 30%; MS: 337.2 Starting from a crude mixture of 4 -{1 4 -(2-butynyloxy) phenyl] sulfonyl) tetrahydro-2H-pyran-4-carboxylic acid (2.59 g, 7.66 mmol), and following the procedure as outlined in Example I (step 1.51 g of 4- 4 2 -butynyloxy) phenyl] sulfonyl}-N-hydrotetrahydro-2H-pyran-.4-carboxamde was isolated as off white crystals. Mp: 210 Yield: 58%; MS: 354.2 'H NMiR (300 MIHz, DMS0d 6 8 1.85 J=2.28 Hz, 3H), 1.92 (in, 2H), 2.20 J=13.1 Hz, 2H), 3.15 (t, J=I 1.52, 2H), 3.86 (d of d, 2H), 4.88 J=2.34 Hz, 2H), 7.16 J=8.7 Hz, 2H), 7.66 J=8.91 Hz, 2H), 9.16 lH), I1I I H).
Example 21 1-ezl4[3(-uyyoypeylufnl--yrx--iedn carboxamide Ethyl -hydroxyphenyl) sulfanyl] acetate was prepared according to the general method as outlined in example I (step starting from ethyl bromoacetate (7.95 g, 47.6 minol) and 3-hydroxythiophenol (7.95 g, 47.6 inmol); 4.21 g yellow oil.
Yield 41 MS: 211.2 (M-HY_ WO 00/44723 WO 0044723PCTUSOO/01 864 -64- Ethyl [3 -(2-butynyloxy)phenyl] sulfanyl acetate was prepared according to the general method as outlined in example 1 (step starti ng from ethyl -hydroxyphenyl)sulfanyl] acetate 3 .87g, 18.3 mmol) and 4-bromo-2-butyne (2.66 g, 20 mmol);- 5.16 g yellow oil. Yield 100%; MS(EI): 264.1 Ethyl{ [3-(2-butynyloxy)phenyl]sulfonyl) acetate was prepared according to the general method as outlined in example 1 (step starting from ethyl{f[3 -(2-butynyloxy)phenyl] sulfanyl) acetate (5g, 18.9 mmol) and oxone (23.3 g, 37.9 mmol); 6.19 g yellow oil. Yield 100%; MS(EI): 296.1 Ethyl I -benzyl-4- -butynyloxy)phenyl] sulfonyl }-4-piperdine carboxylate was prepared according to the general method as outlined in example I (step 6), starting from ethyl{ 3 2 -butynyloxy)phenyl]sulfonyl) acetate (3 g, 10.1 mmol) and Benzyl-bis- (2-chloro-ethyl) amnine hydrochloride (2.88 g, 10.7 mmol);- 2.91 g yellow oil. Yield 63%; MS: 456.3 I -benzyl-4-{ [3'-(2-butynyloxy)phenyl]sulfonyl )-4-piperdine carboxylic acid was prepared according to the general method as outlined in example I (step7), starting from ethyl I -benzyl-4- -(2-butynyloxy)phenyl]sulfonyl} -4-piperdine carboxylate (2.9 g, 6.3 7 mmol); 1. 10 g off white powder. mnp: 171 Yield 40%; MS: 428.4 Starting from 1 -benzyl-4- 3 2 -butynyloxy)phenyl]sulfonyl}-4-piperdine carboxylic acid (I g, 2.34 mmol), and following the procedure as outlined in Example 1 (step 460 mg of l-benzyl- 4 3 2 -butynyloxy)pheny]sufonyl>Nhydroxy-4 piperdine carboxamide was isolated as an off white solid. mp: 91 Yield: 41%; MS: 443.4 'H NMIR (300 MHz, DMSO-d 6 8 1.83 3H), 2.23-2.27 (in, 2H), 2.73-2.89 (in, 2H), 3.29 (in, 2H), 3.68 2H1), 4.31 (in, 1H1), 4.39 J=5 Hz, 111), 4.85 J=2.25, 2H4), 7.25-7.61 (mn, 9H), 9.1 11.2 IH).
WO 00/44723 WO 0044723PCTUSOO/O1 864 Example 22 4-{14-(2-butynyloxy)phenylJ sulfonyl}-N-hydroxy- 1-isopropyl-4-piperidine carboxamide Ethyl 4- f [4-(2-butynyloxy)phenyl] sulfonyl) -1I -isopropyl-4-piperidine carboxylate was prepared according to the general method as outlined in example I (step starting from 4 -but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (6g, 20.3 mmol) and isopropyl [bis(2-chloroethyl)] amine hydrochloride (4.88 g, 22.3 mmol); 5.28 g brown oil. Yield 64%; MS: 408.2 4- {[4-(2-butynyloxy)phenyl]sulfonyl) I-isopropyl-4-piperidine carboxylic acid was prepared according to the general method as outlined in example I (step7), starting from ethyl 4- {[4-(2-butynyloxy)phenyl] sulfonyl} -1-isopropyl-4-piperidine carboxylate (5.25 g, 13 mmol); 2.06 g yellow solid. mp: 233 Yield 42%; MS: 380.1 Starting from 4- 4 -(2-butynyloxy)phenyl]sulfonyl 1-1-isopropyl-4-piperidine carboxylic acid (1.9 g, 5 mmol), and following the procedure as outlined in Example 1 (step 107 mg of 4- {[4-(2-butynyloxy)phenyl]sulfonyl }-N-hydroxy- I-isopropyl-4piperidine carboxamide was isolated as an brown solid. mp: 105 0 C; Yield: MS: 395.2 1 H NMvR (300 MIHz, DMSO-d 6 5 1.2 (in, 6H), 1.85 3H), 2.27 (in, 2H), 2.73 (in, 2H), 3.06 (in, 2H), 3.52 (in, 2H), 3.57 (in, IH), 4.89 (in, 2H), 7.19 (in, 2H), 7.71 (in, 2H), 9.3 I 11. 4 I H).
Example 23 4- 4 2 -butynyloxy)phenyllsulfonyl}-N-hydroxy-l-(3-pyridinylmethy).4 piperidine carboxamide Ethyl 4- {[4-(2-butynyloxy)phenyl]sulfonyl) -pyridinylmethyl)-4-piperidine carboxylate was prepared according to the general method as outlined in example I (step starting from (4-but-2-ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (4g, 16.9 inmol) and 3-pyridyl methyl [bis(2-chloroethyl)] amine, hydrochloride (4.18 g, 18.6 inmol); 370 mg brown oil. Yield MS: 457.4 WO 00/44723 WO 0044723PCT/USOO/01 864 -66- 4- [4-(2-butynyloxy)phenyl]sulfonyl 1 -pyridinylmethyl)-4-piperidine carboxylic acid was prepared according to the general method as outlined in example I (step starting from ethyl 4- {[4-(2-butynyloxy)phenyl]sulfonyl} -l-(3-pyridinylmethyl)-4-piperidine carboxylate (320 mg, 0.7 mmol); 150 mg yellow solid. Yield 50%; MS: 429.2 Starting from 4- {[4-(2-butynyloxy)phenyl]sulfonyl -pyridinyl methyl)-4piperidine carboxylic acid (860 mg, 2 nunol), and following the procedure as outlined in Example 1 (step 800 mg of 4-{[4-(2-butynyloxy)phenyl]sulfonyl}-N-hydroxy-l- (3-pyridinylmethyl)-4-piperidine carboxamide was isolated as a white solid. mp: 115*C; Yield: 84%; MS: 444.1 'H Nlvll (300 MIHz, DMSO-d 6 8 1.86 (t, J=1.98 Hz, 3H), 2.32 (in, 2H), 2.46 2H), 2.84 (in, 2H), 3.46 J=12 Hz, 2H), 4.45 2H), 4.89 2.1 Hz, 2H), 7.17 J=8.9 Hz, 211), 7.68 J=8.85 Hz, 2H1), 7.9 J=5.6 Hz, 1H), 8.0 111), 8.51 J=7.9 Hz, 1H), 8.87 J= 4.6 Hz, 111), 8.99 1H), 11.4 1H).
Example 24 3-{14-(2-Butynyloxy)phenyl] sulfonyl}-l-ethyl-N-hydroxy-3piperidinecarboxamide Step 1: Piperidine-1,3-dicarboxylic acid I-tert-butyl 3-ethyl ester To a stirred solution of ethyl nipecotate 1ig, 3 3 mmol) in CH 2
CI
2 (75 ml) and triethylamine (3.7g, 36 mmol) was added portionwise di-t-butyldicarbonate (7.1g, 33 mmol). The reaction mixture was stiffed at room temperature for 18 h, quenched with ice water and extracted with chloroform. The organic layer was dried over sodium sulfate, filtered, concentrated and chromatographed on a silica-gel column with 20:80 ethyl acetate:hexane. Piperidine 1,3dicarboxylic acid 1-tert-butyl ester-3-ethyl ester was isolated as a waxy solid. Yield 6.86 g MIS m/z 258.2 __TN.N M~h~~iI WO 00/44723 PCT/US00/01864 -67- Step 2: 1-(tert-Butyl) 3-ethyl 3- [4-2-butynyloxy)phenyl]sulfonyl}-1,3piperidine dicarboxylate To a stirred solution of diisopropylamine (7.2g, 28 mmol) in THF (25 ml) at -78° C was added n-butyllithium (1.6m solution in hexanes, 19.0 ml, 30.8 mmol). The mixture was stirred for 30 min at 0°C. The mixture was then cooled to -78o C and piperidine -1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester (5.3g, 28 mmol) in THF (20 ml) was added slowly. The reaction mixture was stirred for 30 min then 4but-2-ynyloxy-benzenesulfonyl fluoride (6.4g, 28 mmol) in THF (15 ml) was added slowly. The reaction was warmed to room temperature and after 4 hrs quenched with ice water and extracted with chloroform. The organic layer was dried over sodium sulfate, filtered, concentrated and chromatographed on a silica-gel column with ethyl acetate:hexane to afford 1-(tert-Butyl) 3-ethyl 3-{[4-2-butynyloxy)phenyl]sulfonyl)-1,3-piperidine dicarboxylate as a white solid. Yield 9.8 g mp 103.4°C; MS m/z 466.4 'H NMR (300 MHz, DMSO-d 6 8 1.07 (t, 3H), 1.34 9H), 3.31 3H), 3.84 2H), 4.00 4H), 4.53 2H), 4.91 (m, 4H), 7.22 2H), 7.71 2H).
Step 3: To a stirred solution of 1-(tert-Butyl) 3-ethyl 3-{[4-2-butynyloxy)phenyl]sulfonyl}-1,3-piperidine dicarboxylate (5.45g, 11.7 mmol) in methylene chloride(25 ml) at O0 C was added a saturated solution of hydrogen chloride in methylene chloride (25 ml). After 5 hours the solution was concentrated to afford ethyl 3-([4-(2-butynyloxy)phenyl]sulfonyl}-3-piperidinecarboxylate hydrogen chloride and is stored under nitrogen. White hygroscopic solid; Yield 3.47g MS (ES): m/z 366.2 (M+H) Step 4: (Ethyl 3- [4-(2-butynyloxy)phenyl]sulfonyl}-1-ethyl-3-piperidinecarboxylate) 3- [4-(2-Butynyloxy)phenyl]sulfonyl}-3-piperidinecarboxylate hydrogen chloride (2.97g, 8.0 mmol), ethyl iodide (1.28g, 8 mmol) and dry powdered potassium carbonate (3.8g) in dry acetone (60 ml) was heated to reflux for 18 hours. The mixture was allowed to cool and the potassium salts were filtered and concentrated. The
~~I
~"lly~l'"ll'l IIIYIIIIII11):lrill~iAt~lo(~sl~~nmau;n WO 00/44723 WO 0044723PCTUSOO/01864 -68residue was extracted with chloroformn and washed with H 2 0, dried over sodium sulfate and concentrated to afford ethyl 3-f [4-(2-butynyloxy)phenyl]sulfonyl}-I -ethyl- 3-piperidinecarboxylate. This product was used without further purification. Amber gum, yield 3.47 g MIS m/z 394 Step 5 3- {[4-(2-butynyloxy)phenyljsulfonyl 1-1-ethyl-3 -piperidinecarboxylic acid 3- {[4-(2-butynyloxy)phenyl]sulfonyl} -1-ethyl-3-piperidinecarboxylic acid was prepared starting from ethyl 3- {[4-(2-butynyloxy)phenyl]sulfonyl 1-1-ethyl-3 piperidinecarboxylate (3.2g, 8.0 mmol) dissolved in THF:Methanol (15:25 ml) and NaOH (15 ml). The resulting reaction misture was worked up as outlined in example I (step Yield 2.1lIg white solid: mp, 159.2' C; MS m/z 366.3 Step 6: 3- {[4-(2-butynyloxy)phenyl]sulfonyl} -1-ethyl-N-hydroxy-3 piperidinecarboxamide Starting from 3- {[4-(2-butynyloxy)phenyl]sulfonyl} -1-ethyl-3 -piperidinecarboxylic acid (2.0g, 5.5 mmol) and and following the procedure as outlined in example 1 (step 0.1 93g of 3- {[4-(2-butynyloxy)phenyl]sulfonyl) -1-ethyl-N-hydroxy-3 -piperidinecarboxamide hydrogen chloride was isolated as a white solid. Yield 10%; mpl190.3' C; MS m/z: 405.3 (M+H) 4 'H NMv~R (300 MIHz, DMSO-d 6 6 1.18 (in, 3H), 1.97 (in, 2H), 2.55 (in, 2H), 3.21(m, 5H), 3.52 9S, 3H), 3.82 1H), 4.91 (in, 2H), 7.19 2H), 7.51 5H), 8.67 1H), 9.48 1H).
Example 3-f{[4-(2-butynyloxy)phenyllsulfonyl}-1-(4-chlorobenzyl)-N-hydroxy-3piperidinecarboxamide Step 1: Ethyl 3- {[4-(2-butynyloxy)phenyl]sulfonyl}- I-(4-chlorobenzyl)-3 -piperidinecarboxylate Starting from ethyl [4-(2-butynyloxy)phenyl]sulfonyl -piperidinecarboxylate hydrogen chloride (1.1g, 2.7 minol) and 4-chlorobenzyl chloride (0.485, 3.0 mmol) in dry acetone (50 ml) and following the procedure outlined in example 24, (step Ethyl 3- {[4-(2-butynyloxy)phenyl]sulfonyl 1-I -(4-chlorobenzyl)-3 -piperidine- I N WO 00/44723 PCT/USOO/OI 864 -69carboxylate was isolated as a brown oil. This product was taken to the next step without further purification. Yield 1 .66g MIS mlz: 491.3 Step 2: 3- 4 2 -butynyloxy)phenyl]sulfonyl) 4 -chlorobenzyl)-3-piperidinecarboxylic acid 4 2 -butynyloxy)phenyljsulfonyl 1-1-( 4 -chlorobenzyl)-I-3-piperidinecarboxyijc acid was prepared starting from ethyl 3- 4 2 -butynyloxy)phenyl]sulfonyl) -1-(4-clilorobenzyl)-3-piperidinecarboxylate (1 .64g, 3.3 mmol) dissolved in THF:Methanol (15:50 ml) and NaGH (15 ml). The resulting reaction mixture was worked up as outlined in example I (step Yield 1.1Ig white solid: mp 115.20 C; MS m/z 462.1 Step 3: 3- 4 2 -butynyloxy)phenyl]sulfonyl} -1 4 -chlorobenzyl)-N-hydroxy- 3 -piperidinecarboxaniide Starting from 3- 4 2 -butynyloxy)phenyl]sulfonyl..I 4 -chlorobenzyl)-3 piperidinecarboxylic acid (1.1Ig, 2.4 mmol) and and following the procedure as outlined in example 1, (step 0.48g of 3 4 2 -butynyloxy)phenyl]sulfonylyl...(4.
chlorobenzyl)-3-N-hydroxcy-3-piperidinecarboxamide hydrogen chloride was isolated as a white solid. Yield 43%; mp 124.40 C; MS mlz: 477.1 'H NMR (300 MHz, DMSO-d 6 6 2.0 (in, 211), 3.39 (in, 5H), 4.27 2H1), 4.89 (mn, 2H1), 7.14 2H), 7.15 (mn, 4H), 7.61 2H), 8.95 1H), 9.46 11H).
Example 26 4 -(1 4 2 -Butynyloxy)phenylj suifonyl}-l- 4 -(2-piperidin1y..ethoxy).benzy]..
piperidine-4-carboxylic acid hydroxyamide.
A mixture of diethanolamine (2.1 g, 20 minol), 4 2 -piperidin-l-yl-ethoxy).benzyI chloride (5.9 g, 20 inmol) and KC,C0 (10 g, excess) was refluxed in acetone (100 ml) for 24 hrs. At the end, reaction mixture was cooled to room temperature and filtered.
It was concentrated to dryness and redissolved in touene (200 ml) and thionyl chloride (6.75 g, 50 minol). It was heated to 800 C for 1 hr and the separated brown solid, bis-(2-chloro-etl) -4(2-piperidin- 1-yl-ethoxy)-benzyl]-ainine was filtered .oli vle /Aw~I WO 00/44723 WO 0044723PCT/USOO/01864 and dried. The crude product was taken to next step with out purification. Yield: g, 4- {[4-(2-Butynyloxy)phenyl]sulfonyl} -1-[4-(2-piperidin- 1-yl-ethoxy)-benzyl]piperidine-4-carboxylic acid ethylester was was prepared according to the general method as outlined in example 1 (step starting from ethyl {[4-(2-butynyloxy)phenyl]sulfonyl acetate (2.9 g, 10.0 mmol) and bis-(2-chloro-ethyl)- [4-(2-piperidin- 1yl-ethoxy)-benzyl]-amine dihydrochioride 10 mmol), 2.8 g of product (brown oil) was isolated.. Yield 48%; MS: 583 4- {[4-(2-Butynyloxy)phenyl]sulfonyl 1-1-[4-(2-piperidin-1I-yl-ethoxy)-benzyl]piperidine-4-carboxylic acid was prepared according to the general method as outlined in example 1 (step7), starting from 4-{[4-(2-Butynyloxy)phenyl]sulfonyl)-l- [4-(2-piperidin-1I-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid ethylester (3.0 g, 5.15 mmol); 2.2 g of white powder. mp: 172 Yield 77%; MS: 5 55 Starting from [4-(2-Butynyloxy)phenyl] sulfonyl}- 1-[4-(2-piperidin- l-ylethoxy)-benzyl]-piperidine-4-carboxyljc acid (5.0 g, 9.0 mmol), and following the procedure as outlined in Example I (step 1.8 g of 4-{[4-(2-Butynyloxy)phenyl]sulfonyl} -1-[4-(2-piperidin- 1-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxyamide was isolated as an yellow spongy solid. The dihydrochloride salt was prepared by dissolving the free amine with methanolic hydrochloric acid. mp: 124'C; Yield: 1. 8 g MS: 570 Example 27 4 4 2 -Butynyloxy)phenyllsulfonyl}-l-(3-pentanyl)..piperidine.4-carboxylic acid hydroxyamide.
4- {[4-(2-Butynyloxy)phenyl]sulfonyl} 3 -p entanyl)-piperidine-4-carboxylic acid ethyl ester was was prepared according to the general method as outlined in example 1 (step starting from ethyl 4 -(2-butynyloxy)phenyl~sulfonyl} acetate (8.8 2~M ~A WO 00/44723 WO 0044723PCT/USOO/01 864 -71 g, 30.0 mmol) and bis-(2-chloro-ethyl)-(3-pentanyl)-amine dihydrochloride (7.4 g, mmol), 3.5 g of product (brown oil) was isolated.. Yield 26%; MS: 436 (M+H) 4 4- {[4-(2-Butynyloxy)phenyl] sulfonyl 3 -pentanyl)-piperidine-4-carboxrlic acid was prepared according to the general method as outlined in example 1 (step7), starting from 4- 4 2 -Butynyloxy)phenyl]sulfonyl -pentanyl)-piperidine-4carboxylic acid ethyl ester (3.0 g, 6.8 mmol); 2.5 g of spongy yellow solid. mp: 98 'C; Yield 90%; MS: 408 Starting from 4- {[4-(2-Butynyloxy)phenyl] sulfonyl 3 -pentanyl)-piperidine-4carboxylic acid (2.5 g, 6.1 mmol), and following the procedure as outlined in Example I (step 1.8 g of 4- {[4-(2-Butynyloxy)phenyl] sulfonyl -pentanyl)-piperidine..4carboxylic acid hydroxyaniide was isolated as an yellow spongy solid. The hydrochloride salt was prepared by dissolving the free amine with methanolic hydrochloric acid. mp: 101 103*C; Yield: 1.1 g MS: 460 1 H NlvMR (300 N1-I, DMSO-d 6 5 1.8 (t, 6H), 1.5-1.7 (in, 6H), 1.9 3H), 2.3- 2.7 (in, 8H), 3.0 (in, 2H), 3.4 3H), 3.6 2H), 4.9 2H), 7.21 2H), 7.8 2H), 9.3 I1H), 9.8 I1H), 11. 2 I H).
Example 28 1-4Mtoybny)4(-rp2yyoybneeufnl-ieiie4 carboxylic acid hydroxyamide.
1-4Mtoybny)4(-rp2yyoybneeufnl-ieiie4 carboxylic acid ethyl ester was prepared according to the general method as outlined in example I (step starting from 4 -prop- 2 -ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (prepared as described in example 11, step 1 and 2)(l 0.0 g, 35.0 inmol) and 4methoxy-benzyl)-bis.(2-.cloro..ethyl).amAne hydrochloride (10.5 g, 35 inmol), 6.0 g of product (brown oil) was isolated.. Yield 36%; MS: 472 1-4Mtoybny)4(-rp2yyoybneeufnl-ieiie4 carboxylic acid was prepared according to the general method as outlined in example I (step7), starting from 1I4Mtoybezl -4pop2yyoybnznsloy) I Pf~ ~W~4 .A~t4, n~ jU~4. z WO 00/44723 PCT/US00/01864 -72piperidine-4-carboxylic acid ethyl ester (6.0 g, 12.73 mmol); 5.0 g of spongy yellow solid. mp: 208 Yield 92%; MS: 444 Starting from 1-(4-Methoxy-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-pipeidine- 4-carboxylic acid (6.0 g, 13.5 mmol), and following the procedure as outlined in Example 1 (step 2.0 g of 1-( 4 -Methoxy-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide was isolated as an yellow spongy solid. The hydrochloride salt was prepared by dissolving the free amine with methanolic hydrochloric acid. mp: 150 0 C; Yield: 2.0 g MS: 459 'H NMR (300 MHz, DMSO-d 6 5 2.3-2.8 (min, 6H), 3.3 2H), 3.5 3H), 4.2 2H), 2H), 7.3 2H), 7.5 2H), 7.6 2H), 7.7 2H),10.9 1H), 11.2 (s, 1H).
Example 29 1-(4-Chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4carboxylic acid hydroxyamide.
1-(4-Chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4carboxylic acid ethyl ester was prepared according to the general method as outlined in example 1 (step starting from 4 -prop- 2 -ynyloxy-benzenesulfonyl)-acetic acid ethyl ester (prepared as described in example 11, step 1 and 2)(10.0 g, 35.0 mmol) and 4chloro-benzyl)-bis-(2-chloro-ethyl)-amine hydrochloride (10.5 g, 35 mmol), 8.0 g of product (brown oil) was isolated.. Yield 48%; MS: 475 1-(4-Chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4carboxylic acid was prepared according to the general method as outlined in example 1 (step7), starting from 1-(4-chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)piperidine-4-carboxylic acid ethyl ester (6.0 g, 12.63 mmol); 5.0 g of spongy yellow solid. mp: 205 Yield 92%; MS: 448 Starting from 1-(4-Chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)piperidine-4-carboxylic acid (6.0 g, 13.4 mmol), and following the procedure as i~~\uv~rrmii~.uullnwiu~,il*a;rji.iil; i r r lr I~or I~~ilr~r lnlluliTvmr !r ,?lv~l~;MtW I "AP, I Wili WO 00/44723 PCT/US00/01864 -73outlined in Example 1 (step 2.0 g of 1-( 4 -chloro-benzyl)-4-(4-prop-2-ynyloxybenzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide was isolated as an yellow spongy solid. The hydrochloride salt was prepared by dissolving the free amine with methanolic hydrochloric acid. mp: 146 0 C; Yield: 4.0 g MS: 499 'H NMR (300 MHz, DMSO-d 6 6 2.0-2.5 6H), 3.2 2H), 4.18 2H), 4.9 (s, 2H), 7.42 2H), 7.61 2H), 7.71 2H), 7.85 2H),11.0 1H), 11.2 1H).
Example tert-butyl-4-({[ 4 -(2-butynyloxy)phenyl]sulfanyl}methyl)-4- [(hydroxyamino)carbonyl]-l-piperidinecarboxylate Step 1: Piperidine-1,4-dicarboxylic acid tert-butyl ester ethyl ester To a solution of of ethyl isonipecotate 4 7 2g, 0.03 mmol) in 30mL of THF was added slowly di-tert-butyl dicarbonate (7.2g, 0.03 mmol) at room temperature.
The resulting mixture was stirred for two hours and diluted with EtOAc. The organics were washed with brine, dried over MgSO 4 filtered and concentrated in vacuo. The residue was chromatographed on silica gel eluting with ethyl acetate:hexanes to provide 7.52g of the desired product as a colorless oil. Electrospray Mass Spec :258.3 Step 2: 1-(tert-Butyl) 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate To a solution of piperidine-l,4-dicarboxylic acid tert-butyl ester ethyl ester (12.8 g, 49.74 mmol) in 73mL of dry THF under N 2 atmosphere at -42 0 C was added 24.87mL (49.74mmol) of 2M Lithium diisopropylamine in heptane/THF/ethylbenzene dropwise to not exceed -40°C. After one hour, 4.0mL (49.74mmol) of diiodomethane was added and the solution was warmed to ambient temperature overnight. The resulting solution was diluted with H 2 0 and extracted with ethyl acetate. The organics were washed with brine, dried over MgSO 4 filtered and concentrated in vacuo to provide 1 8 .84g(95%) of the desired product as a brown oil. Electrospray Mass Spec 398.2
(M+H)
-~,nii':-mirnrin~u";n~i rn~ r~NO V!%FVRAWrIA:mlWI* WO 00/44723 PCT/US00/01864 -74- Step 3: 4 -But-2-ynyloxy-benzenesulfonic acid sodium salt: To a solution of 4-hydroxybenzenesulfonate sodium salt (52.35g, 0.225) in 1L of isopropanol and 225mL of a 1.ON solution of sodium hydroxide was added 5 9.96g (0.45mol) of 1 bromo-2-butyne. The resulting mixture was heated to 700 for 15h and then the isopropanol was removed by evaporation in vacuo. The resulting white precipitate was collected by filtrtation, washed with isopropanol and ether and dried in vacuo to give 45.08g of the desired product as a white solid.
Step 4: 4 -But- 2 -ynyloxy-benzenesulfonyl chloride To a stirred solution of oxalyl chloride (47.8 ml, 0.545 mol) at 0°C in 240mL of CH 2 C12 was added a DMF (43.0 ml) solution of 4 -but-2-ynyloxy-benzenesulfonic acid sodium salt in a drop wise manner. The reaction mixture was stirred at 0 °C for and then let warm to room temperature and stirred for 18h. The reaction was then poured into ice and extracted with hexanes. The organics were washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to provide 42.0g of the desired product as yellow solid Step 5: 4 -But-2-ynyloxy-benzenethiol To a solution of 11.8g (0.045mol) of triphenylphosphine in lOmL of CH 2 C12 and 0.3mL of DMF was added dropwise a solution of 4-but-2-ynyloxy-benzenesulfonyl chloride in 15 mL CH 2 C1 2 Stirred at room temperature for two hours, added of IN HCI, stirred for 30 min., and then added 15mL of brine. The organics were separated and concentrated in vacuo. The residue was diluted with ether and filtered the insolubles. The filtrate was washed with 2.5N NaOH and the aqueous solution separated, acidified and extracted with ether. The organics were washed with H 2 0, brine, dried over MgSO 4 filtered and concentrated in vacuo to give 1.54g of the desired product as a pale yellow oil.
WO 00/44723 WO 0044723PCT/USOO/O1 864 Step 6: 1 -(tert-butyl) 4-ethyl {[4-(2-butynyloxy)phenyl]sulfanyl) methyl)- 1,4piperidinedicarboxylate A mixture of 0.294g (0.74mmol) of 1-(tert-Butyl) 4-ethyl 4-(iodomethyl)piperidine-1I,4-dicarboxylate, 0.145 (0.81 4mmol) of 4-but-2-ynyloxy-benzenethiol and 0.204g (1 .48mmol) of K 2 C0 3 in 2.OmL of DMF was stirred at room temperature for 18 h. The resulting mixture was diluted with EtOAc, washed with H 2 0, brine, dried over MgSO 4 and concentrated in vacuo. The residue was chromatographed on silica gel eluting with EtOAc:Hexanes (1:19) to provide 0.3 28g of the desired product as a colorless oil. Electrospray Mass Spec 448.3 Step 7: 4-(4-But-2-ynyloxy-phenylsulfanylmethyl)-piperidine- 1,4- dicarboxylic acid mono-tert-butyl ester A mixture of 0.288g (0.0643mmo1) of 1-(tert-butyl) 4-ethyl butynyloxy)phenyl] sulfanyl)methyl)-1I,4-piperidinedicarboxylate, 3 .25mL of IN NaGH 3.25mL of THF and 3.25mL of MeOH was heated to reflux for 3h. The organics were removed and the residue was diluted with H 2 0, acidified and extracted with EtOAC.
The organics were washed with H 2 0, brine, dried over n1gSO 4 filtered and concentrated in vacuo to provide 0.24 1g of the desired product as an off white gum. Electrospray Mass Spec: 464.3 (M+FA-H)- Step 8: WAY 173665 tert-butyl-4-({ [4-(2-butynyloxy)phenyl] sulfanyl)methyl)-4- [(hydroxyamino)carbonyl]- I -piperidinecarboxylate To a solution of 0.204g (O.49mmnol) of 4-(4-But-2-ynyloxy-phenysulfanylmethyl)-piperidine-I,4- dicarboxylic acid mono-tert-butyl ester, 0.079g (0.58mmol) of 1-hydroxybenzotriazole in 2.5mL of DMF was added 0.1 12g (0.84mmol) of 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and stirred at room temperature for lh. Then added 0.3mL of 50% aqueous hydroxylamnine and stirred for 18Sh. The resulting mixture was diluted with EtOAc, washed with H 2 0, brine, dried over MgSO 4 filtered and concentrated in vacuo. The residue was chromatographed on silica gel eluting with 1.5% MeOHI CH 2 Cl 2 to provide 0.077g (3 of the desired product as a white solid. Electrospray Mass Spec: 435.2 I' j~T~ i4W~7 ~~ijj i~L~ WO 00/44723 WO 0044723PCT/USOO/01864 -76- Example 31 4-({[4-(But-2-ynyloxy)phenyllthio} methyl)-N-hydroxypiperidine.4-carboxamide To a solution of 0. 143g (0.O33mmol) of tert-butyl-4-({ [4-(2-butynyloxy) phenyl]sulfanyl }methyl)-4- [(hydroxyamino)carbonyl]-lI-piperidinecarboxylate in 5mL of CK.C1 1 and lmL of MeOH was added 5mL of 4M HCl in dioxane and stirred for li. The reaction was concentrated in vacuo and the residue was triturated with ether and filtered to provide 0.093g of the desired product as a pale orange solid. Electrospray Mass Spec: 335.3 Example 32 tert-Butyl-4-({[4-(2-butynyloxy)phenylsulfinyl} methyl)-4-[(hydroxya mino)carbonylJ-1-piperidinecarboxylate To a slurry of tert-butyl-4-( 4 2 -butynyloxy)phenyljsulfanyl}methyl).4- [(hydroxyamnino)carbonyl]-l-piperidinecarboxylate (O.24g, 0.55 mmol) at 0 0 C in 7mL of MeOH was added dropwise 3.5rnL of 30% hydrogen peroxide. The reaction was allowed to warm to room temperature and stirred for 1 8h. The reaction was cooled to OTC and quenched with 3.5mL of a saturated solution of Na 2
SO
3 The organaics were removed and the aqueous solution was extracted with CH 2 Cl 2 The organics were washed with H 2 0, brine, dried over MgSO 4 filtered and concentrated in vacuo.
The residue was triturated with ether to provide 0. 166g of the desired product as an off white solid. Electrospray Mass Spec: 451.3 Example 33 4-(2-Butynyloxy)phenyllsulfinylj methyl]-N-hydroxy-4piperidinecarboxamide 4 2 -Butynyloxy)phenyl]sulfinyl~methyl)-N-hydroxy-4-piperidinecarboxamide was prepared according to the general method as outlined in Example 3 1.
Starting from tert-butyl-4-(( [4-(2-butynyloxy)phenyl]sulfinyl)methyl)-4-[(hydroxyaniino)carbonyl]-l-piperidinecarboxylate (0.082 g, 0.18 mmol), 0.0 6 6g of the desired product was isolated as a white solid. Electrospray Mass Spec:35 1.2 2N W A, WM _Miy W"AWWRIN WO 00/44723 WO 0044723PCTUSOO/0I 864 -77- Example 34 tert-Butyl-4-(14-(but-2-ynyloxy)phenyllsulfonyl~methyi)-4- I(hydroxyamino)carbonyll piperidine-1 -carboxylate To a solution of tert-butyl-4-( {[4-(2-butynyloxy)phenyl]sulfanyllmethyl)-4- [(hydroxyamino)carbonyl]-1-piperidinecarboxylate (0.422g, 0.97 mmol) in 8mL of MeOH, 4mL of CH 2 Cl 2 and 2mL of THEF was added a solution of 1 .79g (2.9 immol) of OXONE in 8mL of H 2 0 and stirred at room temperature for 1 8h. The solid was filtered and the filtrate was concentrated in vacuo. The residue was diluted with EtOAc, washed with H-20, brine, dried over MgSO 4 filtered, and concentrated to provide 0.3 5 1g of the desired product as a white solid. Electrospray Mass Spec: 467.3 Example tert-butyl-4-({14-(2-butynyloxy)phenyllsulfonyl} methyl)-4- I(hydroxyamino)carbonyll-l-piperidinecarboxylate tert-Butyl-4-( {[4-(2-butynyloxy)phenyl]sulfonyl )methyl)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate was prepared according to the general method as outlined in Example 31. Starting from tert-Butyl-4-( {[4-(but-2-ynyloxy)phenylisulfonyl) methyl)-4-[(hydroxyamino)carbonyl]piperidine- 1-carboxylate (0.10Og, 0.2 l4mmol) 0.074g of the desired product was isolated as white solid.
Electrospray Mass Spec: 367.3 Example 36 1 -Acetyl-4- [4-(2-butynyloxy)phenyl] sulfonyll methylj-N-hydroxy-4piperidinecarboxamide Step 1: 4-11114-(2-Butynyloxy)phenyl]sulfonyl]methyl]- 1,4- piperidine dicarboxylic acid, 1 -tert-butyl 4-ethyl ester To a solution of 1-(tert-butyl) 4-ethyl 4-({[4-(2-butynyloxy)phenyl]sulfanyl)methyl)- 1,4- piperidinedicarboxylate (1.66 g, 3.7 mmol) (prepared in example 30, step 6) in 2OmL of CH 2 Cl 2 was added tetrabutylammonium oxone (17.38g, 14.7 mmol) and stirred at room temperature for 1 8h. The reaction was concentrated in vacuo and the WO 00/44723 PCT/US00/01864 -78residue was diluted with EtOAc, washed with H 2 0, 5% KHSO 4 brine, dried over MgSO 4 filtered and concentrated to provide 1.69g of the desired product as a pale yellow gum. Electrospray Mass Spec: 480.3 (M+H) Step 2 4-[[[4-(2-Butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid, ethyl ester 4 2 -Butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester was prepared according to the general method as outlined in Example 31.
Starting from 4 4 2 -Butynyloxy)phenyl]sulfonyl]methyl]-1 4 -piperidinedicarboxylic acid 1-tert-butyl 4-ethyl ester (1.62g 3.4mmol), 1.
3 3 5g of the desired product was isolated as a tan solid. Electrospray Mass Spec: 380.2 Step 3: 1 -Acetyl-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid, ethyl ester To a solution of 4 4 2 -Butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester (0.24g, 0.576mmol), triethylamine (0.32 ml) and catalytic amount of 4 -Dimethylaminopyridine in 6.mL of CH 2 C1 2 was added a solution of acetyl chloride (0.068 ml, 0.864 mmol) in 1.0mL of CH 2
C
2 The reaction stirred at room temperature for 4h and washed with H 2 0, brine, dried over MgSO 4 filtered through a pad of silica gel and concentrated to provide 0.242g (100%) of the desired product as a colorless gum. Electrospray Mass Spec: 422.2 Step 4: 1-Acetyl-4-(4-but-2-ynyloxy-benzenesulfonylmethyl)-piperidine-4- carboxylic acid 1-Acetyl-4-(4-but-2-ynyloxy-benzenesulfonylmethyl)-piperidine-4- carboxylic acid was prepared according to the general method as outlined in Example 30, (step Starting from 1-Acetyl-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid, ethyl ester (0.22 g, 0.524 mmol), 0.141 g of the desired product was isolated as a pale yellow solid. Electrospray Mass Spec: 438.2 (M+FA-H)- 0 ll~UIIIY~I i*ill~~ 1~i* i ii iI1~1~ i~iliill iI* ~IIRrlUY .li~ ni. l 'I n iin. i.l ~rr l t i i li~~l, I AU rh. AL. W i~M~sk4~wo..,s~d ISTL~i.S A~1~ L l~V 3 Ui, M*xrlAr IA'3Ai~ /',AlSJL ,l~il!i l :ArLAnrA' ~rAA(:r l jj3'"3,~ WO 00/44723 WO 0044723PCTIUSOO/01864 -79- Step 5: 1 -Acetyl-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-N-hydroxyA..
piperidinecarboxamide I -Acetyl-4-[[[4-(2-butynyloxy)phenyl] sulfonyl]methyl]-N-hydroxy-4pipenidinecarboxamide was prepared according to the general method as outlined in Example 30 (step Starting from l-Acetyl- 4 -(4-but-2-ynyloxy-benzenesufonylmethyl)-piperidine-4-carboxylic acid, (0.122 g, 0.31 mmol) 0.048g (3 of the desired product was isolated as a pale yellow solid. Electrospray Mass Spec: 409.2 Example 37 l-(2-Butynyl)-4-({14-(2-butynyloxy)phenyljsulfonyl~ methyl)-N-hydroxy-4piperidinecarboxamide hydrochloride Step 1: 1 2 -Butynyl)-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]A..
piperidinecarboxylic acid, ethyl ester A mixture of 4 4 2 -Butynyloxy)phenyl]sulfony]methy1]-4-piperidinecarboxylic acid ethyl ester (0.208 g,0.5 mmol), 1-bromo-2-butyne (0.044 ml, 0.53 mmol) and K 2 C0 3 (0.138 g, 1.0 mmol)in 5.0m.L of DMF was stirred at room temperature for 6h. The reaction was diluted with EtOAc and washed with H 2 0, brine, dried over MgSO 4 filtered, and concentrated in vacuo. The residue was chromatographed. on silica gel eluting with EtOAc:hexanes to provide 0.1 83g of the desired product as a pale yellow gum. Electrospray Mass Spec: 432.2 Step 2: 1 2 -Butynyl)-4-[4-(2-butynyloxy)benzenesulfonylmethyl]..piperidine-4 carboxylic acid I 2 -Butynyl)-4-[4-(2-butynyloxy)benzenesulfonylmethyl]ypiperidine.4carboxylic acid was prepared according to the general method as outlined in example 3 0 (step Starting from 1 2 -Butynyl)-4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid, ethyl ester, (0.153 g, 0.3 54 mmol), 0.12 g (84%) of the desired product was isolated as a white solid. Electrospray Mass Spec: 404.2 WOMM A JWYIII miapno gy -g0- Step 3: 1 utynyl)4-( {[4-(2-butynyloxy)phenyl] sulfonyl )methyl)-N-hydroxy-4piperidinecarboxamnide hydrochloride 1 -(2-Butynyl)-4-( {[4-(2-butynyloxy)phenyljsulfonyl }methyl)-N-hydroxy-4piperidinecarboxamide hydrochloride was prepared according to the general method as outlined in Example 30 (step Starting from l-(2-butynyl)-4-(4-(2-butynyloxy)benzenesulfonylmethyl]-pipenidine-4-carboxylic acid, (0.15g 0.34mmol) ,0.05g of the desired product, which was dissolved in 1.0mb of CH 2 C1 2 and treated with 0.225mL of IM HCI in CH 2
CI
2 The solution was stirred for lh, and concentrated in vacuo. The residue was triturated with ether to provide 0.044g of the hydrochloride of the desired product as a beige solid. Electrospray Mass Spec: 41 9.2.
Example 38 .N-I -(tert-Butyl)-4-(ff4-(2-butynyloxy)phenylj sulfonyl~methyl)-N-4-hydroxy-1,4- 1 ,4-piperidinedicarboxamide Step 1: 1 -tert-Butylcarbamoyl-4-(4-but-2-ynyloxy-benzenesulfonylmethyl)piperidine-4-carboxylic acid ethyl ester To a solution of tert-butylisocyanate (0.097 ml, 0.85 mmnol) in 8.0mb of C11T 2 0 2 was added 4-[[[4-(2-Butynyloxy)phenyl]sulfonyl]methyll-4-piperidinecarboxylic acid ethyl ester (prepared from example 36, step 2) (0.337 g, 0.81 mmol) and triethylamine (0.135 ml, 0.97 mmol) and stirred at room tcmperature for 2h. The reaction was diluted with CH 2
CI
2 and washed with H120, brine, dried over MgSO 4 ~.filtered, and concentrated in vacuo. The residue was triturated with ether:hexanes 25 to provide 0,284g of the desired product as a white solid. Electrospray Mass Spec: 479.2 Step 2: 1 -[(tert-Butylamino)carbonyl]-4-(({[4-(2-butynyJoxy)phonyl] sulfonyl) methyl)-4-onyl]-4-( ([4-(2-butynyloxy)phenyl]sulfonyl )methyl)-4- 30 piperidinecarboxylic acid 1 -[(tert-ButylamiLno)carbonyl]-4-({([ 4 2 -butynyloxy)phenyl]sulfonyl }methyl)- 4-onyl]-4-( {[4-(2-butynyloxy)phenyl]sulfonyl) mcthyl)-4-piperidine WO 00/44723 WO 0044723PCTUSOO/0I 864 -81carboxylic acid was prepared according to the general method as outlined in Example (step Starting from l-tert-butylcarbamoyl-4-(4-but.2-ynyloxy-benzenesulfonylmethyl)-piperidine-4-carboxylic acid ethyl ester (0.
2 59g, 0.54 mmol), 0. 169 g, of the desired product was isolated as white solid. Electrospray Mass Spec: 451.4 Step 3: N-I -(tert-Butyl)-4-({ 4 2 -butynyloxy)phenyl]sulfonyl) methyl)-N-4-hydroxy- 1 4 4 2 -butynyloxy)phenyl]sulfonyl }methyl)-N-4-hydroxy- I 4 -l]sulfonyl~methyl)-N- 4-hydroxy- 1 4 -piperidinedicarboxamide N- I- (tert-Butyl)-4-( {[4-(2-butynyloxy)phenyllsulfonyl }methyl)-N-4hydroxy- 1 4 4 2 -butynyloxy)phenyl]sulfonyl }methyl)-N-4-hydroxy- 1,4-1]sulfonyl }methyl)-N-4-hydroxy- 1,4-piperidinedicarboxamide was prepared according to the general method as outlined in Example 30 (step Starting from l-[tert- Butylamnino)carbonyl]y4..( [4-(2-butynyloxy)phenyllsulfonyl Imethyl)-4-onyl]-4-( [4- (2-butynyloxy) phenyl] sulfonyl }methyl)-4-piperidinecarboxylic acid 149g, 0.33 mmol), 0.077 g of the desired product was isolated as pale yellow solid. Electrospray Mass Spec: 466.3 Example 39 Methyl 4 4 2 -butynyloxy)phenyllsulfony~methyl).4 [(hydroxyamino)carbonylj- 1-piperidinecarboxylate Step 1: 4 4 -But- 2 -ynyloxy-benzenesulfonylmethyl)pipeiine-1,4- dicarboxylic acid ethyl ester methyl ester To a solution of 4 4 2 -Butynyloxy)phenyl]sulfonyl]methyl].4-piperidinecarboxylic acid ethyl ester (0.3 54 g, 0.85 mmol) in 1 .OmL of CH 2
CI
2 under N 2 atmosphere was added dropwise a solution of N,O-bis(trimethylsilyl)acetanjde (0.462 ml, 1.87 mmol) in 0.5mL of CH 2 Cl 2 and stirred for li. The reaction was cooled to OTC and added dropwise a solution of 0.079nmh (1 .O2mmol) of methyichioroformate in of CH 2
CI
2 The reaction was allowed to stir at room temperature for lh and cooled to 0 0 C, quenched with pH7 buffer solution and extracted with EtOAc. The organics was washed with H 2 0, brine, dried over MgSO 4 filtered, and concentrated in WO 00/44723 WO 0044723PCTUSOO/OI 864 -82vacuo. The residue was chromatographed on silica gel eluting with EtOAc:hexanes to provide 0.31 5g of the desired product as a colorless oil. Electrospray Mass Spec: 438.3 Step 2: 4 4 -But- 2 -ynyloxy-benzenesulfonylmethyl)-piperidine-.1,4- dicarboxylic acid monomethyl ester 4 4 -But- 2 -ynyloxy-benzenesulfonylmethyl).piperidine-1 I,4-dicarboxylic acid monomethyl ester was prepared according to the general method as outlined in Example 30 (step Starting from 4 4 -But-2-ynyloxy-benzenesulfonylmethyl).
piperidine-1,4- dicarboxylic acid ethyl ester methyl ester (0.277 g, 0.633 mmol), 0. 175g of the desired product was isolated as white solid. Electrospray Mass Spec: 410.2 Step 3: Methyl [4-(2-butynyloxy)phenyl] sulfonyl }methyl)-4-[(hydroxyamino)carbonyl]- 1 -pip eridinecarb oxylate, Methyl-4-( 4 2 -butynyloxy)phenyl]sulfonyl~methyl)-4-[(hydroxyamino)carbonyl]-l-piperidinecarboxylate was prepared according to the general method as outlined in Example 30 (step Starting from 4 -(4-But-2-ynyloxy-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid monomethyl ester (0.15 g, 0.3 66 mmol),- 0.053g (3 of the desired product was isolated as a white solid. Electrospray Mass Spec: 425.3 Example Benzyl 4-({[4-(2-butynyloxy)phenylsulfonyllmethyl).4 [(hydroxyamino)carbonylJ- 1-piperidinecarboxylate Step 1: 4 4 -But-2-ynyloxy-benzenesulfonylmethyl)-piperidine I ,4-dicarboxylic acid benzyl ester ethyl ester 4 4 -But-2-ynyloxy-benzenesulfonylmethyl)-piperidine-1,4- dicarboxylic acid benzyl ester ethyl ester was prepared according to the general method as outlined in Example 39 (step Starting from 4 4 2 -Butynyloxy)phenyl]sulfonyl]methyl-4- 9 W"W -83piperidinecarboxylicacid ethyl ester (0.3 12 g, 0.75), 0.337g of the desired product was isolated as colorless oil. Electrospray Mass Spec, 514.2 (M+I1r 51 Step 2: 4-(4-But-2-ynyloxy-benzenesulfonylmethyl)-piperidine- 1,4- dicarboxylic acid monobenzyl ester 4-(4-But-2-ynyloxy-benzenesulfonylmethyl)-piperidile- 1,4- dicarboxylic acid monobenzyl ester was prepared according to the general method as outlined in Example 30 (step Starting from 4-(4-But-2-ynyloxy-benzenesulfonylmethyl)piperidine-1,4- dicarboxylic acid benzyl ester ethyl ester (0.32g, 0.623 mmol) 0.2 g.
of the desired product was isolated as white solid.. Electrospray Mass Spec: 484.2 Step 3: Benzyl {[4-(2-butynyloxy)phenyljsulfonyl) methyl)-4-[(hydroxyaniino)carbonyl]- 1 -piperidinecarboxylate Benzyl {[4-(2-butynyloxcy)phenyl]sulfonyl}methyI)-4-[(hydroxyamino) carbonyl)-lI-piperidinecarboxylate was prepared according to the general method as outlined in Example 30, (step Starting from 4-(4-But-2-ynyloxy-benzene sulfonylmethyl)-piperidine-1 ,4-dicarboxylic acid monobenzyl ester (0.18 g, 0.37 mmol), 0.106 g (57%)of the desored product was isolated as off-white solid.
Electrospray Mass Spec: 501.3 Example 41 1-Benzyl-4-({14-(2-butynyloxy)phenyl] sulfonyll methyl)-N-hydroxy-4piperidinecarboxamide Step 1: Ethyl- I -benzyl.4-( {[4-(2-butynyloxy)phenyl]sulfonyl} methyl)-4-4-(2butynyloxy)phenyl]sulforiyl) methyl)-4-piperidinecarboxylate Ethyl- I -benzyl-4-( {[4-(2-butynyloxy)phenyl~sulfonyl) methyl)-4-4-(2-butynyloxy)phenyljsulfonyl }methyl)-4-piperidinecarboxylate was prepared according to the general method as outlined in Example 37 (step Starting from 4-(((4-(2-Butynyloxy)phenyllsulfonyljmethyl]-4-piperidinecarboxylicacid ethyl ester (prepared in WO 00/44723 PCT/USOO/01864 -84- Example 36, step 2) (0.31 2g,0.75 mmol), 0.265g of the desired product was isolated as white solid.Electrospray -Mass Spec: 470.2 (M+H)Y Step 2: 1 -Benzyl-4-( 4 2 -butynyloxy)phenyl] sulfonyl Imethyl)-4-piperidinecarboxylic-benzyl-4({ 4 -(2-butynyloxy)phenyl] sulfonyl }methyl)-4-piperidinecarboxylic acid I -Benzyl-4-(( 4 2 -butynyloxy)phenyllsulfonyl }methyl)-4-piperidinecarboxylic benzyl-4-( 4 -(2-butynyloxy)phenyl] sulfonyl }methyl)-4-piperidinecarboxylic acid was prepared according to the general method as outlined in Example 30 (step 7).
Starting from Ethyl-i -benzyl-4- 4 2 -butynyloxy)phenyljsulfonyl }methyl)-4-4-(2butynyloxy)phenyil]sulfonyl )methyl)-4-piperidinecarboxylate (0.25g, 0.53 mmol), 0.227g of the desired product was isolated as a white solid. Electrospray Mass Spec: 442.2 Step 3: 1 -Benzyl-4-( 4 2 -butynyloxy)phenyl]sulfonyl }methyl)-N-hydroxy-4utynyloxy)phenyl]sulfonyl} methyl)-N-hydroxy-4-piperidinecarboxamide 1 -Benzyl-4-( 4 2 -butynyloxy)phenyl]sulfonyl }methyl)-N-hydroxy-4.butynyl.
oxy)phenyl]sulfonyl }methyl)-N-hydroxy-4piperidinecarboxamide was prepared according to the general method as outlined in Example 30 (step Starting from I- Benzyl-4-( 4 2 -butynyloxy)phenyl]sulfonyl )methyl)-4-piperidinecarboxylic-enzyl.
butynyloxy)phenyljsulfonyl }methyl)-4-piperidinecarboxylic acid 0 .211g, 0.44 mmol), 0.108g of the desired product was isolated as white solid.. Electrospray Mass Spec: 457.2 Example 42 4 4 -(2-Butynyloxy)phenyljsulfonyl} methyl)-N-hydroxy-1-[(2,2,5trimethy-1 ,3dioxan- 5 -yl)carbonylj-4-piperidinecarboxamide Step 1: Ethyl 4 -(2-butynyloxy)phenyflsulfonyl }methyl)- trimethyl- 1,3 dioxan-5-y1)carbonyl]-4-piperidinecarboxcylate Ethyl (2-butynyloxy)phenyl]sulfonyl }methyl)-1- trimethyl- 1,3-dioxan 5-yl)carbonyl]-4-piperidinecarboxylate was prepared according to the general method WO 00/44723 WO 0044723PCT/USOO/O1 864 as outlined in Example 30 (step Starting from 4 -IiI[4-(2-Butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylicacid ethyl ester (0.333g, 0.8 mmol) and 2,2,5-trimethyl-(l,3)dioxane-5-carboxylic acid (0.168g, 0.96 mmol), 0.339g of the desired product was isolated as a white solid. Electrospray Mass Spec: 536.1 Step 2: {[4-(2-Butynyloxy)phenyl]sulfonyl )methyl)- 5-trimethyl- 1,3 -dioxan- 5-yl)carbonyl]-4-piperidinecarboxylic acid {[4-(2-Butynyloxy)phenyllsulfonyl }methyl)-lI- [(2,2,5-trimethyl- 1,3-dioxan-5-yl)carbonyl]-4-piperidinecarboxylic acid was prepared according to the general method as outlined in Example 30 (step Starting from ethyl [4-(2-butynyloxy)phenyllsulfonyl }methyl)- 1-[(2,2,5-trimethyl- 1,3-dioxan-5-yl)carbonyl]-4-piperidinecarboxylate (0.299g, 0.558 mmol), 0.235g of the desired product was isolated as white solid. Electrospray Mass Spec: 506.2 Step 3: {[4-(2-Butynyloxy)phenyl]sulfonyl )methyl)-N-hydroxy-l1-[(2,2,5trimethyl- 1,3 -dioxan-5-yI)carbonyl]-4-piperidinecarboxarnide {[4-(2-Butynyloxy)phenyl]sulfonyl) methyl)-N-hydroxy- trimethyl- 1,3-dioxan-5-yl)carbonyl]-4-piperidinecarboxamide was prepared according to the general method as outlined in Example 30 (step Starting from Butynyloxy)phenyljsulfonyl~methyl)- 5-trimethyl- 1,3 -dioxan-5-yI)carbonyl]-4piperidinecarboxylic acid (0.22g, 0.433 mmol), 0.16 g of the desired product was isolated as white solid. Electrospray Mass Spec: 523.2 Example 43 [4-(2-Butynyloxy)phenyl] sulfonyl} methyl)-N-hydroxy-l-13-hydroxy-2- (hydroxymethyl)-2-methylpropanoyl]-4-piperidinecarboxamide A mixture of [4-(2-Butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy- 1- 5-trimethyl- 1,3 -dioxan-5-yI)carbonyl]-4-piperidinecarboxamide 106 g, 0.2 mmol) and 2mL of IN HCI in 2mL of THF was stirred at room temperature for 4h.
The reaction was diluted with EtOAc, washed with H 2 0, saturated NaHCO 3 brine, ~rI~r.~rr -~8n?~tra-.r-fl, I (LW 4LLIWIrflv w(Amy*vtTt;tVrI,~ -86dried over MgSO 4 filtered, and concentrated in vacuo. The residue was triturated with ether to provide 0.6 7 g of the desired product as an off white solid.
Electrospray Mass Spec: 483.2 (M+H) t Example 44 1-IAmino(imino)methyl-4([4-(2-butynyloxy)phenylsulfon1yllmethyl)-Nhydroxy-4-piperidinecarboxamide Step 1: NN-t-Boc-protected thiourea: To a stirred solution of thiourea (0.57g, mrnol) in l5OxnL of THF under N 2 at 0 0 C was added 60% NaH (1.35g, 33.8 inmol) in mineral oil. After 5 minutes, the ice bath was removed and the reaction mixture was allowed to stir at room temperature for 10 minutes. The reaction mixture was cooled to 0 0 C and 3.6g (I 6.5mrnol) of di-tert-butyl dicarbonate was added. After 30 minutes, the ice bath was removed and the reaction was stirred for 2h. The reaction was then quenched with saturated NaHCO 3 solution, poured into water and extracted with 3x EtOAc. The organics were washed with H 2 0, brine, dried over MgSO 4 filtered, and concentrated in vacuo. The residue was triturated with hexane to provide 1.72g (83%) of the desired product as a white solid.
Step 2: tert-Butyl4.{(tert-butoxyamino)carbonyl]-4-( {[4-{2-yloxy)phenyl] sulfonyl methyl)-]I -piperidinecarboxylate tert-Butyl4-((tert-butoxyamino)carbonyl]-4-( {[4-(2-yloxy)phenyl~sulfonyl) methyl)-l-piperidinecarboxylate was prepared according to the general qiethod as outlined in Example 30 (step Starting from 4-(4-but-2-ynyloxy-benzenesulfonyl 25 methyl)-piperidine- 1,4- dicarboxylic acid mono-tert-butyl ester (2.53 g, 5.6 mmol) and 0-tert-butyl-hydroxylamine hydrochloride (1.4 g, 11.2 mmol), 2.31 g of the desired product was isolated as a white solid. Electrospray Mass Spec: 523.2 Jkql OMNYAOW YLIVK4'A*WI MW* -87- Step 3: N-(tert-Butoxy)-4-({([4-(2-butynyloxy)phenyl] sulfonyl} methyl-4piperidinecarboxamide To a solution of tert-Buty14-[(tert-butoxyamino)carbonylJ-4-( {[4-(2-yloxy)phenyl]sulfonyl)methyl)-l-piperidinecarboxylate (3.0 g, 5.5 mnmol) in 61nt of CI{ 2 C1 2 was added of trimethylsilyltrifluoromethylsulfonate (1.1 ml, 6.05 mnmol) followed by O-7mL of 2,6-lutidine. The reaction was stirred for Ilh and diluted with CH 2
CI
2 The organics were washed with H 2 0, saturated NaHCO 3 brine, dried over MgS04, filtered, and concentrated in vacuo to provide 2O01g of the desired product as an off white solid. Electrospray Mass Spec: 423.2 Step 4: [[4-((tert-Butoxyamino)carbonyl] -4-[[[4-(2-(4-(2-butynyloxy)phenyl)sulfonyl} methyl)-4-piperidinecarboxamide butoxycarbonyl)aminoj methylene]carbamic acid, tert-butyl ester To a mixture of N-(tert-Butoxy)-4-( {[4-(2-butynyloxy)phenyl]sulfonyl)mrethyl)-4-[4- (2-butynyloxy)phenyl]sulfonyl }metbyl)A4-piperidinecarboxaxnide (0.1 27g, 0.mmol), the di-t-boc-protected thiourea (obtained from step 1) (0.091g, 0.33 mmol)and triethylamine (0.092 ml) in 3mL of DMF was added mercury(U) chloride (0.09g, 0.33 mmol) and stirred for Ih at 0 0 C. The reaction was diluted with EtOAc and filtered through a pad of celite, The organics were washed with H 2 0, brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was triturated with hexanes to provide the desired product as a white solid. Electrospray Mass Spec: 665.5 Step 5: 1 -[Amino(imino)methylJ-4-({(4-(2-butynyloxy)phenyl] sulfonyl) methyl)-Nhiydroxy-4-piperidinecarboxamide A mixture of [[4-[(tert-Butoxyamino)earbonyl]-4-[L[4-(2-[4-(2-butynyloxy)phenylisulfonyl }methyl)-4-piperidinecarboxamidebutoxycarbonyl)amninojmethylene] carbamic acid, tert-butyl ester 135g, 0.2 mmol) and 3mL of trifluoroacetic acid in 2mL of C11 2
C
2 was heated at 60'C for 24h. The reaction was concentrated in vacuo and was prep HPLC to provide 0.032g (3 of the desired product as a beige solid.
Blectrospray Mass Spec: 409.3 (M+H)4' -6 ?W l11v;1 ONW'' MV fW~ Example 4-({j4-(2-Butynyloxy)phenyljsulfonyl} methyl)-N-hydroxy-l-(4-hydroxy-2butynyl)-4-piperidinecarboxamide Step 1: Ethyl-4-( ([4-(2-butyyoxy)phenyI]sulfonyI }methyl)- chloroanilino)carbonyl]oxy) -2-butynyl)-4-pipendinecarboxylate Ethy!-4-(({[4-(2-butynyloxy)phenyl~sulfonyl) methyl)- 1 [(3-chioroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate was prepared according to the general method as outlined in Example 37 (step Starting from 4-[[[4-(2-B3utynyloxy)phenyljsulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester (0.291 g,0.7 mmol) and 4-chloro-2-butynyl-(3-chloroplienyl)carbanate (0.1 9g, 0.73S), 0.27 g of the desired product was isolated as pale yellow oil. Electrospray Mass Spec: 601.3 Step 2: Ethyl-4-( ([4-(2-butynyloxy)phenyl]sulfonyl} methyl)- I-(4-hydroxy-2butynyl)-4- nyloxy)phenyl] sulfonyl) methyl)- I -(4-hydroxy-2-butynyl)-4-piperidine carboxylate A solution of ethyl-4-({(4-(2-butynyloxy)phenyl]sulfonyl }methyl)- chioroanilino) carbonyl~oxy} -2-butynyl)-4-piperidinecarboxylate (from step 1) 0.22g, 0.366 mmol) and lithiumhydroxide hydrate (0.019g, 0.44 mmol) in 4mL MeOH was* heated to refhix for 3h. The reaction was concentrated, diluted with H20O, acidified to pH3 and extracted with CH 2
I
2 The organics were washed with H 2 0, bnhne, dried over MgSO 4 filtered, and concentrated in vacuo. The residue was chroinatographed on silica gel eluting wvith 3% MeOH/ CH 2
CI
2 to provide 0.12g 73%) of the desired product as an yellow oil. Electrospray Mass Spec: 448.3 Step 3: {[4-(2-Butynyloxy)phenyljsulfonyl) methyl)- 1-(4-hydroxy -2-butynyl)-4- Anyl]sul-fony1}mtethyl)±l(4-hydroxy2--butynyl)--4-iperidineaboxyic-acid {14-(2-Butynyloxy)phenyljsulfonyl) methyl)- I -(4-hydroxy-2-butynyl)-4-ynyl]sulfonyl }methyl)- 1-(4-hydroxy-2-butynyl)-4-piperidinecarboxylic acid was prepared according to the general method as outlined in Example 30 (step Starting from k'".111 .11" 0 Ie IIP-Y-AkIIKWNAIKAVr WO 00/44723 WO 0044723PCT/USOO/01864 -89ethyl-4-( {[4-(2-butynyloxy)phenyljsulfonyl methyl)- I (4-hydroxy-2-butynyl)-4piperidinecarboxylate 1 15g, 0.257 mmol), 0.08g of the desired product was isolated as white solid. Electrospray Mass Spec: 420.4 Step 4: (2-Butynyloxy)phenyl] sulfonyl }methyl)-N-hydroxy- 1-(4-hydroxy-2butynyl)- henyl] sulfonyl) methyl)-N-hydroxy- I 4 -hydroxy-2-butynyl).4piperidinecarboxamide {[4-(2-Butynyloxy)phenyl) sulfonyl) methyl)-N-hydroxy. I -(4-hydroxy-2butynyl)phenyl]sulfonyl }methyl)-N-hydroxy- I 4 -hydroxy-2-butynyl)-pip en dine..
carboxamide was prepared according to the general method as outlined in Example (step Starting from {[4-(2-Butynyloxy)phenyl]sulfonyl} methyl).I -(4-hydroxy- 2-butynyl)-4-nyl] sulfonyl)methyl)- I-( 4 -hydroxy-2-butynyl)-4-piperidinecarboxylic acid (0.073g, 0.174 mmol), 0.026g of the desired product was isolated as white solid. Electrospray Mass Spec: 435.3 Methods for the solution phase synthesis of the compounds of the present invention is as shown in the following scheme.
O-f ~ONH OtBu B <~NO A 0 F 2 ONHOtBu N A k-I RN
RR
Example 46 4 4 -(But-2-ynyloxy)phenylj sulfonyl) methyl)-1 -ethyl-N-hydroxypiperidine-4carboxamide triflouroacetic acid salt Step A: A solution of N-(tert-butoxy)-4-({[4-2-butynyloxy)phenyl]sulfonyly.
methyl)-4-[4-(2-butynyloxy)phe nyl]sulfonyl )methyl-4-piperidinecarboxyamide (0-097g, 0.23mmol), ethyl iodide (0.Ol9mL ,0.24mmol)and triethylamine (0.096mL, 0.69mmol) in 2mL of CH2CI2 was shaken at room temperature for 1 8h and then concentrated in vacuo.
f-YARMONIXAMI/I VIVAIA lyql INAM 0*101W, OMIAWMWNW "!Ow WO 00/44723 WO 0044723PCTUSOO/01 864 Step B: A solution of the residue from Step A in 1 mL of CH2CI2 and I ml, of trifluoroacetic acid was heated at 50'C for 2h and then concentrated in vacuo to provide the desired product.
The following hydroxamic acids were synthesized according to the procedures of [4-(But-2-ynyloxy)phenyl]sulfonyl)methyl)- I -ethyl-N-hydroxypiperidine-4carboxamide triflouroacetic acid salt using the appropriate reagents.
Example 47: Reagent 0.029mL (O.24mmol) of [4-(But-2-ynyloxy)phenyl] sulfonyl} methyl)- 1 -I(5-chlorothien-2-yl)methyl]-Nhydroxypiperidine-4-carboxamide triflouroacetic acid salt Example 48: Reagent 0.0496g (0.24mmol) of 4-picolyl chloride hydrochloride [4-(But-2-ynyloxy)phenyl] sulfonyl)methyl)-N-hydroxy- 1-(pyridin-4-ylmethyl)piperidine-4-carboxamide triflouroacetic acid salt Example 49 4-((4-(But-2-ynyloxy)phenyllsulfonyl~methyl)-N-liydroxy- 1-(pyridin-3 ylcarhonyl)piperidine-4-carboxamide tniflouroacetic acid salt Step A: A solution of N-(tert-butoxy)-4-(114-92-butynyloxy)phenyl]sulfonyl) methyl)-4-[4-(2-butynyloxy)phenyl]sulfonyl~methyl-4-piperidine carboxyamide (0.097g, 0.23mmol), triethylamine (O.064mL, 0.64mmol), nicotinoyl chloride hydrochloride (0.061g ,O.34mmol), and 4-dimethylaminopyridine, (0.002 g) in 2mL of CH2CI2 was shaken at room temperature for 1 8h and then concentrated in vacuo.
Step B: same as Step B of Example 46.
The following hydroxamic acids were synthesized according to the procedures of 4- [4-(But-2-ynyloxy)phenyl] sulfonyl }methyl)-N-hydroxy- I -(pyridin-3-ylcarbonyl)piperidine-4-carboxamide triflouroacetic acid salt using the appropriate reagents.
TI
WO 00/44723 WO 0044723PCT/USOO/01 864 -91- Example Reagent 0.04mb (0.276mmol) of benzoyl chloride 1-Benzoyl-4-({[4-(but-2-ynyloxy)phenylsulfonyl} methyl)-N-hydroxypiperidine- 4- carboxamide Example 51 Reagent 0.O37mL (0.276mmo1) of 2-thiophenecarbonyl chloride 4-((14-(But-2-ynyloxy)phenylj sulfonyl) methyl)-N-hydroxy--(thien-2.
ylcarbonyl) piperidine-4-carboxamjde Example 52 4-(14-(But-2-ynyloxy)phenyll sulfonyl) methyl)-N- l-ethyl-N-4-hydroxypiperidine- 1,4-dicarboxamide Step A: A solution of N-(tert-butoxy)-4-( 4 9 2 -butynyloxy)phenyl) sulfonyl }methyl)- 4 -[4-(2-butynyloxy)phenyl] sulfonyl~methyl-4-piperidinecarboxyamiide 097g, .23mmol), triethylamine (0.064mb, 0.64mmol) and ethyl isocyanate (0.02mL, 0.253mmo1) in 2mL of CH2C12 was shaken at room temperature for 1 8h and then concentrated in vacuo.
Step B: same as Step B of Example 46.
The following hydroxamic acids were synthesized according to the procedures of Example 52.using the appropriate reagents.
Example 53 Reagent 0.275mL (0.253mmol) of phenylisocyanate, 4 -(1 4 -(But- 2 -ynyloxy)phenyllsulfonyl~methyl).N..4.hydroxy..N-1phenylpiperidine-1 ,4-dicarboxamide Example 54 Reagent 0.32mb (0.253mmo1) of diethylcarbamyl chloride 4 4 -(But-2-ynyloxy)phenyllsulfonyl} methyl)-N-1-,N-1-diethyl-N.4hydroxypiperidine- 1,4-dicarboxamide WO 00/44723PC/SO086 PCT/USOO/01864 -92- Example Reagent O.O295mL (O.253mmo1) of morpholine carbonyl chloride 4-({[4-(But-2-ynyloxy)phenyllsulfonyl~metbyl)-N-hydroxy-1-(morpbolin-4ylcarbonyl)piperidine-4-carboxamide Example 56 Reagent 0.043g (O.253mmol) of methyiphenylcarbamoyl chloride 4-({[4-(But-2-ynyloxy)phenyl]sulfonyl }methyl)-N-4-hydroxy-N- 1-methyl-N-Iphenylpiperidine-1,4-dicarboxamide Example 57 Octyl-4-({[4-(but-2-ynyloxy)phenyl]sulfonyllmethyl)-4- [(hydroxyamino)carbonyl]piperidine- 1-carboxylate Step A: A solution of 0.097g (0.23mmol) of N-(tert-butoxy)-4-({[4-92-butynyloxy)phenyl]sulfonyl~methyl)-4-[4-(2-butynyloxy)phenyl] sulfonyl) methyl-4-piperidinecarboxyamide (0.097g, 0.23mmol), octyl chioroformate (0.0495 ml, 0.253 mmol) and diisopropylethylamine (0.08 ml, 0.46 mmol) in 2mL of CH2Cl2 was shaken at room temperature for 1 8h and then concentrated in vacuo.
Step B: same as StepB of Example 46.
The following hydroxamic acids were synthesized according to the procedures of Example 57 using the appropriate reagents.
Example 58 Reagent O.O38mL (O.253mmo1) of 4-methoxyphenyl chloroformate 4-Methoxyphenyl4-({14-(but-2-ynyloxy)phenyl] sulfonyl) methyl)-4- [(hydroxyamino) carbonyljpiperidine-l-carboxylate 4 110 0 ,O ON""w- WO 00/44723 WO 0044723PCTUSOO/01 864 -93- Example 59 Reagent 0.O323mL (0.253mmo1) of benzenesulfonyl chloride 4 -(But- 2 -ynyloxy)phenyllsulfonyljmethyl)-N-hydroxy.1-(phenylsulfonyl) piperidine-4-carboxamide Example Reagent 0.0457g (0.253mmo1) of 1-methylimidazole-4-sulfonyl chloride 4-({j4-(But-2-ynyloxy)phenyllsulfonyl} methyl)-N-hydroxy- 1-(-methyl-illimidazol-4-yl)sulfonylJ piperidine-4-carboxamide Example 61 1- 1 2 -(Benzylamino)acetylj-4-({14-(but-2-ynyloxy)phenylsulfonyl} methyl)-Nhydroxypiperidine-4-carboxamide Step A: A solution of N-(tert-butoxy)-4-({ [4-2-butynyloxy)phenyl] sulfonyl) methyl)- 4-[4-(2-butynyloxy)phenyl] sulfonyl)methyl-4-piperidine carboxyamide (0.0O97g, 0.23mmol), triethylamine (0.064mL, 0.64mmol), chloroacetyl chloride (0.064 mlA, 0.64 mmol), and 4-dimethylaminopyridine (0.002 g) in 2mL of CH2Cl2 was shaken at room temperature for 18h. The solution was then treated with benzyl amine (O.075mL, 0.69mmol) and was shaken for 1 8h and then concentrated in vacuo.
Step B: same as Step B of Example 46.
The following hydroxamic acids were synthesized according to the procedures of Example 61 using the appropriate amine reagents.
Example 62 Reagent 0.O6OmL (0.69mmol) of morpholine 4-(14-(But-2-ynyloxy)phenyllsulfonyl} methyl)-N-hydroxy-1-(2-morpholin-4ylacetyl)piperidine-4-carboxamide WO 00/44723 WO 0044723PCT/USOOIOI 864 -94- Example 63 Reagent 0.076mL (0.69mmol) of N-methylpiperazine 4-({[4-(But-2-ynyloxy)phenylj sulfonyl) methyl)-N-hydroxy-1-[2-(4methylpiperazin-1-y)acetyl] piperidine-4-carboxamide Example HPLC retention time MS 2 46 1.85 395 47 2.20 498 48 1.71 458 49 2.11 472 52 2.30 438 53 2.85 486 57 3.80 523 58 2.98 517 54 2.87 466 2.33 480 56 2.84 500 59 2.92 507 2.40 511 2.67 471 51 2.64 477 61 12.14 514 62 1.86 494 63 1.84 507 LC conditions: Hewlett Packard 1100; YMC ODS-A 4.6 mmx50 mm5 u column at 23'C; lOuL injection: Solvent A: 0.05% TEA/water; Solvent B: 0.05% TFAlacetonitrile; Gradient: Time 0: 98% A; 1 min: 98% A;7 min: 10% A, 8 min: 98% A; Post time 1 min. Flow rate 2.5 mL/min; Detection: 220 and 254 n DAD 2 Mass Spec conditions: API-electrospray.
Example 64 1-Acetyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide Step 1: 4-But-2-ynyloxybenzenesulfonyl fluoride: To a solution of 4-but-2-ynyloxybenzenesulfonyl chloride (prepared from Example 30, step 4) (2.0 g, 8.18 mmol) in acetonitrie (10 ml) was added KF-CaF, (2.85g, 16.3 mmol) and the resulting mixture was stirred for 4 hours at room temperature. The reaction mixture was filtered and the filterate was concentrated.
The crude product was dissolved in EtOAc and washed with water. The organic layer V"M 7VE rW WC1 0'AW] A AM til WO 00/44723 PCT/US00/01864 was dried over anhydrous Na 2 SO, and the solvent was removed to obtain 1.5 g of the product as solid.
Step 2: 4-(4-But-2-ynyloxybenzenesulfonyl)-piperidine-1,4-dicarboxylic acid tertbutyl ester methyl ester To a solution of diisopropylamine(1.58 mL, 11.3 mmol) in THF(25 mL) at 0° C was added 2.5M n-BuLi(4.68 mL, 11.7 mmol) and the resulting mixture was stirred for 15 min at that temperature. The reaction mixture was cooled to -780 C and a solution of 1-(tert-butyl)-4-methyl 1,4-piperidinecarboxylate (prepared from example 30, step 1) (2.67g, 11.0 mmol) in THF(40 mL) was added. The resulting mixture was stirred for Ih and a solution of 4-but-2-ynyloxy benzenesulfonyl fluoride (2.5g, 11.0 mmol) in THF(25 mL) was added into it. After stirring for 4h at rt, the reaction was quenched with satd. aqueous NH 4 CI solution and extracted with EtOAc, dried over anhydrous Na 2
SO
4 The crude product was purified by silica gel chromatography to obtain 2.6g(53%) of the product as a solid; 'H NMR(300 MHz, CDC1 3 5 1.44(s, 9H), 1.87(m, 3H), 1.98(m, 2H), 2.32(m, 2H), 2.62(m, 2H), 3.74(s, 3H), 4.17(m, 2H), 4.74(m, 2H), 7.09(d, 2H, J= 7.2 Hz), 7.71(d, 2H, J= 7.2 Hz).
Step 3: 4-(4-but-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester: To a solution of product from step 2 (500 mg, 1.11 mmol) in methylene chloride (10 ml) was added 4M HC1 (2 ml) and the resulting mixture was stirred for 2 hours at room temperature. The solid was filtered, washed with ether to obtain 410mg(95%) of the product as a solid. 'H NMR(300 MHz, CDC13):5 1.86(m, 3H), 2.52(m, 4H), 2.89(m, 2H), 3.52(m, 2H), 3.74(s, 3H), 4.74(m, 2H), 7.10(d, 2H, J= 8.7 Hz), 7.69(d, 2H, J= 8.7 Hz).
Step 4: 1-Acetyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid methyl ester To a solution of product from step 3 (105 mg, 0.23 mmol) in methylene chloride (1 ml) was added triethylamine (93 mg, 0.92 mmol), acetyl chloride(18 mg, WO 00/44723 PCT/US00/01864 -96- 0.23 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 8 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 75 mg of the product as a solid.
Step 5: 1 -Acetyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid: A solution of the ester, from step 4 (240 mg, 0.61 mmol)) and lithium hydroxide (18 mg, 0.75 mmol)) in tetrahydrofuran/methanol/water mixture was stirred at room temperature for 15 hours. The mixture was concentrated, acidified to pH 3-5 with IN aqueous hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous sodium sulfate.
Removal of the solvent under vacuuo gave the acid. Yield 200 mg, 'H NMR(300 MHz, acetone-d 6 1.84(t, 3H, J= 2.8 Hz), 1.90-2.05(m, 2H), 2.06(s, 3H), 2.25-2.51(m, 3H), 3.06(m, 1H), 4.04(m, 1H), 4.63(m, 1H), 4.86(q, 1H, J= Step 6: 1-Acetyl- 4 4 -but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide: To a solution of 1-acetyl- 4 4 -but-2-ynyloxybenzenesulfonyl)piperidine-4carboxylic acid (180 mg, 0.48 mmol) in dimethylformamide was added hydroxybenzotriazol (77mg, 0.57 mmol) followed by 1-( 3 -dimethylaminopropyl)-3-ethylcarbodimide hydrochloride (127 mg, 0.66) and N-methylmorpholine (0.078 ml, 0.71 mmol). The resulting mixture was stirred for 1 h at room temperature when 50% aqueous hydroxylamine solution (0.145 ml, 2.37 mmol) was added and the mixture was stirred for 15 h at that temperature. The solvent was removed in vacuo and ethyl acetate/water was added to the crude product. The organic layer was separated and washed successively with IN aqueous hydrochloric acid, water, saturated aqueous sodium bicarbonate, and water. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed in vacuo to obtain 100 mg of the product as a solid. 'H NMR(300 MHz, CDCl3):5 1.64(m, 1H), 1.85(m, 3H), 1.99(s, 3H), 2.31(m, 4H), 2.83(m, 1H), 3.88(m, 1H), 4.41(m, 1H), 4.88(m, 2H), 7.16(d, 2H, J= Hz), 7.66(d, 2H, J= 9.0 Hz), 9.20(m, 1H), 11.00(m, 1H); MS-ES: m/z395.2 ~~jOW ART~i WO 00/44723 PCTUSOO/0I 864 -97- Example 1-Benzoyl-4-(4-but-2-ynyloxybenzeslUfonyI)piperidile-4-carboxylic acid hydroxamide Step 1: 1 -Benzoyl-4-(4-but-2-ynyloxybezeesulfoflyl)piperdie-4-carboxylic acid methyl ester To a solution of 4-(4-but-2-ynyloxy-benzenesulfonyl)-piperidile-4-carboxylic acid methyl ester, (400 mg, 1.03 mmol) in chloroform (10 ml) was added triethylamine (416 mg, 4.12 mmol), benzoyl chloride(144 iLd, 1.24 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 375 mg of the product as a solid. MS-ES: mlz 456.1 Step 2: 1 ezy--4bu--nlxbnensloy~ieidn--abxh acid 1-Bnol4(-u--nlxbneesloy~ieiie4croyi acid was prepared, starting from 1 -benzoyl-4- (4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid methyl ester (300 mg, 0.66 mmol) and lithium hydroxide (18 mg, 0.75 mmol). The resulting reaction mixture was worked up as outlined in Example 64, (step Yield: 250 mg(86%) of the acid. HR MS: m/z Calculated for C 23
H
23 N0 6 5 442.1319; Found 442.1317.
Step 3: 1 ezy--4bt2ynlxbneeufnlpieiie4croyi acid hydroxamide The general procedure for step 6 (Example 64) was followed using l-benzoyl- 4-(4-but2ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid (100 mg, 0.23 mmol) in dimethylformamide (2 ml), 1-hydroxybenzotriazole(36 mg, 0.27 mmol), 1- [3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride(62 mg, 0.32 mmol), N-methylmorpholine (0.038 ml, 0.35 mmol), and hydroxylamine (0.083 ml, 1.15 mmol) to obtain 40 mg( 38%) of the product as a solid. MS-ES: m/z 457.2 WO 00/44723 WO 0044723PCTIUSOO/0I 864 -98- Example 66 l-(4-Methoxybenzoyl)-4-(4-but-2-ynyloxy benzenesuifonyl)piperidine-4 carboxylic acid hydroxamide.
Step 1: 1- 4 -Methoxybenzoyl)-4-(4-but-2-ynyloxybenzenesulfonyl) piperidine-4carboxylic acid methyl ester To a solution of 4 4 -but- 2 -ynyloxy-benzenesulfonyl)-ppeidin-4-carboxylic acid methyl ester (260 mg, 0.77 mmol) in chloroform (7 ml) was added triethylamine (311 mg, 3.08 mmol), 4-methoxybenzoyl chloride(158 mg, 0.92 mnmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 280 mg of the product as a solid. HR MS: m/z Calculated for C,,H 27 N0 7 S 486.158 1; Found 486.1576.
Step 2: 1 (-ehxbnol--4bt--nlxbneeufnl piperidine-4carboxylic acid.
1-4Mtoyezy)4(-u--nyoyeznsloy~ieiie4 carboxylic acid. was prepared following the procedure of Example 64 (step Starting from 1 (-ehxbnol--4bt--nlxbneeufnl piperidine- 4-carboxylic acid methyl ester 250 mg, 0.52 mmol) in 4ml of tetrahydrofuran: methanol and IN sodium hydroxide (1.03 ml, 1.03 mmol) 150 mg of of the acid was isolated. HR MS: m/z Calculated for CQH,.NO 7 S 472.1425; Found 472.1426.
Step 3: 1 4 -Methoxybenzoyl)-4-(4-but-2-ynyloxybenzenesulfonyl) piperidine-4carboxylic acid-hydroxamide: 1-4Mtoyezy)4(-u--nyoyeznsloy~ieiie4 carboxylic acid..hydroxamide was prepared following the procedure Example 64 (step Starting from I 4mtoyenol--4bt--nlxbnznsloy) piperidine-4-carboxylic acid (90 mg, 0.19 mmol) in dimethylformamide (2 ml), Ihydroxybenzotriazole (31 mg, 0.23 mmol), 3 -(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride(51 mg, 0.27 mmol), N-methylmorpholine (0.031 ml, VVr
NPARMWIFF
WO 00/44723 PCT/USO/01864 -99- 0.28 mmol), and hydroxylamine (0.068 ml, 0.95 mmol), 70 mg( 76%) of the product was isolated as solid. HR MS: m/z Calculated for C 24
H
26 N0S 487.1534; Found 487.1531.
Example 67 4 4 -But-2-ynyloxybenzenesulfonyl)-N-hydroxy. -(pyrrolidine- 1-carbonyl)-4piperidinecarboxamide Step1: 4 4 -but-2-ynyloxybenzenesulfonyl). 1-(pyrrolidine-l -carbonyl)-piperidine-4carboxylic acid methyl ester To a solution of 4- 4 -but- 2 -ynyloxybenzenesulfonyl)pipedine4carboxylic acid methyl ester (400 mg, 1.03 mmol) in chloroform (10 ml) was added triethylamine (208 mg, 2.06 mmol), pyrrolidinecarbonyl chloride (206 mg, 1.54 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 400 mg of the product as a solid; MS- ES: m/z 449.3 Step 2: 4 4 -but-2-ynyloxybenzenesulfonyl)- 1-(pyrrolidine- 1 -carbonyl)-piperidine-4carboxylic acid 4 4 -But-2-ynyloxybenzenesulfonyl) 1-(pyrrolidine-l -carbonyl)-piperidine-4carboxylic acid was prepared following the procedure of Example 64 (step Starting from 4 4 -but-2-ynyloxybenzenesulfonyl) I-(pyrrolidine-l -carbonyl)piperidine-4-carboxylic acid methyl ester (250 mg, 0.52 mmol) in 4m of tetrahydrofuran: methanol and IN sodium hydroxide (1.03 ml, 1.03 mmol), 150 mg of of the acid was isolated. HR MS: m/z Calculated for C 2
H
25
NOS
472.1425; Found 472.1426.
Step 3: 4 4 -But- 2 -ynyloxybenzenesulfonyl)-N-hydroxy -(pyrrolidine-l -carbonyl)- 4-piperidinecarboxamide was prepared following the procedure Example 64 (step 6).
Starting from 4 4 -But-2-ynyloxybenzenesulfonyl)-N-hydroxy I -(pyrrolidine- I carbonyl)-4-piperidinecarboxalic acid (255 mg, 0.23 mmol) in dimethylformamide (6 FOIRQ- :'"346111!p ijl 11 Wkl"11 "'AA11W TV11"RIM. iW-ke WO 00/44723 PTUO/16 PCT/USOO/01864 -100ml), 1-hydroxybenzotriazole(96 mg, 0.71 mmol), l-[3-(dimethylamino)propyl]-3ethylcarbodiimide hydrochloride(157 mg, 0.82 mmol), N-methylmorpholine (0.099 ml, 0.84 mmol), and hydroxylamine (0.181 ml, 2.8 mmol), 150 mg( 60%) of the product was isolated as a solid. HR MS: mlz Calculated for C,,H 27
N
3 0S 450.1693; Found 450.1692.
Example 68 Ethyl 4-(4-but-2-ynyloxybenzenesulfonyl)-4-[(hydroxyamino)carbonyll- 1piperidinecarboxylate Step 1: I-Ethyl 4-methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 1,4-piperidinedicarboxylate To a solution of 4-(4-but-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester (400 mg, 1.03 mmol) in chloroform (10 ml) was added sodium bicarbonate (865 mg, 10.3 mmol), ethylchloroformate(0.147 ml, 1.54 mmol). The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 425 mg of the product as a solid. MS- ES: m/z 424.4 Step 2: 1- (Ethylcarbonyl)-4-(4-but-2-ynyloxybenzenesulfonyl)-l1-piperidinecarboxylic: acid 1 -(Ethylcarbonyl)-4-(4-but-2-ynyloxybenzenesulfonyl)-l1-piperidinecarboxylic acid was prepared following the procedure of Example 64 (step Starting from 1-Ethyl 4-methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 1,4-piperidinedicarboxylate (400 mg, 0.95 mmol) in 8m1 of tetrahydrofuran: methanol; water and lithium hydroxide (50 mg, 2.O4mmol), 340 mg of of the acid was isolated. HR MS: m/z Calculated for C 19 HKN0,S 408.1122; Found 408.1126.
Step 3: Ethyl 4-(4-but-2-ynyloxybenzenesulfonyl)-4-[(hydroxyamino)carbonyl -1piperidinecarboxylate Ethyl 4- (4-but- 2-ynyloxybenzenesulf onyl)-4-[(hydroxyamino)carbonyll- piperidinecarboxylate was prepared following the procedure Example 64 (step 6).
'AVM1 AN4 'AMY11111*1 On M 011- FIVARRI'l-I WO 00/44723 WO 0044723PCT/USOO/01 864 -101- Starting from 1 -(Ethylcarbonyl)-4-(4-but-2-ynyloxybenzenesulfonyl)- 1-piperidinecarboxylic acid (225 mg, 0.55 mmol) in dimethylformamide (6 ml), 1-hydroxybenzotriazole (89 mg, 0.66 mmol), l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride(148 mg, 0.77 mmol), N-methylmorpholine (0.091 ml, 0.86 mmol), and hydroxylamine (0.168 ml, 2.75 mmol), 150 mg( 64%) of the product was isolated as a solid. HR MS: m/z Calculated for C,,HNO 7 S 425.1377; Found 425.1375.
Example 69 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy-l1-[(trifluoromethyl)sulfonyl]-4piperidinecarboxamide Step 1: Methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 1-[(trifluoromethyl) sulfonyl]-4piperidinecarboxylate To a solution of 4-(4-but-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester (350 mg, 0.90 mmol) in chloroform (10 ml) was added triethylamine (182 mg, 1. 81 mmol), trifluoromethanesulfonyl chloride(0. 125 ml, 1. 17 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 245 mg of the product as a solid. HR MS: mlz Calculated for C, 8 2 ,FN0 7 S, 484.0706; Found 484.0700.
Step 2: 4-(4-but-2-ynyloxybenzenesulfonyl)- I-[(trifluoromethyl) sulfonyl]-4piperidinecarboxylic acid 4-(4-but-2-ynyloxybenzenesulfonyl)- I-[(trifluorornethyl)sulfonyl] -4piperidinecarboxylic acid was prepared following the procedure of Example 64 (step Starting from Methyl 4-(4-but-2-ynyloxybenzenesulfonyl)-1- [(trifluoromethyl) sulfonyl]-4-piperidinecarboxylate (225 mg, 0.47 mmol) in 8m1 of tetrahydrofuran: methanol; water and lithium hydroxide (24 mg, 0.98mmol), 175 mg of of the acid was isolated. MS-ES: m/z 468.1 WO 00/44723 PCTIUSOO/0I 864 -102- Step 3: 4-(4-but-2-ynyloxybenzenesufonyl)-N-hydroxy- 1-[(trifluoromethyl)sulfonyl] -4-piperidinecarboxamfide.
4-(4-but-2-ynyloxybenzenesulfolyl)-N-hydroxy- 1-[(trifluoromethyl)sulfonyl]-4-piperidinecarboxamide was prepared following the procedure Example 64 (step Starting from 4-(4-but-2-ynyloxybelzeesulfoflYl)-1- [(trifluoromethyl)sulfonyl]-4-piperidilecarboxylic acid (145 mg, 0.31 mmol) in dimethylformamide (3 ml), l-hydroxybenzotriazole(5O mg, 0.37 mmol), l-[3-(dimethylamino)propyl]-3ethylcarbodiimide hydrochloride(83 mg, 0.47 mmol), N-methylmorpholine (0.051 ml, 0.47 mmol), and hydroxylamnine (0.095 ml, 1.55 mmol), 90 mg( 60%) of the product was isolated as a solid. HIR MS: mlz Calculated for C7 H F N 0,S, 485.0659; Found 485.0666.
Example 4-4Bt2yyoyeznsloy)Nhdoyl(-yiiycroy) 4pip eridinecarboxamide Step 1: Methyl 4-(4-but-2-ynyloxybelzeesulfony1)- 1 -(3-pyridinylcarbonyl)- 4piperidinecarboxylate To a solution of 4-4bt2yyoybneeufnl-ieiie4croyi acid methyl ester (500 mg, 1.29 mmol) in methylene chloride (10 ml) was added triethylamine (443 mg, 4.39 mmol), nicotinyl chloride (276 ml, 1.55 mmol) followed by a catalytic amount of dimethylaminopyridifle. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 460 mg of the product as a solid. HR MS: m/z Calculated for C,,H,,N,0S 457.1428; Found 457.1428.
Step 2 4-(4-But-2-ynyloxybelzenesulfonYl)-1- (3-pyridinylcarbonyl)- 4-piperidinecarboxylic acid 4-(4-But-2-ynyloxybenzenesulfonyl)- 1 -(3-pyridinylcarbonyl)-4-piperidine carboxylic acid was prepared following the procedure of Example 64 (step Starting from Methyl 4-(4-but-2-ynyloxybenzelesulfonyl)- 1-(3-pyridinylcarbonyl)- OMMA"N% W V WWA TA, WWP 1041#±Ll VIAMMI P1 4#114APS11- WO 00/44723 WO 0044723PCTIUSOO/01864 -103- 4-piperidinecarboxylate (430 mg, 0.94 mmol) in 8m] of tetrahydrofuran: methanol and IN sodium hydroxide (1.89 ml, 1.89 mmol) to obtain 235 mg(57%) of the acid. HR MS: m/z Calculated for C, 2 H11 2
N
2 OS 443.127 1; Found 443.1270.
Step 3: 4 -(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy-lI-(3-pyridinylcarbonyl)- 4piperidinecarboxamide was prepared following the procedure Example 64 (step 6).
Starting from 4-(4-But-2-ynyloxybenzenesulfonyl)- 1 -(3-pyridinylcarbonyl)-4piperidinecarboxylic acid (195 mg, 0.44 mmol) in dimethylformamide (4 ml), I hydroxybenzotriazole (72 mg, 0.53 mmol), l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride(1 19 mg, 0.62 mmol), N-methylmorpholine (0.072 ml, 0.66 mmol), and hydroxylamine (0.135 ml, 2.2 mmol), 65 mg( 32%) of the product was isolated as a solid. HR MS: mlz Calculated for C,,H 23 N,0 6 S 458.1380; Found 458.1373.
Example 71 4 4 -but-Z-ynyloxybenzenesulfonyl)-N-hydroxyl..(zthienylcarbonyl)- 4pipenidinecarboxamide Step 1: Methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 1 -(2-thienylcarbonyl)- 4piperidinecarboxylate To a solution of 4 4 -but-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester (500 mg, 1.29 mmol) in methylene chloride (10 ml) was added triethylamine (261 mg, 2.58 mmol), thiophenylcarbonyl chloride(227 mg, 1.55 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 480 mg of the product as a solid. HR MS: m/z Calculated for C 22
H
23 N0 6
S
2 462.1040; Found 462.1039.
Step 2: 4 -(4-but-2-ynyloxybenzenesulfonyl)- 1-(2-thienylcarbonyl)- 4-piperidinecarboxylic acid 4-(4-but-2-ynyloxybenzenesulfonyl)-1- (2-thienylcarbonyl)-4-piperidinecarboxylic acid was prepared following the procedure of Example 64 (step WO 00/44723 WO 0044723PCT/USOO/O1 864 -104- Starting from Methyl 4- (4-but-2-ynyloxybenzenesulfonyl)- 1 -(2-thienylcarbonyl)-4piperidinecarboxylate (435 mg, 0.94 mmol) in 8m] of tetrahydrofuran: methanol and IN sodium hydroxide (1.89 ml, 1.89 mmol) to obtain 360 mg(86%) of the acid. HR MS: mlz Calculated for C 2
H,
21 6S 448.0883; Found 448.0882.
Step 3: 4 4 -but-2-ynyloxybenzenesulfony1)-N-hydroxy- I -(2-thienylcarbonyl)- 4piperidinecarboxamide 4 4 -but- 2 -ynyloxybenzenesulfony1)-N-hydroxy. 1 -(2-thienylcarbonyl)-4piperidinecarboxamide was prepared following the procedure Example 64 (step 6).
Starting from 4 -(4-but-2-ynyloxybenzenesulfonyl)- 1 -(2-thienylcarbonyl)-4piperidinecarboxylic acid (335 mg, 0.75 mmol) in dimethylformamide (7 ml), Ihydroxybenzotriazole, (121 mg, 0.90 mmol), 1 -[3-(dimethylamino)propyl]-3.ethylcarbodiimide hydrochloride(201 mg, 1.05 mmol), N-methylmorpholine (0.124 ml, 1.13 mmol), and hydroxylamine (0.229 ml, 3.75 mmol), 216 mg( 62%) of the product was isolated as a solid. HR MS: m/z Calculated for C 21
H,
2
N
2 0 6 463.0992; Found 463.0988.
Example 72 4 4 -but- 2 -ynyloxybenzenesulfonyl).Nhydroxy.l-[(4-methoxyphenyl)sulfonyl].
4-piperidinecarboxamide.
Step I Methyl 4 4 -but-2-ynyloxybenzenesulfonyl)- 1-[(4-methoxyphenyl)sulfonyl]-4-piperidinecarboxylate To a solution of 4 4 -but- 2 -ynyloxy-benenesulfony)-piperidine-.4-cabox,1jc acid methyl ester (500 mg, 1.29 mmol) in methylene chloride(10 ml) was added triethylamine (261 mg, 2.58 mmol), 4-methoxyphenylsulfonyl chloride(320 mg, 1.55 mmol) followed by a catalytic amount of dimethylaminopyridine. The resulting mixture was stirred for 15 hours at room temperature, quenched with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and concentrated to give 590 mg of the product as a solid.
HR MS: m/z Calculated for CQH 7 2 4N0,S, 522.125 1; Found 522.1252.
OW %WPIWI RJO"'WMI PAP WM" IMM 0 ION ';AP&LV N WO 00/44723 WO 0044723PCTIUSOO/01864 -105- Step 2: 4 -(4-But-2-ynyloxybenzenesulfonyl)- 1-1(4-methoxyphenyl) sulfonyl]-4piperidinecarboxylic acid 4-(4-But-2-ynyloxybenzenesulfonyl)-lI-[(4-methoxyphenyl)sulfonyl] -4piperidine carboxylic acid was prepared following the procedure of Example 64 (step Starting from methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- I -[(4-methoxyphenyl)sulfonyll-4-piperidinecarboxylate (545 mg, 1.04 mmol) in 8m1 of tetrahydrofuran: methanol and IN sodium hydroxide (2.09 ml, 2.09 mmol) to obtain 446 mg of the acid. HR MS: m/z Calculated for CH 5
NO
8
S
2 508.1094; Found 508.1073.
Step 3 4 4 -but-2-ynyloxybenzenesulfonyl)-N-hydroxy. 1 -[4-methoxyphenyl)sulfonyll-4-piperidinecarboxamide 4 4 -But-2-ynyloxybenzenesulfonyl).N..hydroxy. I -[(4-methoxyphenyl)sulfonyl]-4-piperidinecarboxamide was prepared following the procedure Example 64 (step Starting from 4-(4-But-2-ynyloxybenzenesulfonyl)- I-[(4-methoxyphenyl)sulfonyl]-4-piperidinecarboxylic acid (402 mg, 0.79 mmol) in dimethylformamide (8 ml), I -hydroxybenzotriazole (128 mg, 0.95 mmol), 1 -(dimethylamino)propyl]-3 ethylcarbodiimide hydrochloride (212 mg, 1.11 mmol), N-methylmorpholine (0.130 ml, 1.19 mmol), and hydroxylamnine (0.242 ml, 3.95 mmol), 396 mg of the product was isolated as a solid. HR MS: m/z Calculated for C23H 26
N
2
O
8
S
2 523.1203; Found 523.1198.
Example 73 4 4 -but- 2 -ynyloxybenzenesulfonyl)-N-hydroxy-l[(2,2,5..trimethyl. 1,3-dioxan-5yl)carbonyll-4-piperidinecarboxamidde Step 1: Methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 5-trimethyl-1I,3-dioxan-5yl)carbonyl]-4-piperidinecarboxylate Methyl 4-(4-but-2-ynyloxybenzenesulfonyl)- 5-trimethyl- 1,3 yl)carbonyl]-4-piperidinecarboxylate was prepared following the procedure Example 64 (step Starting from 4 4 -but- 2 -ynyloxy-benzenesulfonyl)-piperidine-4 carboxylic acid methyl ester (500 mg, 1.29 mmol) in dimethylformamide (10 ml), (2,2,5-trimethyl-1 ,3-dioxan-5-yl)carboxylic acid (224 mg, 1.29 mniol), I -hydroxyk M I WO 00/44723 PCTJUSOOioI 864 -106benzotriazole (209 mg, 1.56 mmol), l-[ 3 -(dimethylamino)propy}]3-ethylcarbodiimlde hydrochloride (346 mg, 1.81 nixol), and N-methylmorpholine (0.212 ml, 1.94 mmol), to obtain 385 mg( 59%) of the product as a solid. BR MS: m/z Calculated for
C
25
H
33 N0 8 S 508.2000; Found 508.1998.
Step 2: 4- 4 -but- 2 -ynyloxybenzenesulfonyly .I -[(2,2,5-trimethyl-1I,3-dioxan-5yI)carbonylj-4-piperidinecarboxylic acid 4 4 -But- 2 -ynyloxybenzenesulfonyl)- 2 ,2,5-trimethyl-1I,3-dioxan-5-yl)carbonyl]-4-piperidinecarboxylic acid was prepared following the procedure of Example 40 (step Starting from Methyl 4 4 -but-2-ynyloxybenzenesulfonyl..I-.
5-trimethyl- 1,3 -dioxan-5-yl)carbonyl]-4.piperidinecarboxlate (335 mg, 0.66 mmnol) in 4m1 of tetrahydrofuran: methanol and 1IN sodium hydroxide (1.3 ml, 1.3 mmol) to obtain 315 mg(97%) of the acid. HIR MS: m/z Calculated for C2H 3 ,NOS 494.1843; Found 494.1835.
Step 3: 4 4 But- 2 ynyloxybenzenesulfony1)-N..hydroxy. I-[(2,2,5-trimethyl- 1,3dioxan-5S.yl)carbonyly4.piperidinecarboxmide: 4 4 But..
2 .ynyloxybenzenesulfonyl)Nhydroxy 2 ,2,5-trimethyl- 1 ,3-dioxan-5-yl)carbonyl4piperidinecarboxmide was prepared following the procedure Example 64 (step Starting from 4 4 -but- 2 -ynyloxybenzenesuffonyl)l..{(2,2,5 trimethyl..l, 3 .dioxan5yl)carbonyl-4-piperidinecarboxylic acid (280 mg, 0.57 mimol) in dimethylformamide (6 nml), 1-hydroxybenzotriazole (92 mg, 0.57 mmol), l-[3- (dinmethylamino)propyl-3ethylcarbodiimide hydrochloride (153 mg, 0.80 mnol), Nmethylmorpholine (0.094 ml, 0.85 mimol), and hydroxylamine (0.174 ml, 2.85 mmol), 180 mg of the product was isolated as a solid. HR MS: m/z Calculated for Q2HNOS 53.7 ;Found 531.1768.
Example 74 4 4 -But-2-ynyloxybenzenesulfonyl).Nhydroxy. -[3-hydroxy-2.
(hydroxymethyl)2methypropanoyI-4pipedinecarboxmde To a solution of product from Example 73 (150 mg, 0.29 mmol) in tetrahydrofuran (2 ml) was added IN aqueous hydrochloric acid (2 ml) and the WO 00/44723 PCT/US00/01864 -107resulting mixture was stirred for 4 hours. The organic layer was washed with sodium bicarbonate, brine and dried over anhydrous sodium sulfate. Solvent was removed to obtain 40 mg of the product. HR MS: m/z Calculated for C,,
H
NO2,S 469.1639; Found 469.1637.
Example Tert-butyl 4-{[4-(2-butynyloxy)phenyl]sulfonyl}-4-[(hydroxyamino)carbonyl]-1piperidinecarboxalate Step 1: 1-(tert-butoxycarbonyl)- 4-{[4-(2-butynyloxy)phenyl]sulfonyl}-4 piperidinecarboxylic acid A solution of 4-(4-but-2ynyloxybenzenesulfonyl)-piperidine-1,4-dicarboxylic acid tert-butyl ester methyl ester (from example 64, step 2) (15g, 33.2 mmol) in water (100 mL), methanol (50 mL) and tetrahydrofuran (50 mL) was treated with lithium hydroxide hydrate (2.73g, 66.4 mmol) and heated at reflux for 8h. The reaction mixture was concentrated in vacuo and filtered through celite. To the filtrate was added aqueous IN hydrochloric acid. A thick gum was obtained which was dissolved in dichloromethane and washed with water. Concentration of the organic phase gave a foam (14.9 Trituration with diethyl ether gave 1-(tert-butoxycarbonyl)-4-{[4-(2butynyloxy)phenyl]sulfonyl}-4 -piperidinecarboxylic acid as a white powder.
Electrospray MS m/z 482 Step 2 Tert-butyl 4- [4-(2-butynyloxy)phenyl]sulfonyl}-4-[(hydroxyamino) carbonyl]-1 -piperidinecarboxalate Dimethylformamide (3.53 mL, 46 mmol) was added to a solution of oxalyl chloride (22.9 mL of a 2.0M solution in dichloromethane) in dichloromethane mL) at 0°C. After 15 min a solution of l-(tert-butoxycarbonyl)-4-{[4-(2-butynyloxy)phenyl]sulfonyl}-4-piperidinecarboxylic acid (10g, 22.9 mmol) in dimethylformamide was added and the reaction mixture was allowed to warm to room temperature. After Ih the reaction mixture was added to a mixture of hydroxylamine hydrochloride (16 g, 229 mmol), triethylamine (48 mL, 344 mmol), water (123 mL) and tetrahydrofuran (500 mL) that had been stirring at 0 °C for 15 min. The reaction was allowed to warm to room temperature. After 18h it was then diluted with ethyl acetate and washed with vwww~sw~waws^^^ iw WO 00/44723 WO 0044723PCTUSOO/01 864 -108saturated aqueous sodium bicarbonate then dried over potassium carbonate and concentrated in vacuo. Trituration with diethyl ether gave tert-butyl butynyloxy)phenyl]sulfonyl) -4-[(hydroxyamino)carbonyl]-lI-piperidinecarboxalate as a white powder 'H NMR (dmso d6, 300 MHz) 5 1.38 9H, t-butyl), 1.6 1.7 (in, 2H, CI-H), 1.85 3H, CH3, J 2.2 Hz), 2.2 2.3 (in, 2H, CHH), 2.5 2.7 (in, 2H, NCHH), 3.9 4.0 (in, 2H, NCHH), 4.87 2H, OCH2, J 2.2 Hz), 7.1 7.7 (in, 4H, ArH). Electrospray MIS in/z 453 Example 76 4-{[4-(2-butynyloxy)phenyllsulfonyl }-N-hydroxy-4-piperidinecarboxamide hydrochloride To tert-butyl 4- {[4-(2-butynyloxy)phenyl] sulfonyl )-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxalate (prepared from Example 75) (6.3g, 13.9 minol) was added 4N hydrochloric acid in dioxane. After 6h the reaction mixture was comcentrated in vacuo. Methanol was added and the resulting mixture concentrated in vacuo. Dichloromethane was added and removed in vacuo Trituration with diethyl ether gave [4-(2-butynyloxy)phenyl]sulfonyl) -N-hydroxy-4-piperidinecarboxainide hydrochloride as a white powder 14g). 'H NlvlR (dmso d6, 300 MHz) 5 1.86 31-I CH3, J 2.2 Hz), 2.0 2.7 (in, 8K, CH2), 4.89 2H, OCH2, J 2.2 Hz), 7.1 7.8 (in, 4H, ArH), 8.8 11.0 (mn, 4H, NH12, NHOH). Electrospray MS inlz 353 Example 77 Methyl [4-(2-butynyloxy)phenylj sulfonyl}-4- I(hydroxyamino)carbonyll-1piperidinyi~methyl)benzoate hydrochloride To 4- {[4-(2-butynyloxy)phenyl]sulfonyl} -N-hydroxy-4-piperidinecarboxamide hydrochloride (prepared from Example 76) (2.5 g, 6.43 mmol) and methyl 4- (bromoinethyl)benzoate 62 g, 7.07 inmol) in methanol (100 inL) at 50'C was added triethylanuine (2.25 inL, 16.1 inmol). After 30 min additional methanol (50 mL) was added. After 18 h the reaction mixture was concentrated in vacuo and IN aqueous hydrochloric acid (10 inL) and water was added. The resulting solid was isolated and Alflytl OlkwAk"N', 01141 W io* WO 00/44723PCUSO186 PCTIUSOO/01864 -109to it was added methanol (20 niL) and IN hydrochloric acid in diethylether (15 mL).
To the resulting solution was added diethyl ether. Trituration of the precipitate gave methyl {[4-(2-butynyloxy)phenyl]sulfonyl)}-4-[(hydroxyamino)carbonyl]- 1piperidinyl~methyl)benzoate hydrochloride as a white powder (2.4 'H NNM (dmso d6, 300 MIHz) 5 1.85 3H, CH3, J 2.2 Hz), 2.1 3.5 (mn, 8H-, CH2), 3.87 3H, OCH3), 4.40 (bd s, 2H, NCH2Ar), 4.89 2H, OCH2, J 2.2 Hz), 7.1 8.1 (in, 8H, ArH), 9.3 -11.2 (mn, 3H, NH, NHOH). Electrospray MS m/z 501.5 (M+HY* Example 78 4-({4-{[4-(2-butynyloxy)phenyllsulfonyl}-4-[(hydroxyamino)carboiiylJ-lpiperidinyl) methyl)benzoic acid hydrochloride To methyl {[4-(2-butynyloxy)phenyl] sulfonyl)4-4-[(hydroxyamnino)carbonyl]-lI-piperidinyl~methyl)benzoate hydrochloride (Prepared from example 77) (0.072g, 0.134 iniol) in methanol (I niL) was added IN aqueous sodium hydroxide (0.5 mL). After 18 h IN aqueous hydrochloric acid (0.5 rnL) was added and the reaction mixture concentrated in vacuo. Water was added and the precipitate triturated to give {[4-(2-butynyloxy)phenyl] sulfonyl) -4-[(hydroxyamino)carbonyl]-l1-piperidinyl}methyl)benzoic acid hydrochloride as an off-white solid (0.040 'H NM~R (dmso d6, 3 00 MHz) 5 1. 85 3H, CH3, J =2.2 Hz), 2.1 3.5 (mn, 8H, CH2), 4.37 (bd s, 2H, NCH2Ar), 4.89 2H, OCH2, J 2.2 Hz), 7.0 8.1 (in, 8H, ArH), 9.3 11.2 (in, 3H, NH, NHOH), 13.1 (bd s, 1H, COOH). Electrospray MS m/z 487.1 Example 79 1-4(mncroy~ezl--[-2btnlx~hnlsloy)Nhdoy4 piperidinecarboxamide hydrochloride To methyl [4-(2-butynyloxy)phenyl] sulfonyl }-4-[(hydroxyamino)carbonyl]-1-piperidinyl~inethyl)benzoate hydrochloride (from example 77) (0.20 g) in methanol (10 ml) was added concentrated aqueous aminoniumn hydroxide (4 mL).
After several weeks the reaction mixture was concentrated in vacuo and chroinatographed on silica gel (methanol/dichioromethane) to give a white powder which was dissolved in dichloroinethane and methanol. IN Hydrochloric acid in 4 M 'L A WO 00/44723 PCTUSOO/01864 -110diethylether was added followed by additional diethylether. Trituration gave 1 (aminocarbonyl)benzyl-4.{ 4 -(2-butynyloxy)phenyl] sulfonyl) -N-hydroxy-4piperidinecarboxamide hydrochloride as a white powder 106 'H NMR (Dmso d6, 300 MiHz) 5 1.85 3H, CH3, J =2.2 Hz), 2.2 3.5 (in, 8H, CH2), 4.33 (bd s, 2H, NCH2Ar), 4.89 2H, OCH2, J =2.2 7.1 8.0 (in, 8H, ArH), 7.47 111, CONII), 8.04 I H, CONH), 9.3 5 (bd s, I H, NHOH), 10. 44 (bd s, I H, NHOH), 11. 1 I H, NIH). Electrospray MS m/z 486.3 Example Tert-hutyl 4 -{1i 4 -(but-2-ynyloxy)phenyljsulflnyl}.4 [(hydroxyanmno)carbonyllpiperidine-l -carboxalate To tert-butyl 4- 4 -(but- 2 -ynyloxy)phenyl]sulfanyl)}- 4 -[(hydroxyainino)carbonyl]piperidine-1-carboxalate (0.30 g) (obtained from example 14) in methanol (10 mL) was added 30% aqueous hydrogen peroxide (3 mL). After 3 days water and dichioromethane were added and the organic phase washed with aqueous Na2SO3.
Concentration of the organic phase gave material which was dissolved in methanol (8 inL) and treated with 30% aqueous hydrogen peroxide. After several days workup as above gave tert-butyl 4- 4 -(but-2-ynyloxy)phenyl] sulfinyl)}- 4 -[(hydroxyamino)carbonyljpiperidinel carboxalate, as a colorless foam (0.26 'H NNM (dmso d6, 300 IvLHz) 6 1.38 911, t-butyl), 1.5 1.7 (in, 211, CHH), 1.85 3H, CH3, J 2.2 Hz), 2.1 2.2 (in, 211, CHH), 2.5 2.7 (in, 211, NCHH), 3.8 4.0 (in, 2K1 NCHH), 4.81 2H, OCH2, J 2.2 Hz), 7.1 7.4 (in, 411, ArH), 9.1 IH, NEIGH), 10.8 (s, 111, NHOH). Electrospray MS in/z 43 7.2 Example 81 4 4 -(But-2-ynyloxy-benzenesulfinyl)..piperidine.4carboxylic acid hydroxamide hydrochloride To tert-butyl 4- 4 -(but-2-ynyloxy)phenyl] sulfinyl) 4 -[(hydroxyaniino)carbonyl]piperidine-1I-carboxalate (prepared from example 80) (0.26 g) was added 4N hydrochloric acid in dioxane (4 mL). After I h the reaction mixture was concentrated in vacuo. Methanol was added and removed in vacuo. Dichloroinethane was added and removed in vacuo 3X to give 4 4 -(But-2-ynyloxy-benzenesulfinyl).pipe.jdine.4- WO 00/44723 PCT/US00/01864 -111carboxylic acid hydroxamide hydrochloride as a yellow solid (0.19 'H NMR (dmso d6, 300 MHz) 6 1.86 3H, CH3, J 2.2 Hz), 1.7 2.8 8H, CH2), 4.82 2H, OCH2, J 2.2 Hz), 7.1 7.5 4H, ArH), 8.4 11.0 4H, NH2, NHOH).
Electrospray MS m/z 337.2 Example 82 1-(4-Bromo-benzyl)-4-(4-But-2-ynyloxy-benzenesulfinyl)-piperidine-4-carboxylic acid hydroxamide hydrochloride To a solution of 4 4 -(But-2-ynyloxy-benzenesulfinyl)-piperidine-4-carboxyic acid hydroxamide hydrochloride (prepared from example 81) (0.162 g, 0.434 mmol) and 4-bromobenzylbromide (0.120 g, 0.478 mmol) in methanol was added triethylamine (0.13 mL, 0.91 mmol). After 4 h the reaction mixture was concentrated in vacuo and chromatographed on silica gel (methanol/dichloromethane) to give an oily solid which was dissolved in dichloromethane. To the solution was added IN hydrochloric acid in ether (I mL). Concentration in vacuo gave 1-(4-Bromo-benzyl)- 4 4 -But- 2 -ynyloxy-benenesulfinyl)piperidine-4-carboxylic acid hydroxamide hydrochloride as a tan solid (0.102 'H NMR (dmso d6, 300 MHz) 6 1.85 3H, CH3, J 2.2 Hz), 1.9 3.5 8H, CH2), 3.87 3H, OCH3), 4.3 (bd s, 2H, NCH2Ar), 4.82 2H, OCH2, J 2.2 Hz), 7.0 7.8 8H, ArH), 9.2 11.1 (m, 3H, NH, NHOH). Electrospray MS m/z 505.1/507.2 Pharmacology Representative compounds of this invention were evaluated as inhibitors of the enzymes MMP-1, MMP-9, MMP-13 and TNF-a converting enzyme (TACE).
The standard pharmacological test procedures used, and results obtained which establish this biological profile are shown below.
Test Procedures for Measurin2 MMP- 1. MMP-9. and MMP- 13 Inhibition These standard pharmacological test procedures are based on the cleavage of a thiopeptide substrates such as Ac-Pro-Leu-Gly(2-mercapto-4-methyl-pentanoyl)-Leu- Gly-OEt by the matrix metalloproteinases MMP-1, MMP-13 (collagenases) or MMP-9 (gelatinase), which results in the release of a substrate product that reacts Op, p 4 V WO 00/44723 PCT/US00/01864 -112colorimetrically with DTNB (5,5'-dithiobis(2-nitro-benzoic acid)). The enzyme activity is measured by the rate of the color increase. The thiopeptide substrate is made up fresh as a 20 mM stock in 100% DMSO and the DTNB is dissolved in 100% DMSO as a 100 mM stock and stored in the dark at room temperature. Both the substrate and DTNB are diluted together to 1 mM with substrate buffer (50 mM HEPES pH 7.5, 5 mM CaC12) before use. The stock of enzyme is diluted with buffer (50 mM HEPES, pH 7.5, 5 mM CaC12, 0.02% Brij) to the desired final concentration. The buffer, enzyme, vehicle or inhibitor, and DTNB/substrate are added in this order to a 96 well plate (total reaction volume of 200 pi) and the increase in color is monitored spectrophotometrically for 5 minutes at 405 nm on a plate reader and the increase in color over time is plotted as a linear line.
Alternatively, a fluorescent peptide substrate is used. In this test procedure, the peptide substrate contains a fluorescent group and a quenching group. Upon cleavage of the substrate by an MMP, the fluorescence that is generated is quantitated on the fluorescence plate reader. The assay is run in HCBC assay buffer HEPES, pH 7.0, 5 mM Ca+ 2 0.02% Brij, 0.5% Cysteine), with human recombinant MMP-1, MMP-9, or MMP-13. The substrate is dissolved in methanol and stored frozen in 1 mM aliquots. For the assay, substrate and enzymes are diluted in HCBC buffer to the desired concentrations. Compounds are added to the 96 well plate containing enzyme and the reaction is started by the addition of substrate. The reaction is read (excitation 340 nm, emission 444 nm) for 10 min. and the increase in fluorescence over time is plotted as a linear line.
For either the thiopeptide or fluorescent peptide test procedures, the slope of the line is calculated and represents the reaction rate. The linearity of the reaction rate is confirmed (r 2 The mean (xsem) of the control rate is calculated.and compared for statistical significance (p<0.05) with drug-treated rates using Dunnett's multiple comparison test. Dose-response relationships can be generated using multiple doses of drug and IC50 values with 95% CI are estimated using linear regression.
WY 4! Wo'YU VYi VINNN~nl 1j WO 00/44723 PCTIUSOO/01864 -113- Test Procedure for Measuring TACE Inhibition Using 96-well black microtiter plates, each well receives a solution composed of 10 pL TACE (final concentration lg/mL), 70pL Tris buffer, pH 7.4 containing glycerol (final concentration 10 mM), and 10 L of test compound solution in DMSO (final concentration 1pM, DMSO concentration and incubated for minutes at room temperature. The reaction is initiated by addition of a fluorescent peptidyl substrate (final concentration 100 pM) to each well and then shaking on a shaker for 5 sec.
The reaction is read (excitation 340 nm, emission 420 nm) for 10 min. and the increase in fluorescence over time is plotted as a linear line. The slope of the line is calculated and represents the reaction rate.
The linearity of the reaction rate is confirmed (r 2 The mean (x±sem) of the control rate is calculated and compared for statistical significance (p<0.05) with drug-treated rates using Dunnett's multiple comparison test. Dose-response relationships can be generate using multiple doses of drug and IC50 values with CI are estimated using linear regression.
Human Monocvtic THP-1 Cell Differentiation Assay For Soluble Proteins (THP-1 Soluble Protein Assay) Mitogenic stimulation of THP-1 cells cause differentiation into macrophage like cells with concomitant secretion of tumor necrosis factor (TNF-a) and TNF receptor (TNF-R p75/80 and TNF-R p55/60) and Interleukin-8 among other proteins. In addition, non-stimulated THP-1 cells shed both the p75/80 and the p55/60 receptors over time. The release of membrane bound TNF-a and possibly TNF-R p75/80 and TNF-R p55/60, but not IL-8, is mediated by an enzyme called TNF-a converting enzyme or TACE. This assay can be used to demonstrate either an inhibitory or a stimulatory compound effect on this TACE enzyme and any cytotoxic consequence of such a compound.
THP-1 cells (from ATCC) are a human monocytic cell line which were obtained from the peripheral blood of a one year old male with acute monocytic WO, Arl l-~l ~iwi WO 00/44723 PCT/US00/01864 -114leukemia. They can be grown in culture and differentiated into macrophage like cells by stimulation with mitogens.
For the assay, THP-1 cells are seeded from an ATCC stock which was previously grown and frozen back at 5 x 106/ml/vial. One vial is seeded into a flask with 16 mis of RPMI-1640 with glutamax (Gibco) media containing 10 fetal bovine serum, 100 units/ml penicillin, 100 pg/ml streptomycin, and 5 x 10 5 M 2mercapto-ethanol (THP-1 media). Each vial of cells are cultured for about two weeks prior to being used for an assay and then are used for only 4 to 6 weeks to screen compounds. Cells are subcultured on Mondays and Thursdays to a concentration of 1 x 105/ml.
To perform an assay, the THP-1 cells are co-incubated in a 24 well plate with ml/well of a 24 mg/ml stock of Lipopolysacharide (LPS) (Calbiochem Lot# B13189) at 37iC in 5% CO, at a concentration of 1.091 x 106 cells/ml (1.1 ml/well) for a total of 24 hours. At the same time, 50 ml/well of drug, vehicle or THP-1 media is plated in appropriate wells to give a final volume of 1.2 ml/well. Standard and test compounds are dissolved in DMSO at a concentration of 36 mM and diluted from here to the appropriate concentrations in THP-1 media and added to the wells at the beginning of the incubation period to give final concentrations of 100 mM, mM, 10 mM, 3 mM, 1 mM, 300 nM, and 100 nM. Cell exposure to DMSO was limited to 0.1 final concentration. Positive control wells were included in the experiment which had mitogen added but no drug. Vehicle control wells were included as well, which were identical to the positive control wells, except that DMSO was added to give a final concentration of 0.083%. Negative control wells were included in the experiment which had vehicle but no mitogen or drug added to the cells. Compounds can be evaluated for their effect on basal (non-stimulated) shedding of the receptors by replacing the LPS with 50 ml/well of THP-1 media.
Plates are placed into an incubator set at 5% CO2 and at 37o C. After 4 hours of incubation, 300 ml/well of tissue culture supernatant (TCS) is removed for use in an TNF-a ELISA. Following 24 hours of incubation, 700 ml/well of TCS is removed and used for analysis in TNF-R p75/80, TNF-R p55/60 and IL-8 ELISAs.
?Wii9i4RIT; MP"hINVAIIi N, LION",s WO 00/44723 PCT/US00/01864 -115- In addition, at the 24 hours timepoint, and the cells for each treatment group are collected by resuspension in 500 pl/well of THP-1 media and transferred into a FACS tube. Two ml/tube of a 0.5 mg/ml stock of propidium iodide (PI) (Boerhinger Mannheim cat. 1348639) is added. The samples are run on a Becton Dickinson FaxCaliber FLOW cytometry machine and the amount of dye taken up by each cell is measured in the high red wavelength (FL3). Only cells with compromised membranes (dead or dying) can take up PI. The percent of live cells is calculated by the number of cells not stained with PI, divided by the total number of cells in the sample. The viability values calculated for the drug treated groups were compared to the viability value calculated for the vehicle treated mitogen stimulated group ("vehicle positive control") to determine the "percent change from control". This "percent change from control" value is an indicator of drug toxicity.
The quantity of soluble TNF-a, TNF-R p75/80 and TNF-R p55/60 and IL-8 in the TCS of the THP-1 cell cultures are obtained with commercially available ELISAs from R&D Systems, by extrapolation from a standard curve generated with kit standards. The number of cells that either take up or exclude PI are measured by the FLOW cytometry machine and visualized by histograms using commercially available Cytologic software for each treatment group including all controls.
Biological variability in the magnitude of the response of THP-1 cell cultures requires that experiments be compared on the basis of percent change from "vehicle positive control" for each drug concentration. Percent change in each soluble protein evaluated from the "vehicle positive control" was calculated for each compound concentration with the following formula: Change pg/ml (compound) pg/ml (veh pos control) x 100 pg/ml (veh pos control) pg/ml (veh neg control) For the soluble protein (TNF-a, p 7 5 8 0, p55/60, IL-8) studies under stimulated conditions, the mean pg/ml of duplicate wells were determined and the results expressed as percent change from "vehicle positive control". For the soluble protein (p75/80 and p55/60 receptors) studies under non-stimulated conditions, the WO 00/44723 PCT/US00/01864 -116mean pg/ml of duplicate wells were determined and the results expressed as percent change from "vehicle positive control" utilizing the following formula: Change pg/ml (compound neg control) pg/ml (veh neg control X 100 pg/ml (veh neg control) values for each compound are calculated by non-linear regression analysis using customized software utilizing the JUMP statistical package.
For the cell viability studies, the viabilities (PI exclusion) of pooled duplicate wells were determined and the results expressed as change from "vehicle positive control". The viability values calculated for the compound treated groups were compared to the viability value calculated for the "vehicle positive control" to determine "percent change from control" as below. This value "percent change from control" is an indicator of drug toxicity.
Change live cells (compound) -1 X 100 live cells (veh pos control) References: Bjornberg, Lantz, Olsson, and Gullberg, U. Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms. Lymphokine Cytokine Res. 13:203-211, 1994.
Gatanaga, Hwang, Gatanaga, Cappuccini, Yamamoto, and Granger, G. The regulation of TNF mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro. Cellular Immun.
138:1-10, 1991.
Tsuchiya, Yamabe, Yamagughi, Kobayashi, Konno, and Tada, K.
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer. 26:1711-176, 1980.
OMMMYMA11M, O#N* WO 00/44723 PCT/USOO/01864 -117- Results of the above in vitro matrix metalloproteinase inhibition, TACE inhibition and THP standard pharmacological test procedures are given in Table 1 below.
Table 1: Example TACE IC,, THP @31M MMP1 ICSO C MMP9 IC 0 a MMP13 IC,,o 1 65 46% 3.3 385 155 2 82 68% 2.57 164 39.6 3 55 34% 9 280 4 90 25% 2.6 148 47.3 188 30% .3 400 180 6 393 NT 32.9% 58.9% 7 123 21% 2.5 225 59.4 8 195 21% 4.7 218 72 9 166 12% 2.1 96.2 35.2 11 98 7% 0.143 5.8 3.1 12 41.8% +58 15 1000 1500 13 882 +69% 10 2000 800 14 67% NT 26% 21% 32% 38% NT 24% 25% 24% 16 46% NT 10 2056 1465 17 139 0 10 2296 946 18 11.4 45% 10 1276 98 19 74 4% 10 10000 1321 30.1 47% 2643 nM 568 121 21 509 6% 10 3504 858 22 48.4% 5% 10 1814 1076 23 86.2 62% 3206 nM 160 64.4 24 180 41% 5671 nM 2078 463 695 3% >10 2740 1177 26 136 63% 1994 nM 25.1 22.1 27 168 13% 10 1542 426 28 150 13% 106 nM 15.4 5.3 29 127 13% 91 nM 16 4.7 102 0 >10 5899 2911 31 314 8 >10 >10000 >10000 32 100 0 >10 >10000 2752 33 327 8 >10 -5000 -10000 34 33 68 -10 1393 102 57 14 >10 >10000 -10000 36 4.8 58 3.9 2828 380 37 18 NT 8.6 8575 1024 38 19 53 -10 1443 279 39 11 NT 3.77 4275 809 63 41 0.707 425 36 41 37 60 2.677 1121 254 YIFWf7MWW 9CN Www WO 00/44723 WO 0044723PCT/USOO/01 864 -118ab caa Example TACE IC, 50 THP @3p.M MMP1 IC,, MMP9 IC,o" MMP1 3 IC." 42 12 78% -10 >10000 1627 43 13 66 -10 >10000 1640 44 56 49 35% 50.6% 2381 25 48 3.8 3584 423 46 105 NT NT NT 55.6% 47 227 NT NT NT 275 48 66 NT NT NT 1035 49 32.6 NT NT NT 1727 18.3 NT NT NT 352 51 21.5 NT NT NT 403 52 41.8 NT NT NT 3710 53 20.8 NT NT NT 1165 54 32.2 NT NT NT 104 70.7 NT NT NT 600 56 31.1 NT NT NT 3.2 57 694 NT NT NT 458 58 21.1 NT NT NT 179 59 53.3 NT NT NT 11.2 38.4 NT NT NT 61 56.4 -NT NT NT 575 62 64.6 NT NT NT 64.6 63 66.6 NT NT NT 2229 64 47 30 4.076 560 136 73 3 3.532 448 105 66 106 73 2.768 430 81 67 72 18 2.028 853 345 68 77 10 2.249 1333 503 69 115 14 3.999 1246 499 87 62 2.963 639 113 71 113 14 3.117 811 183 72 221 56 4.157 1211 369 73 NT NT NT NT NT 74 132 39 4.338 963 287 134 -4 2.588 1951 284 76 201 26 4.503 7886 4019 77 114 52 2.187 149 349 78 64.5 64 1.051 364 73.7 79 70 83 2.420 129 50.6 90 -7 186 122 81 277 25 1.877 1035 593 82 135 16 257 125 62 a nM or inhibition b inhibition c 9~M or inhibition, unless otherwise indicated WO 00/44723 PCT/USOO/01864 -119- Based on the results obtained in the standard pharmacological test procedures described above, the compounds of this invention were shown to be inhibitors of the enzymes MMP-1, MMP-9, MMP-13 and TNF-a converting enzyme (TACE) and are therefore useful in the treatment of disorders such as arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, graft rejection, insulin resistance, bone disease and HIV infection.
The compounds of this invention are also useful in treating or inhibiting pathological changes mediated by matrix metalloproteinases such as atherosclerosis, atherosclerotic plaque formation, reduction of coronary thrombosis from atherosclerotic plaque rupture, restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, angiogenesis, tumor metastasis, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization and corneal graft rejection.
Compounds of this invention may be administered neat or with a pharmaceutical carrier to a patient in need thereof. The pharmaceutical carrier may be solid or liquid.
Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl ,Ladbt I,'tat~W fl ~P44 t..i M~UMhI4't~, fl ~va~~~4h MA'X' WO 00/44723 PCT/USOO/01864 -120cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such a solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, cellulose derivatives, preferable sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, glycols) and their derivatives, and oils fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.
The compounds of this invention may be administered rectally in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol. The compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semi-solid emulsions of either the oil in water or water in oil type. Pastes comprised of absorptive powders i WAIT WO 00/44723 PCT/US00/01864 -121dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.
The dosage to be used in the treatment of a specific patient suffering a MMP or TACE dependent condition must be subjectively determined by the attending physician. The variables involved include the severity of the dysfunction, and the size, age, and response pattern of the patient. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached.
Precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated and standard medical principles.
Preferably the pharmaceutical composition is in unit dosage form, as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage form can be packaged compositions, for example packed powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
K40vW'T!6AQ'7 "i WY6 W *'N'4'XN W' "WTIR vo;

Claims (12)

1. A compound of formula 0 R
2 R /II\9 R1 x A(C)n N/ 41OI wherein: RI is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2.6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C4- C8-cycloheteroalkyl; R 2 and R 3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH; R 7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R 1 -S0 2 -RI, -C(O)-NUR 1 -C(O)NR5R 6 C(O)RINRsPR 6 -C(O)-0R 1 -C(NH)-NH 2 :R 5 and Rs are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of
3-6 carbon atoms, aryl, aralkyl, heteroaryl, heteroaralkyl or -C4-C8- cycloheteroalkyl; 15 R 5 ,19, RI., and RIare each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C4-C8-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs Rs and R(9, R9 and Rio or Rio and R, 1 together With the ~e ~:carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a-C4C-cyclohcteroalkyl ring; R 1 2 is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C4-C8-cyclo- heteroalky], or alkyl of 1-6 carbon atoms; -123- A is O, S, SO, SO 2 NR 7 or CH 2 X is O, S, SO, SO2, NR 7 or CH2; Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof, said aryl being phenyl or naphthyl optionally mono- or di substituted; said heteroaryl being a 5-10 membered mono- or bicyclic aromatic ring having from 1-3 heteroatoms selected from N, NR 7 S and O optionally mono- or di- substituted; said aralkyl being aryl as defined herein and the alkyl portion has 1-3 carbon atoms, said heteroaralkyl being heteroaryl as defined herein and the alkyl portion has 1-3 carbon atoms, S. 56 6 0 00** S. @0 S .O S 5 4 S@ 4 @0 said -C4-Cg-cycloheteroalkyl being disubstituted: defined as optionally mono- or C Q 0 S S C .4 0 005 @550 0 K.N R, NR7. r-\ NR 7 K K K N r-K K *or N R7 1-1W.WV-W 1h l 1. AIO I-"14 'll" Ap ~lt#P"-Ik-A -v .1,V WIVII -124- wherein K is 0, S or NR 7 and R 7 is as hereinbefore defined; and said alkyl, alkenyl, alcynyl, cycloalkyl groups being optionally mono or poly substituted; and said substituents being selected from: halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alicynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -OR 5 -CN, -CORs, perfluoroalkyl of 1-4 carbon atoms, -O-perfluoroalkyl of 1-4 carbon atoms, -CONR 5 R 6 -S(O)nas -OPORs0R- 6 -PO(OR.5)R. 6 .OC(O)NR5R. 6 6 -CQOR 5 -SO 3 H, -NRSR 6 -N[(CH 2 2 2 NR 5 -NR 5 COR 6 NR 5 COOR 6 -SO 2 NR 5 R 6 -NO 2 -N(RS)S0 2 6 -NRSCON'R 5 R6, NR 5 C(=NR 6 )NRsR 6 -NRsC('=NR 6 )N(S02R 5 )R. 6 NR,5C(=N 6 )N(C-OR5)R 6 -SO 2 NHCN, -SO2NHCONR5R, 6 phenyl, heteroaryl or C 4 -C 8 cycloheteroalkyl; wherein -NR 5 R& may form a pyrrolidine, piperidine, morpholine, thiomorpholine, oxazolidine, thiazolidine, pyrazolidine, piperazine, or azetidine ring. 2. A compound of Claim 1 wherein Y is phenyl, pyridyl, thienyl, furanyl,. imidazolyl or triazolyl or thiadiazolyl. 3. A compound of Claim I selected from the group consisting of: 1 .(4-Bromo-benzyl)-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperfidine-4- carboxylic acid hyd roxyamide;
4-(4-But-2-ynyloxy-benzenesulfonyl)- I-(4-methoxy- benzyl)-piperidine-4- carboxylic acid hydroxyamide; 0../~~~3*4VSMI,3 W,3*YY33~ 3 AW N3 J33N\3 ~M.V&,k -125- 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1-(4-chloro-benzyl)-piperidine-4- carboxylic acid hydroxyamide; I -BenzyI-4-(4-but-2-ynyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxamide; 1-(4-Bromo-benzyl)-4-(4-pent-2-yriyloxy-benzenesulfonyl)-piperidine-4- carboxylic acid hydroxyamide; I romo-benzyl)-4-(4-oct-2-ynyloxy-benzenesulfonyl)-piperidine-4- carboxylic acid hydroxyamide; 4-(4-B-ut-2-ynyloxy-benzenesulfonyl)-1 -(4-fluoro-benzyl)-piperidine-4- carboxylic acid hydroxyaznide; 4-(4-But-2-ynyloxy-berizenesulfonyl)- 1-(4-cyano-benzyl)-piperidine-4- carboxylic acid hydroxamnide; 4-(4-But-2-ynyloxy-benzenesulfonyl)- 1-(4-methyl-benzyl)-piperidine-4- carboxylic acid hydroxamide; 4-(4-B3ut-2-ynyloxy-benzenesulfonyl)- dichloro-benzyl).piperidine-4- carboxylic acid hydroxamide; I -(4-Bromo-benzyl)-4-(4-prop-2-ynyloxy-bcnzenesulfonyl)-piperidine-4- carboxylic acid hydroxyaniide;I I -(4-Bronio-benzyl)-4-[4-(4-piperdin-4-yI-but-2-ynyloxy)-benzenesulfonylJ- piperidine-4-carboxylic acid hydroxyaniide; I -(4-Bromo-benzyl)-4-[4-(4-morpholin-4-yl-but-2-ynyloxy)-benzene- sulfonylj-piperidine-4-carboxylic acid hydroxyamide; 4 4 -But-2-ynyloxy-phenylsulfanyl)-4-hydroxycarbamoyl-piperidine- I1- carboxylic acid tert-butyl ester; 25 4 4 -But-2-ynyloxy-phenylsulfanyl)-pipei-idine-4-carboxylic acid hydroxyamide l-( 4 -Bromo-benzyl)-4-(4-but-2-ynyloxy-phenylsulfanyl)-piperidine-4 carboxylic acid hydroxyamnide; 4 4 -But- 2 -ynyloxy-phenysufanylmethyI)-tetrabydro-.pyran.4-carboxylic acid hydroxyamide; -126- 4-(4-But-2-ynyloxy-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; 4-(4-But-2-ynyloxy-benzenesulfinylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyaniide; 4- (2-butynylox-y)phenyl]sulfonyl -N-hydroxytetrahydro-2H-pyran-4- carboxamide; 1 -benzyl-4- -(2-butynyloxy)phenyl]sulfonyl I -N-hydroxy-4-piperidine carboxamide; 4- [4-(2-butynyloxy)phenyl isulfonyl -N-hydroxy- 1 -isopropyl-4-piperidine carboxamide; 4- [4-(2-butynyloxy)phenyl]sulfonyl) -N-hydroxy- l-(3-pyridinylmetliyl)-4- piperidine carboxamide; 3- 4-(2-Butynyloxy)phenyl]sulfonyl) -1-ethyl-N-hydr-oxy-3-piperidine- carboxamide; 3- [4-(2-butynyloxy)phenyl]sulfonyl) I-(4-chlorobenzyl)-N-hydroxy-3- piperidinecarboxannde; 4- {(4-(2-Butynyloxy)phenyl]sulfonyl}-1 -[4-(2-piperidin-1I-yl-ethoxy)-benzyl]- piperidine-4-carboxylic acid hydroxyamide; 4-{(4-(2-Butynyloxy)phenyl~sulfonyl} -1-(3-pentanyl)-piperidine-4-carboxylic acid hydroxyarnide; 1 -(4-Methoxy-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4- carboxylic acid hydroxyamide; 1 -(4-Chloro-benzyl)-4-(4-prop-2-ynyloxy-benzenesulfonyl)-piperidine-4- carboxylic acid hydroxyamide; 25* tert-butyl-4-( ([4-(2-butynyloxy)phenyl]sulfanyl }methyi)-4-[(hydroxyamino)- carbonyl]- 1 -piperidinecarboxylate; {(4-(B3ut-2-ynyloxy)phenyl]thio) methyl)-N-hydroxypiperidine- carboxamide; tert-Butyl-4-( {[4-(2-butynyloxy)phenyl]sulfinyl )methyl)-4-[(hydroxyamino)- carbonyl]-I -piperidinecarboxylate; -127- 4-[[[4-(2-Butynyloxy)phenyl]sulfinyllmethylj-N-hydroxy-4-piperidine- carboxamide; tert-Butyl-4-( ([4-(but-2-ynyloxy)phenylJsulfonyI }xnethyl)-4-[(hydroxyarnino)- carbonyl]piperidine-l1-carboxylate; tert-butyl-4-( ([4-(2-butynyloxy)phenyl~sulfonyl} methyl)-4-[(hydroxyamino)- carbonyl]- I -piperidinecarboxylate; 1 -Acetyl-4-(([4-(2-butynyloxy)phenyl]sulfonyl~methyl]-N-hydroxy-4- piperidinecaboxamide; 1-(2-Butynyl)-4-(f {4-(2-butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy-4- piperidinecarboxamide hydrochloride;, N-i -(tert-Butyl)-4-( {[4-(2-butynyloxy)phenyllsulfonyl) methyl)-N-4-hydroxy- -1 ,4-piperidinedicarboxamide; Methyl 4-({(4-(2-butynyloxy)phenyl]sulfonyl }methyl)-4-((hydroxyamino)- carbonyl]- I -piperidinecarboxylate; Benzyl {[4-(2-butynyloxy)phenyl]sulfonyl) methyl)-4-[(hydroxyaznino)- carbonyl]- I -piperidinecarboxylate; I -Benzyl-4-( {[4-(2-butynyloxy)phenylI sulfonyll methyl)-N-bydroxy-4- piperidinecarboxamide; ([4-(2-Butynyloxy)phenyl]sulfonyllmethyl)-N4-hydroxy-lI-[(2,2,5-trimethyl- 1 ,3-dioxan-5-yI)carbonyl]-4-piperidinecarboxamide ([4-(2-Butynyloxy)phenyljsuffonyl) methyl)-N-hydroxy- -hydroxy-2- .(hydroxymnethyl)-2-methylpropanoyl]4-piperidinecarboxamide; I -[Aniino(imino)methylj-4-( 4-(2-butynyloxy)phenyl]sulfonyl methyl)-N- hydroxy-4-piperidinecarboxamide; 25 {[4-(2-Butynyloxy)phenyl]sulfonyl~methyl)-N-hydroxy-l1-(4--hydroxy-2- butynyl)-4-piperidinecarboxamide; {[4-(But-2-ynyloxy)phenyljsulfonyl )methyl)-lI-ethyl-N-hydroxypiperidine- 4- carboxarnide trifluoroacetic acid salt; -128- thiophene4-( {[4-(But-2-ynyloxy)phenyl]-sulfonyl)}- methyl)-I -((5-chlorothien-2-yl)methyl]-N- hydroxypiperidine-4-carboxarnide trifluoroacetic acid salt; {[4-(But-2-ynyloxy)phenyl]sulfonyl }methyl)-N-hydroxyi-1I-(pyridin-4- ylmethyl)piperidineA4-carboxamide trifluoroacetic acid salt; ([4-(But-2-ynyloxy)phenyl]sulfonyl) methyl)-N-hydroxy-l -(pyridin-3 ylcarbonyl)piperidine-4-carboxamide trifluoroacetic acid salt; I -Benzoyl-4-({([4-(but-2-ynyloxy)phenyl]sulfonyl }methyl)-N-hydroxy- piperidine-4- carboxamide; 4- (4-(But-2-ynyloxy)phenyl]sulfonyl }methyl)-N-hydroxy- l-(thien-2- ylcarbonyl) piperidine-4-carboxarnide; 4-((4-(But-2-ynyloxy)phenyljsulfonyl} methyl)-N- 1 -ethyl -N-4-hydroxy- piperidine-1I,4-dicarboxamide; 4-(({[4-(But-2-ynyioxy)phenyljsulfonyl} methyl)-N-4-hydroxy-N- 1- phenyl- piperidine-1,4-dicarboxamide; ([4-(But-2-ynyloxy)phenyl]sulfonyl~methyl)-N-lI-,N-1 -diethyld4-4- hydroxypiperidine-1I,4-dicarboxamide; 4-(({[4-(But-2-ynyloxy)phenyljsulfonyl) methyl)-N-hydroxy-I -(morpholin-4- ylcarbonyl)piperidine-4-carboxamide; ([4-(But-2-ynyloxy)phenyl]sulfonyl }methyl)-N-4-hydroxy-N- 1-methyl-N- 1 -phenylpiperidine-1I,4-dicarboxamide; Octyl-4-( {[4-(but-2-ynyloxy)phenyl]sulfonyl }methyl)-4-((hydroxyami no)- carbonyl] piperidine-1 -carboxylate; 4-Methoxyphenyl4-( ([4-(but-2-ynyloxy)phenyl]sulfonyl rethyl)-4-((hydroxy- amino) carbonyl]piperidine-1 -carboxyl ate; {[4-(But-2-ynyloxy)phenyljsulfonyl) methyl)-N-hydroxy- 1-(phenylsulfonyl) piperidine-4-carboxamide; ([4-(But-2-ynyloxy~phenyl]sulfonyl }methyl)-N-hydroxy- I1-(I1-methyl-i H- irnidazol-4-yl)sulfonylpiperidine-4-carboxaxnide; -129- 1 -[2-(Benzylamino)acetylj-4-( ([4-(but-2-ynyloxy)pheny]-sulfonyl methyl)- N- hydroxypiperidine-4-carboxamide; {[4-(But-2-ynyloxy)phenyllsulfonyl }methyl)-N-hydroxy-lI-(2-rncrpholin-4- ylacetyl)piperidine-4-carboxamide; {[4-(But-2-ynyloxy)phenyl]sulfonyl} methyl)-N-bydroxy- I-[2-(4-methyl- piperazin- 1 -yl)acetyl]piperidine-4-carboxamide; I -Actyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide; I -Benzoyl-4-(4-but-2-ynyloxybenzenesulfonyl)piperidine-4-carboxylic acid hydroxamide; 1 -(4-Methoxybenzoyl)-4-(4-but-2-ynyloxy benzenesulfonyl)piperidine-4- carbaxylic acid hydroxamide; 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy-I -(pyrroldine- 1-caubonyl)-4- piperidinecarboxamide; Ethyl 4-(4-but-2-ynyloxybenzenesulfonyl)-4-[(hydroxyamino)carbonyl]- 1- piperidinecarboxylate; 4-(4-B3ut-2-ynyloxybenzenesulfonyl)-N-hydroxy-I -[(trifluoromethyl)sulfonyl)- 4- piperidinecarboxamide; 4-(4-But-2-ynyloxybenzenesulfonyl)-N-hydroxy- 1-(3 -pyridinylcarbonyl)- 4- piperidinecarboxamide; 4-(4-but-2-ynyloxybenzenesulfonyl)-N-hydroxy- 1-(2-thienylcarbonyl)- 4- piperidinecarboxamide; 4-(4-but-2-ynyloxybenzenesulfonyl)-N-hyckoxy-l1 .(4-methoxyphenyl)- sulfonylj-4-piperidinecarboxarnide; 25 4-(4-but-2-ynyloxybeizenesulfonyl)-N-hydroxy-lI-[(2,2,5-trimethyl- 1,3- dioxan-5-yI)caxbonyl]-4-piperidinecarboxarnide; Tert-butyl-4- f{[4-(2.-butynyloxy)phenyljsulfonyl -4- [(hydroxyarnino)carbonyl] -piperidinecarboxalate;, 4- [4-(2-butynyloxy)phenyl~sulfonyl -N-hydroxy-4-piperidinecarboxamide hydrochloride; Methyl( {[4-(2-butynyloxy)phenyl]sulfonyl -4-[(hydroxyamino)carbonyl]- 1- piperidinyl}methyl~benzoate hydrochloride; {4-{[4-(2-butynyloxy)phenyl]sulfonyl} -4-[(hydroxyamino)carbonyl]-l- piperidinyl~methyl)benzoic acid hydrochloride; 1-[4-(Aminocarbonyl)benzyl]-4-{[4-(2-butynyloxy)phenyl]sulfonyl}-N-hydroxy-4- piperidinecarboxamide hydrochloride; Tert-butyl4- {[4-(but-2-ynyloxy)phenyl]sulfinyl -4-[(hydroxyamino)-carbonyl]piperidine- 1 -carboxalate; 4-(4-(But-2-ynyloxy-benzenesulfinyl)-piperidine-4-carboxylic acid hydroxamide hydrochloride; and 1-(4-Bromo-benzyl)-4-(4-But-2-ynyloxy-benzenesulfinyl)-piperidine-4-carboxylic acid hydroxamide hydrochloride; and pharmaceutical salts thereof. 4. A process for preparing a compound of formula I as claimed in claim 1, which Is comprises one of the following: a) reacting a compound of formula 0 R2 R3 R8 R 9I ,A X \X OH R, RIO R 1 1 wherein n, X, Y, A, R 1 R 2 R 3 R 8 R 9 RIO and R 11 are as defined in claim 1 or a reactive derivative thereof, with a compound of formula 0* R 1 2 NHOH wherein R 1 2 is as defined in claim 1, to give a compound of formula I; or b) deprotecting a compound of formula: 0 R2 R3 R8 R 9 x/ A> C)n NR 12 0R 30 R1 Rio R 1 [I:\DAYLIB\LIBXX]06067.doc:NSS 'C 131 wherein n, X, Y, A, RI, R 2 R 3 Rs, R 9 Rio, RII and R 12 are defined in claim 1, and R 30 is a suitable protecting group such as t-butyl, benzyl, and trialkylsilyl, to give a corresponding compound of formula I or c) cleaving a resin supported hydroxamate derivative containing the group 0 R 8 R 9 R 3 R 2 -O-NH (C)n A X Rio R R wherein n, X, Y, A, R 1 R2, R3, R8, R 9 Rio and RI, are defined in claim 1 to give a compound of formula I wherein R 1 2 is hydrogen; or d) resolving a mixture racemate) of optically active isomers of a compound of formula I to isolate one enantiomer or diastereomer substantially free of the other enantiomer or diastereomers; or e) acidifying a basic compound of formula I with a pharmaceutically acceptable acid to give a pharmaceutically acceptable salt; or f) converting a compound of formula I having a reactive substituent group or site to a compound of formula I having a different substituent group or site. 20
5. A compound of formula I, as defined in claim 1, substantially as hereinbefore described with reference to any one of the examples.
6. A process for preparing a compound of formula I, said compound of formula I being as defined in claim 1, substantially as hereinbefore described with reference to any one of the examples.
7. A compound of formula I, as defined in claim 1, whenever prepared by the process of claim 4 or claim 6.
8. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and a o** pharmaceutically acceptable carrier. [I:\DAYLIB\LIBXX]06067.doc:NSS 132
9. The use of a compound according to any one of claims 1 to 3, 5 or 7 in the preparation of a medicament for inhibiting pathological changes mediated by TNF-a converting enzyme (TACE) in a mammal.
The use according to claim 9 wherein the condition treated is rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
11. A method of inhibiting pathological changes mediated by TNF-a converting enzyme (TACE) in a mammal said method comprising administration to said mammal of a therapeutically effective amount of a compound according to any one of claims 1 to 3, or 7, or a pharmaceutical composition according to claim 8.
12. A compound according to any one of claims 1 to 3, 5 or 7, or a pharmaceutical composition according to claim 8 when used for inhibiting pathological changes mediated by TNF-a converting enzyme (TACE) in a mammal. Dated 3 November, 2003 Wyeth Holdings Corporation Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [I:\DAYLIB\LIBXX]06067.doc:NSS ,.10 -7 X ,ZIW N ONO h- V I: l .7 i L .i I 'i R, E
AU26305/00A 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors Ceased AU769418B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23803899A 1999-01-27 1999-01-27
US09/238038 1999-01-27
PCT/US2000/001864 WO2000044723A1 (en) 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors

Publications (2)

Publication Number Publication Date
AU2630500A AU2630500A (en) 2000-08-18
AU769418B2 true AU769418B2 (en) 2004-01-29

Family

ID=22896246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26305/00A Ceased AU769418B2 (en) 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors

Country Status (13)

Country Link
JP (1) JP2002535390A (en)
KR (1) KR20010101732A (en)
AR (1) AR035312A1 (en)
AT (1) ATE309986T1 (en)
AU (1) AU769418B2 (en)
CA (1) CA2356313A1 (en)
CZ (1) CZ20012711A3 (en)
DE (1) DE60024056D1 (en)
EA (1) EA200100806A1 (en)
HU (1) HUP0200223A3 (en)
IL (1) IL144345A0 (en)
NZ (1) NZ512566A (en)
ZA (1) ZA200105222B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003252361A1 (en) * 2002-12-26 2004-07-29 Carna Biosciences Inc. Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
BRPI0713119A2 (en) * 2006-06-30 2012-04-17 Schering Corp Substituted piperidines that increase the activity of p53 and the uses of these
WO2009147389A2 (en) * 2008-06-02 2009-12-10 Cipla Limited Processes for the synthesis of levocetirizine and intermediates for use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037877A1 (en) * 1997-02-27 1998-09-03 American Cyanamid Company N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AU9120198A (en) * 1998-02-19 1999-09-06 American Cyanamid Company N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037877A1 (en) * 1997-02-27 1998-09-03 American Cyanamid Company N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AU9120198A (en) * 1998-02-19 1999-09-06 American Cyanamid Company N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ATE309986T1 (en) 2005-12-15
AR035312A1 (en) 2004-05-12
NZ512566A (en) 2004-02-27
KR20010101732A (en) 2001-11-14
CZ20012711A3 (en) 2002-05-15
DE60024056D1 (en) 2005-12-22
EA200100806A1 (en) 2002-08-29
JP2002535390A (en) 2002-10-22
IL144345A0 (en) 2002-05-23
ZA200105222B (en) 2002-09-25
CA2356313A1 (en) 2000-08-03
AU2630500A (en) 2000-08-18
HUP0200223A2 (en) 2002-06-29
HUP0200223A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
EP1147085B1 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US20030171400A1 (en) Heterocyclic side chain containing metalloprotease inhibitors
JP2000510162A (en) Aryl sulfonyl hydroxamic acid derivatives
NO314302B1 (en) Matrix metalloproteinase inhibitors, their use and pharmaceutical composition
AU8237698A (en) Acyclic metalloprotease inhibitors
SK11352001A3 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
US20020099035A1 (en) Method for preparing alpha-sulfonyl hydroxamic acid derivatives
JP2004513063A (en) Cell adhesion inhibiting anti-inflammatory and immunosuppressive compounds
US6825354B2 (en) Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors
WO2001055112A1 (en) Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US6949545B2 (en) Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6753337B2 (en) Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6022873A (en) Metalloproteinase inhibitors
AU769418B2 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors
US6878700B1 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
MXPA01007573A (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
MXPA99001808A (en) Arylsulfonylamino hydroxamic acid derivatives
MXPA99005822A (en) Piperazine compounds as inhibitors of mmp or tnf

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: WYETH HOLDINGS CORPORATION

Free format text: FORMER NAME: AMERICAN CYANAMID COMPANY

FGA Letters patent sealed or granted (standard patent)